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Abstract  
Autonomic neuropathy is a complication of diabetes and, where the innervation of the 
gut is involved, results in disordered gut motility. In vivo, sympathetic nerves and 
subpopulations of enteric neurons supplying the ileum are differentially affected by 
diabetes. The overall of aim of this study was to establish whether such differential 
susceptibility could be reproduced in vitro using wholemount preparations of myenteric 
plexus and sympathetic ganglion explants from the adult rat and to use such models to 
examine potential mechanisms underlying the development of neuropathy and its 
prevention. Preparations were exposed to a range of stimuli that mimic the diabetic 
environment including high glucose, advanced glycation endproducts (AGEs), carbonyl 
stress and oxidative stress. Evidence is presented that exposure of myenteric neurons to 
oxidative stress in vitro mimicked the effects of diabetes as reflected by increased 
expression of vasoactive intestinal polypeptide (VIP), decreased expression of  neuronal 
nitric oxide synthase (nNOS) and unaltered calbindin expression. However, the 
mechanism underlying oxidative stress was not uniform, increased VIP expression only 
occurred on exposure to high glucose and carbonyl stress whereas decreased nNOS 
expression was only induced by AGEs. Neurons containing calbindin were resistant to 
all stimuli. Potential therapeutic agents produced differing effects depending on whether 
they primarily acted against oxidative or carbonyl stress. Using two photon microscopy 
and fluorescence lifetime imaging (FLIM), the effect of high glucose on reduced 
nicotinamide adenine (phosphate) (NAD(P)H) metabolism was investigated over time. 
Comparisons were made between sympathetic neurons from superior cervical ganglia 
(SCG), which are unaffected in diabetes, and from superior mesenteric/coeliac ganglia 
(CG/SMG) which develop axonal dystrophy. High glucose temporarily increased 
NAD(P)H levels selectively in the CG/SMG which coincided with a significant 
difference between the two ganglia in the fluorescence lifetime of free NAD(P)H. These 
results may explain the complex pattern of change that occurs in enteric nerves in 
diabetes. 
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Chapter 1: General introduction 
 
1.1 Diabetes and gastrointestinal problems 
 
 
The incidence of diabetes mellitus is reaching epidemic proportions, particularly 
in the Western world. In addition to the control of the diabetic condition, the treatment 
of complications that arise as a consequence of diabetes represents a significant burden 
to health care costs. Complications due to diabetes involving the gastrointestinal tract 
(GI tract) are referred to as enteropathy or gastrointestinal neuropathy (Camilleri, 1996). 
Diabetic gastrointestinal neuropathy may cause symptoms such as dysphagia, heartburn, 
nausea, vomiting, abdominal pain, constipation, diarrhea and fecal incontinence. 
Epidemiological studies of diabetic gastrointestinal neuropathy provide conflicting 
results depending on the population studied. 76% of diabetic patients may present with 
a complex of gastrointestinal symptoms, the most common being constipation (Feldman 
& Schiller, 1983;Bytzer et al., 2001). Gastrointestinal symptoms can lead to dangerous 
complications such as ketoacidosis, infection and bezoar formation and further 
glycaemic deregulation (Feigenbaum, 2006). In many cases, these symptoms are due to 
abnormal gastrointestinal motility suggesting pathophysiology of the autonomic and 
enteric nervous systems (ANS, ENS) leading to motor and sensory abnormalities in the 
GI tract, the nature of which are not completely understood. At present there is an 
absence of markers that accurately predict which diabetic patients are at risk of 
developing enteropathy. 
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1.2 Diabetes and peripheral neuropathy 
 
 
Diabetes mellitus is associated with a wide spectrum of neuropathy syndromes. 
Diabetic peripheral neuropathy has been defined as the presence of symptoms and/or 
signs of peripheral nerve dysfunction in people with diabetes, after exclusion of other 
causes (Boulton et al., 1998). It affects the sensory, autonomic or motor nerves and, in a 
subclinical form, the nerves are affected without overt symptoms. Depending on the 
nerves and the level that are affected, diabetic neuropathy can appear mild or 
asymptomatic or be disabling or painful, causing a serious decline in the quality of life 
of the diabetic patient (Greene et al. 1999). 
Reports about the prevalence of diabetic neuropathy vary from 10% up to as 
high as 90% in a subclinical form, depending on the duration and severity of diabetes. 
This variability also derives from the difficulties in diagnosis and its early detection in 
routine diabetic care.  
 
 
 Many different classification systems have been proposed because of a wide 
range of clinical presentations. A broad separation into rapidly reversible or more 
persistent phenomena has been proposed by Thomas (Thomas, 1997). Rapidly 
reversible syndromes can be categorized as "hyperglycaemic neuropathy" and include 
minor sensory symptoms, reduced nerve conduction velocity and resistance to 
ischaemic conduction failure. Focal and multifocal lesions give rise to cranial, thoraco-
abdominal, and limb neuropathies, including proximal lower limb motor neuropathy 
(diabetic amyotrophy). Diabetic amyotrophy, initially considered resulting from 
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metabolic changes, and later ischaemia, is now attributed to immunological changes. 
Focal neuropathies tend to occur after 50 years of age and mostly in patients with long 
standing diabetes.  The overall prognosis of focal neuropathies is good.  
Of the more persistent phenomena, distal symmetric polyneuropathies 
predominantly affect sensory and autonomic function and are the most common 
manifestation, accounting for 75% diabetic neuropathies (Bansal et al., 2006). Distal 
symmetric polyneuropathies are distal axonopathies of the dying-back type (Cavanagh, 
1979). The fully expressed syndrome is a symmetrical distal lower limb sensorimotor 
polyneuropathy with a varying degree of autonomic involvement (Sinnreich et al., 
2005). It is predominantly sensory, but in severe cases distal weakness and foot drop 
may be present. Almost with no exception sensorimotor involvement is restricted to 
lower extremities of the lower limbs. Large fiber dysfunction is assessed by nerve 
conduction velocity tests and small fibres dysfunction by skin biopsies. New diagnostic 
tools are appearing but need further evaluation (Papanas & Ziegler, 2011). 
 Multiple clinical studies suggest that autonomic dysfunction is a common characteristic 
of both type 1 and type 2 diabetes. Autonomic neuropathy can affect the function of 
virtually every organ because typically it occurs as a system-wide disorder affecting all 
parts of the autonomic nervous system (Vinik et al., 2003). The cardiovascular, 
gastrointestinal and urogenital systems can all be affected leading in a range of 
debilitating symptoms.  Somatic peripheral neuropathy is usually concurrent. Standard 
reliable non-invasive measures are used to identify autonomic failure and quantify 
disease severity. Diagnosis of diabetic autonomic neuropathy commonly includes tests 
on heart rate variability to measure the cardiovagal parasympathetic function, the 
Valsalva Maneuvre and various sudomotor tests to assess the sympathetic system 
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(Weimer, 2010). Tests to evaluate the function of the gastrointestinal motility require 
special expertise and are not standard practice.  
 
 
 
 
 
1.3 Innervation of the GI tract 
 
 
The proper function of the GI tract requires the integrated activity of the central 
nervous system (CNS), the ANS, and the ENS. The ENS is a neural subsystem of the 
ANS, incorporated in the walls of the gut. Because their cell bodies are located 
intramurally the neurons are termed enteric. Although, the activity of the ENS is to a 
large extent independent in vitro (Langley, 1921), the autonomic ganglia modulate the 
function of the ENS and, forming the extrinsic innervation of the GI tract, they serve as 
integrating centres between the ENS and the CNS. Sensory inputs from the GI tract 
enter the spinal cord via the dorsal roots and subsequently synapse on spinal cord 
neurons that supply higher centres in the brain. Higher brain centres include the frontal 
cerebral cortex, stria terminalis, paraventricular nucleus of the hypothalamus, and the 
central nucleus of the amygdala, all projecting into the vagal outflow centre in the 
medulla oblongata. The effector systems of the GI tract innervation are the musculature, 
mucosal epithelium, vasculature, immune cells, enteric neurons and interstitial cells of 
Cajal (ICC). 
     .  
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1.3.1 Extrinsic Innervation 
 
The autonomic innervation of the GI tract comprises an efferent system sending 
signals from the CNS.  Efferent neurons modulate motor and secretomotor functions in 
the GI tract operated by the ENS. 
Generally, there are two types of efferent neurons in the ANS, the preganglionic 
neuron and the postganglionic neuron. Preganglionic cell bodies are found in the CNS 
and postganglionic cell bodies are located outside the CNS and their fibres end in the 
walls of the gut (see Jacobson & Marcus, 2008). The ratio of sympathetic preganglionic 
to postganglionic neurons is 1:10. Conversely, the divergence is considerably less for 
the parasympathetic neurons, which have a preganglionic to postganglionic ratio of 
about 1:3 neurons. Postganglionic autonomic fibres synapse with a vast amount of 
effector neurons. In this way, autonomic neurons function as command neurons that 
inhibit or stimulate neural circuits in the ENS. These circuits generate organised and 
repetitive behavioural patterns associated with gastrointestinal motility or secretion 
(Wood, 2008).         
 The GI tract receives dual extrinsic innervation, sympathetic and 
parasympathetic. In general, sympathetic nerves inhibit peristalsis and secretion and 
parasympathetic nerves stimulate these functions. Blood flow in the crypts and muscle 
layers, epithelial transport of fluids and electrolytes, motility and release of hormones 
from the enterochromaffin cells are activities that are controlled by the ANS (Lundgren, 
2000). This occurs indirectly through postganglionic synapses with enteric neurons or 
directly as sympathetic and parasympathetic fibres interpenetrate the enteric plexuses 
and influence the crypt epithelium (Lundgren, 2000;Powley, 2000).  
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Different segments of the GI tract are innervated by different autonomic ganglia. 
The stomach as far as the proximal colon receives sympathetic input from the CG/SMG 
which is located on the celiac and superior mesenteric arteries. Renal ganglia lie 
laterally to the CG/SMG mass (Decktor & Weems, 1981).  Preganglionic fibers of 
CG/SMG originate from thoracic levels T5-12 of the spinal cord to form the greater and 
lesser splachnic nerves. They bypass the sympathetic trunk without synapsing to 
activate the CG/SMG. Postganglionic fibres from there are distributed to the stomach, 
pancreas, small intestine, the ascending portion of the colon and the kidneys. 
Parasympathetic input to these areas comes from the dorsal motor nucleus of the vagus 
nerve and postganglionic cell bodies are located close to the viscera.  Also, there is a 
different degree of innervation in the stomach and small intestine in comparison to 
oesophagus, showing a less direct parasympathetic control in these areas.  
The distal colon as far as the rectum receives sympathetic input from the inferior 
mesenteric ganglion (IMG) found on the inferior mesenteric artery. The sympathetic 
preganglionic fibers originate from the first and second lumbar segments of the spinal 
cord to end in the IMG. From there, postganglionic fibres innervate the descending 
colon, the rectum, the urinary bladder, the ureter and the external genitalia. These areas 
receive parasympathetic input from neurons that originate in the second to forth sacral 
spinal cord levels, form the pelvic nerve and synapse with postganglionic neurons very 
close to the target organs (Snell, 2010).  
Neuromuscular junctions in ANS have the following characteristics: 1) the 
autonomic effector is not a single cell; 2) the unmyelinated postganglionic fibres do not 
form specific pre- and postsynaptic sites but varicosities. These are up to 2 μm in 
diameter and packed with vesicles and mitochondria. And 3) neurotransmitters are 
released en passage from varicosities inducing excitatory or inhibitory junction 
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potentials to facilitate or prevent action potentials (see Milner et al., 1999). 
Parasympathetic postganglionic neurons release acetylcholine (ACh) and sympathetic 
postganglionic neurons release noradrenaline (NA). The action of these two 
neurotransmitters is often antagonistic. ACh is also a neurotransmitter in preganglionic 
autonomic neurons. However, there is also a multitude of non adrenergic non 
cholinergic (NANC) substances utilised as neurotransmitters such as peptides, purines 
and gases cotransmitted with and modulating the release of the classic neurotransmitters 
NA and ACh (Burnstock, 1976;Milner et al., 1999;Burnstock, 2004). For example, 
postganglionic sympathetic nerves in CG/SMG can co-release in varying proportions 
NA, somatostatin and neuropeptide Y (NPY) (Macrae et al., 1986). Postganglionic 
parasympathetic nerves can co-release ACh, VIP, adenosine triphosphate (ATP) and 
nitric oxide (NO). Besides different neurochemical properties (or chemical codes), 
different functional groups of autonomic nerves have distinct electrophysiological 
properties (Janig & McLachlan, 1992).  
 
1.3.2 Extrinsic primary afferent/sensory innervation of the GI tract 
 
Extrinsic afferent innervation from the GI tract involves extrinsic sensory 
neurons with receptors sensitive to multiple stimuli. Afferent fibres from the ENS send 
sensory information that are relayed in the vagus nerve or dorsal root ganglia and then 
sent to higher brain centres. This sensory input also affects the local processing circuit 
in ENS and the prevertebral sympathetic ganglia. Intramurally, the intestinofugal 
neurons project to prevertebral ganglia. Non-painful physiologic sensations that do not 
reach consiousness include responses to thermal or mechanical stimuli such as muscle 
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tension and mucosal brushing, or luminal chemical stimuli such as pH, osmolarity and 
the concentration of glucose, amino acids and long chain fatty acids. Sensory 
information also consists of nociceptive signals.  
The visceral afferent neurons have their endings in the gut wall and their cell 
bodies, similarly to the somatic afferent neurons, are located in the dorsal root ganglia 
(DRG) ending in the spinal cord. Their fibres pass through the prevertebral CG, SMG or 
IMG and through the paravertebal ganglia, influencing the efferent transmission taking 
place in the autonomic plexuses. Sensory fibres are also contained in the vagus and 
pelvic nerves and terminate in the brain stem and lumbosacral spinal cord, respectively. 
The vagal afferents course from the nucleus tractus solitarius and innervate the GI tract 
from the esophagus to the transverse colon. Sensory fibres coursing from the 
lumbosacral spinal cord innervate the rest lower parts of the GI tract (Gebhart, 
2000;Wood, 2007). 
 
 
 
 
1.3.3 Intrinsic innervation 
 
The ENS comprises the intrinsic innervation of the GI tract and involves as 
many neurons as found in the grey matter of the spinal cord (see Furness, 2005).  The 
structure, function, and neurochemistry of enteric ganglia differ significantly from other 
autonomic ganglia. Unlike other autonomic ganglia, ENS ganglia are interconnected 
and, like in the brain and spinal cord, the ENS works with three functional categories of 
neurons identified as sensory, inter-, and motor neurons (see Wood et al., 1999;Hansen 
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2003b). The ENS is involved in a range of activities including motility, secretion, 
microcirculation and immunologic and inflammatory responses. Thus the effector 
systems of the ENS are the enteric neurons themselves, smooth muscle cells responsible 
for gastrointestinal motility; mucosal secretory cells; gastrointestinal endocrine cells; 
the gastrointestinal microvasculature that maintains mucosal blood flow during 
intestinal secretion; fibroblast–like cells; and the immunomodulatory and inflammatory 
cells of the gut that are involved in mucosal immunologic, allergic, and inflammatory 
responses. The ENS may influence these targets directly or may do so indirectly 
through intermediate cells, which include endocrine cells, the interstitial cells of Cajal 
(ICCs), and cells of the immune system, such as mast cells (see Hansen, 2003c).  
 The general structure of the ENS is similar from the oesophagus to the rectum. 
The neuronal cell bodies are grouped into small ganglia that are connected by bundles 
of nerve processes forming two major plexuses, called the myenteric (or Auerbach’s) 
plexus and the submucosal (or Meissner’s) plexus  (see Furness, 2005). The neurons in 
the myenteric plexus lie between the outer longitudinal muscle and circular muscle 
layers and predominantly regulate motility. The neurons in the submucosal plexus lie in 
the submucosa near the inner surface of the circular muscle and predominantly regulate 
secretion of water and electrolytes across the intestinal epithelium. 
Different types of neurons in the myenteric plexus project their fibres to neurons 
in the same plexus, the submucosal plexus and prevertebral ganglia, and to cells in the 
circular and longitudinal muscle layers (see Hansen, 2003a). The myenteric plexus 
provides motor innervation to the two muscle layers and secretomotor innervation to the 
mucosa. In the striated-muscle portion of the esophagus, the myenteric plexus 
innervates motor end plates with NO and calcitonin gene-related peptide (CGRP). This 
innervation is unique to the esophagus (Worl et al., 1994). 
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The submucous plexus is best developed in the small intestine, where it plays an 
important part in secretory control (see Goyal & Hirano, 1996). Besides innervating the 
glandular epithelium, neurons in the submucous plexus innervate the muscularis 
mucosa, intestinal endocrine cells, and submucosal blood vessels.  
Glial cells are an integral component of the ENS, and they outnumber enteric neurons. 
Enteric glial cells resemble the astrocytes of the CNS; their laminar extensions cover 
most of the surface of enteric neuronal cell bodies. They participate in modulation of 
inflammatory responses in the intestine, the regulation of neurotransmission and 
information processing in the gut (Ruhl, 2005).  
 
 
 
 
1.3.3.1 Coordination of enteric neurons  
Enteric neurones work in assemblies and generate cyclic patterns of behaviour 
(motility, secretory etc.) (see Furness, 2005). Neural circuits formed by interneuronal 
synaptic connections called central pattern generators generate organized and repetitive 
motor patterns. The entire sequence of the motor program may be initiated by input 
signals from a single neuron called a command neuron (Wood et al., 1999;Kunze & 
Furness, 1999;Wood, 2008). Thus, subsets of neural circuits control distinct patterns of 
behaviour in each effector system and coordinate activity of multiple systems.   
Integration of the patterns of behaviour is the result of reflexes. Reflexes are a form of 
neural-mediated behaviour of effector systems as a response to stimulation of sensory 
neurons (Wood et al., 1999).  For example, the peristaltic reflex is the response to 
distension or mucosal stroking in the wall of the intestine and involves contraction of 
the circular muscle coat above the site of stimulation and relaxation of the circular 
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muscle below the site.  Reflexes involve both plexi and during normal motility the 
longitudinal and circular muscle layers are synchronously activated (Spencer & Smith, 
2001).   
 
1.3.3.2 Classification of enteric neurons 
 
Different methods, including light and electron microscopy, 
immunohistochemistry, electrophysiological analysis, intracellular dyes, and retrograde 
tracing of neuronal projections have allowed the classification of enteric neurons with 
respect to morphological, neurochemical, electrical and functional criteria (see Wood et 
al., 1999;Hansen, 2003b).  
 
 
 
a) Morphological and electrical classification 
According to their morphology, neurons have been classified into Dogiel type I 
to type VII. Although these seven morphologic forms of neurons have been identified, 
the majority are types I-III. Type I neurons have many processes and a single long, thin 
process, whereas type II neurons are multipolar and have multiple long processes. Type 
III are similar to type I but with a shorter axon (Wood, 1994;Furness, 2000;Hansen, 
2003b;Furness, 2005). 
Synaptic (S) and after hyper-polarisation (AH) types are distinguished by their 
electrophysiological properties. AH type neurons have prolonged hyper-polarisation 
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after they fire an action potential that inhibits further excitation. AH neurons lack a 
prominent fast excitatory synaptic input, but they do receive slow synaptic input, which 
regulates their excitability. S Neurons with synaptic type electrophysiological behaviour 
have the morphology of Dogiel type I neurons, whereas the AH after hyper-polarisation 
type are most often Dogiel type II (Wood, 1994;Furness, 2000; Hansen, 2003b) .   
 
b) Functional classification 
The neurons that make up the ENS can be widely classified by functional 
criteria as sensory, interneurons, motor or secretomotor neurons (Goyal & Hirano, 
1996;Hansen, 2003b). Furness describes 14 functionally defined neuron types, each 
with a characteristic combination of morphological, neurochemical and biophysical 
properties (Furness, 2000;Furness, 2005). In general, sensory neurons connect with each 
other primarily through slow synaptic excitation and thus constitute a self-reinforcing 
network. Similarly, the ascending and descending interneurons form interconnecting 
chains. Lastly, the muscle motor neurons and secretomotor neurons innervate muscle 
and the mucosa, respectively (Hansen, 2003b). 
 
 
 
Intrinsic Primary Afferent Neurons (IPANs)  
Intrinsic and extrinsic sensory neurons have receptor regions specialized for 
detecting changes due to thermal, chemical, or mechanical stimuli. The intrinsic sensory 
neurons or IPANs are located in both the myenteric and submucous plexuses. Thermal, 
chemical or mechanical changes in energy are transformed into signals that induce 
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action potentials. These are subsequently transmitted along sensory nerve fibers to 
stimulate other enteric or extrinsic neurons (Wood et al., 1999).  
IPANs maintain numerous connections to the mucosa and fibres that run through 
the circular muscles. They make direct contact with motor neurons and interneurons 
projecting circumferentially to them in the surrounding myenteric and submucous 
plexuses, and with the postganglionic termini of extrinsic autonomic nerve fibers. 
IPANs also forward information from the enterochromaffin cells that are located in the 
mucosa, release serotonin (5-HT) and facilitate GI function. Connections finally include 
endocrine and immune cells located in the gut. Apparently the role of the interaction 
with immune cells is protective (Hansen, 2003a). 
Electrophysiologically, IPANs are characterized as AH neurons and 
morphologically are type II. They typically contain calbindin, ACh, CGRP and 
substance P (see Goyal & Hirano, 1996).  
 
 Interneurons  
 Interneurons are located between IPANs and the motor or secretomotor 
neurons. They process sensory information and signals from other types of neurons to 
control the behaviour of motor neurons. Interneurons of the enteric nervous system form 
networks with numerous connections making multisynaptic pathways. Thus, the various 
groups of interneurons comprise integrative circuits that organize reflex responses to 
sensory inputs (see Goyal & Hirano, 1996;Wood et al., 1999). 
At least one type of ascending and three types of descending interneurons have 
been characterised in guinea pig (Furness, 2000). Several subgroups of interneurons 
have been defined on the basis of their neurotransmitter content. The ascending 
interneurons are mainly cholinergic, whereas the descending ones have a complex 
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chemical coding typically including ACh, NO, VIP, 5-HT, and somatostatin. ACh/ 
NO/VIP/ somatostatin neurons are involved in local motility reflexes, whereas ACh/ 5-
HT neurones are involved in the local secretomotor reflexes. Interneurons are both AH 
and S types and usually Dogiel type II neurons (see Hansen, 2003c;Smith et al., 2007). 
 
Motor neurons 
Motor neurons are the final pathways to the effector systems. There are five 
broad types, and many subtypes, of enteric motor neurons: excitatory neurons to gut 
muscle, inhibitory neurons to gut muscle, secretomotor / vasodilator neurons, 
secretomotor neurons that are not vasodilator and neurons innervating enteroendocrine 
cells, such as those innervating the gastrin secreting endocrine cells of the stomach 
(Furness, 2000). 
Muscle motor neurons. The longitudinal and the circular muscle layers are 
innervated by both inhibitory and excitatory motor neurons. These are S/Dogiel type I 
neurones. The motor neurons project anally or orally to the muscle. Transmission is 
predominantly muscarinic cholinergic and tachykinergic (substance P and neurokinin 
A) in excitatory neurons. Inhibitory neurons typically utilise NO, VIP, ATP, and 
possibly pituitary adenylate cyclase-activating polypeptide, gamma aminobutyric acid 
(GABA), NPY and carbon monoxide as transmitters (see Goyal & Hirano, 1996;Wood 
et al., 1999;Hansen, 2003a;Hansen, 2003b).  
Fibroblast-like cells and ICCs are cells concentrated in close apposition with the 
varicosities of enteric motor neurons and smooth muscle cells. The physiological role of 
fibroblast-like cells has not been established but they seem to participate in motor 
neurotransmission. ICCs are non neuronal cells that generate electrical slow waves and 
function as pacemakers. Action potentials of motor neurons and pacemaker potentials 
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spread rapidly to every smooth muscle cell in three dimensions. The activity of 
inhibitory motor neurons determines when the slow waves initiate a contraction, as well 
as the distance and direction of spread once the contraction has begun (Wood, 2007). 
Inhibitory motor neurons fire continuously and release neurotransmitters to 
inhibit contraction (Wood, 2007). Contraction can only occur when inhibitory neurons 
cease to fire after input from interneurons. The opposite occurs in the sphincters where 
inhibitory motor neurons only fire in the appropriate timing for coordination of the 
opening of the sphincter. Inhibitory neurons are normally switched off orally, resulting 
in contractile activity that spreads in the anal direction. During vomiting, the inhibitory 
motor neurons must be switched off in the reverse direction, anally, for the propulsion 
to travel from the small intestine towards the stomach. 
 
Secretomotor and vasomotor neurons. Secretions and blood flow are controlled 
by secretomotor and vasomotor enteric neurons, respectively. Most secretomotor 
neurons have their cell bodies located in the submucosal plexus. Other submucosal 
neurons innervate the muscularis mucosae. Vasomotor (dilator) neurons also have their 
cell bodies in the submucous layer. There are two main types of intestinal 
secretomotor/vasodilator neurons: cholinergic and non-cholinergic. ACh released from 
the cholinergic neuron acts on muscarinic receptors on the mucosal epithelium. The 
non-cholinergic neurons appear to mediate most of the local reflex responses and utilise 
VIP as a transmitter (see Furness, 2000;Hansen, 2003b).  
c) Chemical Classification 
     Finally, neurotransmitter content may be used as a classification tool (Kunze 
& Furness, 1999;Hansen, 2003b). Enteric neurotransmitters are either small molecules 
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(e.g. ACh, GABA, 5-HT, ATP), larger molecules (neuropeptides) or gases (NO and 
carbon monoxide). Functional subtypes of neurons express particular unique 
combinations of transmitters and other molecules, a phenomenon known as chemical 
coding. Enteric neurons contain many combinations of transmitters, transmitter-related 
molecules, such as choline acetyltransferase, and other regulatory molecules, such as 
calcium-binding proteins (e.g. calbindin, calretinin) that can be considered and used as a 
chemical code for identification of functional subtypes. The chemical code of a 
functional group may vary depending on the species and the intestinal segment. ACh is 
the major excitatory transmitter of the enteric nervous system and neurons that contain 
VIP or nNOS are inhibitory motor neurons. Using colchicine to enhance VIP-
immunolabelling, 90-100% of nNOS-containing myenteric neurons have been reported 
to contain VIP in the mouse and guinea-pig ileum (Costa et al., 1992; Qu et al., 2008).   
 
 
 
 
1.4 Changes in intrinsic and extrinsic nerves due to diabetes mellitus 
 
 
When neuropathy occurs, gastrointestinal functions (motility, secretion etc.) are 
disturbed, depending on the subpopulation of neurons affected. For example, loss or 
malfunction of inhibitory motor neurons is the pathophysiological starting point for 
random contractions spreading in the uncontrolled syncytium. These random 
contractions result in pseudoobstruction, spasticity and sphincteric achalasia (or failure 
to relax) (Wood, 2007).  Secretomotor neuronal hyperactivity is associated with 
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neurogenic secretory diarrhea and hypoactivity is associated with decreased secretion 
and a constipated state. Primary causes of abdominal pain of digestive tract origin are 
hypersensitivity or lower sensory threshold of sensory mechanoreceptors to distension 
and extensively strong muscular contractions (however it may also reflect abnormal 
processing of more central pathways in the spinal cord or/and in the brain). Therefore, 
knowledge of the gastrointestinal innervation is required for understanding the 
pathophysiology of ENS due to diabetes mellitus.  
 
1.4.1 Clinical diabetes 
 
Neuropathologic studies of human diabetic autonomic neuropathy suggest a 
prominence of autonomic nerve terminal damage or degeneration in various end organs, 
in the absence of significant neuronal loss within sympathetic ganglia (Schmidt et al., 
1993). In an extensive study of human biopsies, the neuropathologic hallmark of 
diabetic autonomic neuropathy was neuroaxonal dystrophy, markedly swollen structures 
originating as distal axonopathy, involving terminal axons (Schmidt et al., 1993; 
Schmidt, 2002).  It was also noted that neuroaxonal dystrophy in diabetes preferentially 
involved the prevertebral CG/SMG and largely spared the paravertebral SCG.    
In parasympathetic nerves, and specifically in the vagus nerve and its 
projections, axonopathy is also described but not with consensus. No morphologic 
abnormalities of the gastric wall or abdominal vagus were identified in diabetic 
gastroparesis using conventional histology techniques (Yoshida et al., 1988). This 
evidence was challenged by an ultrastructural study of vagus nerves from diabetic 
patients who had undergone vagotomy. The vagus nerve showed pathological changes 
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including: reduced myelinated fibre density, degeneration and regeneration of 
unmyelinated fibres, and capillary basement membrane thickening (Britland et al., 
1990). In another study the conduction velocity of afferent vagal pathways were 
reduced, suggesting vagal neuropathology (Tougas et al., 1992).  
Abnormal relaxation of the gastric fundus or excessive contraction of pylorus 
and small intestine of diabetic patients has been described as indicative of excitatory-
inhibitory motor neuron pathology (Camilleri & Malagelada, 1984;Mearin et al., 
1986;Samsom et al., 1998).  
  
1.4.2 Animal models of diabetes  
 
In humans, it is difficult to examine the nerves of autonomic nervous system, 
particularly those innervating the GI tract using non-invasive techniques (Samsom & 
Smout, 1997). In addition, the available information from diabetic patients is limited by 
the relatively small number of studies and the difficulties in obtaining biopsies and 
controlling for variables, such as the type and duration of diabetes and the adequacy of 
glycemic control. For this reason, research studies have extensively used rodent models 
to characterise and identify changes in intrinsic and extrinsic innervation in various 
segments of the GI tract during diabetes. Unlike many animal models of diabetic 
somatic sensory polyneuropathy, autonomic neuropathy in rodent animals shows many 
of the neuropathological features described in human subjects (Schmidt, 2002).         
There are three main categories of animal models of diabetes: a) those in which 
type 1 diabetes is induced by a chemical toxin (streptozotocin, STZ, or alloxan) that 
selectively destroys the insulin secreting pancreatic islet cells. The STZ-induced 
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diabetic rat is the most commonly used animal model mainly for practical reasons (see 
sections 1.4.3.1 and 1.4.3.2); b) those in which strains of mice or rats that are 
genetically predisposed to developing either type 1 or type 2 diabetes are selectively 
bred and c) dietary models of diabetes (Lincoln & Shotton, 2008;DeAngelis et al., 
2009).  
Two spontaneously diabetic rat strains (BB/Wor and BBZDR/Wor), that are 
closely related genetically, enable the comparison of neuropathic changes in type 1 and 
type 2 diabetes since the BB/Wor rat is a hyperglycaemic, hypoinsulinaemic model of 
type 1 diabetes and the BBZDR/Wor rat is a hyperglycaemic, hyperinsulinaemic model 
of type 2 diabetes. The onset of diabetes is confirmed by glucosuria, weight loss and 
hyperglycaemia.  
The non-obese diabetic (NOD) mouse is a model of insulin deficiency. Mice 
develop diabetes as the result of T-cell mediated autoimmune attack on the pancreatic 
islets, a process which begins at approximately 4–8 weeks of age (Sreenan et al., 1999). 
There is a greater incidence in females (80%) than males. NOD mice are 
hypoinsulinaemic and hyperglycaemic and require insulin replacement to survive. 
Another model for insulin deficient spontaneous diabetes is the Wistar Bonn/Kobori rat. 
These animals develop hyperglycaemia, glucosuria, hypoinsulinaemia and glucose 
intolerance (Nakama et al., 1985). The disease is prominent at 8–9 months and is seen 
only in males. 
Models for type 2 diabetes are obese rodents with gene mutation(s) in leptin 
production or metabolism. For example, the Zucker strain, first described in the 1960s 
(Zucker, 1965), has a mutation in the leptin receptor gene resulting in impairment in the 
ability of leptin to suppress food intake. The genetically diabetic db/db mouse 
(BKS.Cgm+/+Leprdb/j) used as a model of insulin resistant type 2 diabetes also has a 
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leptin mutation resulting in hyperglycemia, insulin resistance and hyperinsulinemia 
(Chen et al., 1996). Other genetic obese models are KKAy and ob/ob mice.  
Finally, the use of dietary methods for the induction of diabetic states is 
common, particularly because of the relevance to the human condition (DeAngelis et 
al., 2009). For example, the rationale for the use of high fructose as a test diet comes 
from the predominance of high fructose corn syrup in processed food and increased 
consumption of such food in Western society. 
 
1.4.3 Experimental studies 
1.4.3.1 Enteric neurons 
Gastrointestinal dysfunction in diabetes has been extensively investigated in 
experimental studies based on the hypothesis that pathological changes in the enteric 
nervous system underlie gastrointestinal symptoms. There is considerable evidence for 
this hypothesis. However, reported changes do not give a straightforward conclusion. 
One reason might be the different animal models used. For example, NOD mice 
have a short lifespan (5–8 weeks after onset of diabetic symptoms) and are difficult to 
study because of the rapid progression of the disease (Watkins et al., 2000). NOD mice 
show early onset and marked neuropathy in the prevertebral sympathetic ganglia. A 
comparative study demonstrated that the severity of the autonomic damage is much 
greater in NOD mice than in STZ treated animals (Schmidt et al. 2003). Also, in another 
study, STZ was suggested to be responsible directly for some neuronal reduction in the 
duodenum (Buttow et al., 1997).  
In addition, using the STZ-induced diabetic rat, there is extensive evidence that 
enteric neuronal subpopulations respond differently to diabetes. Some exhibit 
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degeneration, for example VIP neurons and extrinsic NA-containing nerve fibresfibres 
(Lincoln et al., 1984, Belai et al. 1988). However, CGRP-containing nerve fibres 
(intrinsic and/or extrinsic) exhibit a loss of neurotransmitter without evidence of 
degeneration (Belai et al. 1988). Finally some are unaffected, for example Substance P 
containing enteric neurons (Belai et al. 1985). Similarly in Crohn’s disease, a chronic 
disease that affects the intestine, the enteric neuronal changes in neurochemical 
composition are not homogeneous either (Belai et al., 1997).  It is interesting to note 
that nerves that contain the same neurotransmitter but innervating a specific region of 
GI tract are also differentially affected in diabetes (Belai et al., 1991). Thus, 
neurochemical plasticity or morphometric changes not only depend on the animal model 
used but also depend on the GI region, diabetes duration and the age of the animal.  
There is a relatively common agreement that inhibitory neurons are particularly 
affected in diabetes in comparison to intrinsic excitatory neurons. Numerous studies 
have investigated the expression of nNOS in the GI tract arguing that downregulation of 
the enzyme can be one of the main contributors of the dysmotility of the gut. Reduction 
in intestinal nNOS activity is associated with an impairment of the NANC relaxation 
(Martinez-Cuesta et al., 1995). Tagahashi et al. and Wrzos et al. in 1997 found 
reduction of NOS in gastric myenteric plexus of BB/Wor and STZ rats using various 
methods of analysis (Takahashi et al., 1997; Wrzos et al., 1997). Similar changes were 
found in NOD and obese mice in antrum and duodenum (Spangeus et al., 2000; 
Spangeus & El-Salhy, 2001). In the duodenum and ileum of STZ rats and the jejunum 
of BB/Wor rats, nNOS activity was also reduced (Martinez-Cuesta et al., 1995; Shotton 
& Lincoln, 2006;Zandecki et al., 2008). However, one study reported an increase in the 
tissue content of nNOS, but not the number of cell bodies in STZ-diabetic mice 
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(Adeghate et al., 2003) and another did not find any difference in nNOS levels in the 
small intestine and colon (Wrzos et al., 1997).   
Differential effects of diabetes have also been reported in the intrinsic inhibitory 
motor nerves containing VIP. In the gastric and intestinal myenteric plexus, the number 
of VIP-containing neurons and/or levels of VIP protein and mRNA have been reported 
to be increased, unchanged or decreased in response to diabetes (Belai et al., 1985; 
Belai et al., 1988;Belai et al., 1991;Belai et al., 1993;Adeghate et al., 2001). Using 
electron microscopy, Loesch et al. reported disrupted structural integrity of VIP 
containing neurons with degenerative processes occurring within the axons (Loesch et 
al., 1986). A study of VIP release following nerve stimulation suggested that impaired 
release of VIP at the terminal site and/or defective axonal transport may account for the 
accumulation of VIP in the neuronal cell body (Belai et al., 1987). VIP mRNA is also 
increased in diabetic rats indicating either defective mRNA breakdown or increased 
synthesis (Belai et al. 1993). However, a longer duration of diabetes results in a 
decrease in the number of VIP-positive cell bodies and VIP levels in the ileum and 
proximal colon, together with a decrease in density of VIP-positive fibres. To date there 
is no information in the literature as to whether the changes in VIP occur in nNOS-
containing neurons. The concentration of galanin, another inhibitory peptide, was 
reduced in the colon of obese diabetic mice (El-Salhy, 1998). However, an increase in 
galanin was observed in colon of NOD mice (El-Salhy, 2001) and ileum of 12-week-old 
STZ-induced diabetic rats (Belai et al., 1996). 
In contrast, cholinergic, serotoninergic and substance P-containing nerves were 
intact in the ileum-myenteric plexus of 8 w STZ-induced diabetic rats (Lincoln et al., 
1984). Also, endogenous release of the excitatory transmitters ACh, 5-HT, and 
substance P was unaffected by the diabetic state (Belai et al. 1985, Belai et al. 1987).  
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1.4.3.2 Sympathetic neurons 
Sympathetic innervation to alimentary tract is also affected in experimental 
diabetes. Ileal mesenteric nerves show dystrophic axonopathy the frequency of which 
increases with the duration of diabetes (Schmidt & Plurad, 1986). In addition, the 
activity of tyrosine hydroxylase (TH), the rate limiting enzyme that modulates the 
synthesis of catecholamines in sympathetic nerves, increases in CG and SMG of 
diabetic STZ rats (Schmidt & Cogswell, 1989).  Increased size of varicosities 
containing TH in the diabetic STZ rat ileum suggests neurodegeneration of the nerve 
fibres (Shotton et al., 2007). Increased activity of TH was accompanied with increased 
endogenous Neuronal Growth Factor (NGF) in CG /SMG (Schmidt et al., 2000). 
Neuroaxonal dystrophy in sympathetic nerves accompanied with diminished 
regenerative response has been reported in several diabetic animal models such as BB 
rat, NOD mice, STZ-induced diabetic rat and BBZDR/Wor rat (Yagihashi & Sima, 
1985; Schmidt et al., 2003; Schmidt et al., 2004). 
The selective distribution of lesions in sympathetic nerves occurs in 
experimental diabetes similarly to clinical diabetes. Paravertebral SCG or prevertebral 
IMG are relatively unaffected by diabetes compared to CG/SMG (Schmidt, 2002, Belai 
et al., 1991). CG/SMG of diabetic rats present identical ultrastructural changes with 
those observed in human studies. Experimental studies demonstrated accumulation of 
TH and increased NA levels in the CG and loss of NA in the ileum together with 
reduced TH-positive fibres with swollen varicosities (Belai et al., 1988, Schmidt & 
Cogswell, 1989, Shotton et al., 2007). Increased TH mRNA in mesenteric nerves is 
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accompanied by decrease in the level of dopamine-β-hydroxylase and NA in the ileum 
but not in the distal colon (Belai et al., 1991, Schmidt & Cogswell, 1989).  
It has been suggested that this differential response occurs because the 
mesentery nerves are lengthier or the hypertrophic/ hyperplastic small bowel of diabetes 
evokes these degenerative responses (Schmidt & Plurad, 1986; Schmidt & Cogswell, 
1989). However, the selective vulnerability of the prevertebral CG/SMG in diabetes was 
reproduced in vitro in response to glucose and oxidative stress challenge. CG/SMG 
showed a slower neurite regenerative capacity than SCG neurons in vitro after exposure 
to high glucose for 24 h. Low levels of oxidative stress selectively caused increased TH 
immunoreactivity in CG/SMG (Semra et al., 2004;Semra et al., 2006). These findings 
raise the question whether vulnerability in diabetes reflects properties of the neurons 
themselves. 
 
 
1.5 Pathogenetic mechanisms 
 
Important progress was made by the Diabetes Control and Complications Trial 
Research Group (DCCT) and the UK Prospective Diabetes Study Group, which 
confirmed that neuropathy is correlated with hyperglycaemia, and that strict glycaemic 
control can reduce the occurrence or progression of diabetic neuropathy (The Diabetes 
Control and Complications Trial Research Group, 1993). High glucose may affect 
neurons directly through several proposed metabolic pathways and indirectly through 
microangiopathy. 
Glucose is the major energy molecule for neurons of both peripheral and central 
nervous systems. The uptake of glucose by glucose carriers (for example GLUT1, 
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GLUT8) is not an insulin dependent process and depends on the extracellular 
concentration of glucose (Tomlinson & Gardiner, 2008b). Glucose is not stored in the 
form of fat and glycogen intracellularly in neurons as occurs in adipose tissue and liver, 
but is phosphorylated straight away and enters into glycolysis. This fact makes neurons 
vulnerable to excess glucose concentrations.  
Increased extracellular and intracellular glucose becomes toxic for the neuronal 
cell leading to various biochemical alterations. Thus, sustained or regular episodes of 
hyperglycaemia interfere with metabolic pathways (discussed below) that impact upon 
neuronal phenotype.  
In addition, microangiopathy is an undoubted accompaniment to diabetic 
neuropathy and its mechanisms for development centre on endothelial damage with 
features that include impaired vasodilation by NO, damage from oxidative stress, and 
alterations generated by the polyol pathway. Overall, diabetic vessels have more 
prominent impairment of vasodilatory mechanisms, favouring excessive functional 
vasoconstriction. Microangiopathy is then exacerbated by alterations in local oxygen 
release, contributing to an eventual cascade of hypoxia and ischaemia. Neuropathy may 
therefore be associated with abnormalities of oxygen delivery (Cameron et al., 2001). 
These two forms of high glucose involvement in diabetic neuropathy, direct and 
indirect, may eventually become parallel and synergistic (Theriault et al., 1997; 
Cameron et al., 2001). 
 
1.5.1 Metabolism of nutrients in neurons and cell respiration 
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The metabolism of glucose and fatty acids are non insulin dependent processes 
in neurons and, after entering the cell, they immediately undergo phosphorylation. After 
a series of catabolic biochemical processes, glucose and fatty acids are metabolised to 
acetyl CoA during the tricarboxylic acid (TCA) cycle in mitochondria (Campbell & 
Smith, 2000). The co-enzymes nicotinamide/ flavin adenine (NADH and FADH2) are 
also produced during the Krebs cycle.  NADH and FADH2 oxidation occurs and the 
hydrogen atoms that are removed release energy and they serve as electron donors to 
molecular oxygen in the electron transport chain.  
The electron transport chain is a series of enzyme complexes (oxidoreductase I, 
II & III and cytochrome c IV) in the inner membrane of mitochondria. The electron 
transport chain uses the energy released from the oxidation of NADH (complexes I, II 
& IV) and FADH2 (complexes II & III) to pump protons across the inner membrane of 
the mitochondria. This causes protons to build up in the intermembrane space, and 
generates an electrochemical gradient across the membrane. The energy stored in this 
potential is then used by ATP synthase to produce energy in the form of ATP (Campbell 
& Smith, 2000).  
The chemical energy stored in ATP is used to fuel most of the biochemical 
reactions of the neuron. For example, special proteins in the neuronal membrane use the 
energy released by the breakdown of ATP into ADP to pump certain substances across 
the membrane, to establish concentration differences between the inside of the neuron 
and the outside, for anterograde transport etc.  
 
1.5.2 Oxidative stress, anti-oxidants and diabetic neuropathy 
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As an unavoidable by-product of these biochemical processes, chemical species 
that contain unpaired electrons, the free radicals, are produced. Unpaired electrons 
increase the reactivity of the molecules (or atoms). Free radicals then react with all 
biological macromolecules to form new radicals that react with further macromolecules. 
The toxicity of free radicals thus arises in chain reactions and may cause lipid 
peroxidation (and disruption of cell membrane), protein damage or eventually 
apoptosis. Most common free radicals, with a varying degree of reactivity, are the 
reactive oxygen species (ROS) such as hydroxyl radical, superoxide anion. Other 
reactive molecules are, for example, the transition metals such as iron and copper, and 
the reactive nitrogen species (RNS) such as NO and peroxynitrite (Betteridge, 2000).  
The cell has defences to inhibit or delay these reactions, such as the anti-oxidant 
enzymes, dismutases, peroxidases and catalases. Superoxide Dismutase (SOD) in the 
mitochondrion converts the highly reactive superoxide to hydrogen peroxide and 
oxygen. Hydrogen peroxide is more stable than superoxide and it diffuses easier 
through the cell membrane. Catalase converts hydrogen peroxide to water and therefore 
its activity is required when SOD is active. The detoxification of hydrogen peroxide 
also occurs through glutathione peroxidases, present in the cytosol and mitochondria 
with the oxidation of glutathione (GSH). GSH is the most important cellular anti-
oxidant for neurons. To regenerate GSH, glutathione disulfide is reduced by NADPH 
and glutathione reductase. 
Vitamin C and vitamin E are dietary anti-oxidants. The anti-oxidants vitamin E 
(the generic name for the family of tocopherol related compounds), β-carotene and 
coenzyme Q are present in cell membrane and interrupt lipid peroxidation.  Vitamin C 
(ascorbic acid) scavenges an array of ROS including, hydroxyl, alkoxyl, peroxyl, 
superoxide anion, hydroperoxyl radicals and reactive nitrogen species such as nitrogen 
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dioxide, nitric oxide, and peroxynitrite at very low concentrations. In addition, ascorbic 
acid regenerates other anti-oxidants such as α-tocopheroxyl, urate and β-carotene 
radical cation from their radical species (Vincent & Feldman, 2004).  
When the balance between the production of free radicals and anti-oxidant 
defences is disturbed, oxidative stress is induced in the cell. During hyperglycemia, 
excess glucose metabolism evokes the overload of mitochondrial pathways and the over 
abundance of NADH and FADH2. Thus, increased production of free radicals occurs 
with the parallel depletion of anti-oxidants leading to oxidative stress. The 
mitochondria, the main source of ROS and RNS production, are the first cellular 
compartments that are affected.  
           Oxidative stress is important factor but it does not necessarily cause the onset of 
neuropathy. It may be a consequence rather than a primary cause of broad-based 
dearrangements since ROS and RNS production is intersected with other pathways 
(Betteridge, 2000;Figueroa-Romero et al., 2008).  
 
 
1.5.3 Altered NADPH and NADH metabolism 
 
NAD(H) and NADP(H) are involved in numerous pathways regulating energy 
metabolism, calcium regulation, antioxidation, gene expression and cell death. NAD(H) 
is prominent in its oxidised form and thus is used by enzymes that catalyse substrate 
oxidation. In contrast, NADP(H) is more abundant in its reduced form, therefore used 
by enzymes that catalyse substrate reduction (Pollak et al., 2007;Ying, 2008). Under 
pathological conditions, the ratio of the reduced and oxidised form of NAD(H)   
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(NAD+/ NADH) and NADP (NADP+/ NADPH) -termed the redox state of the cell- 
may change. In diabetes, it has been proposed that the polyol pathway leads to depletion 
of NADPH and furthermore excessive activity of the TCA cycle in mitochondria leads 
to an increase in NADH (Ido et al., 1997;Ido, 2007).  
The polyol pathway initiates a cascade of events, induced by the toxicity of 
intracellular glucose overload, in various cell types, including neurons. The enzyme 
aldose reductase metabolises the excess glucose in sorbitol and sorbitol dehydrogenase 
further metabolises sorbitol to fructose (Fig. 1.1). 
 
 
Figure 1.1: The polyol pathway 
 
 There are various signal transduction pathways that link the polyol 
intermediates with cellular stress but they are extremely complex. Among these is a 
metabolic flux that leads to the depletion of the anti-oxidant GSH. GSH depletion is 
linked with the deficiency of NADPH. Aldose reductase competes with glutathione 
reductase for NADPH which, of itself, participates in the production of GSH. Thus, one 
hypothesis is that coenzyme imbalances lead to anti-oxidant depletion and the cell is 
more susceptible to ROS. Another hypothesis is that the poorly membrane-permeable 
sorbitol accumulates in the cytosol and induces osmotic stress. This can also alter the 
anti-oxidant potential of the cell by the release of the osmolyte and anti-oxidant taurine. 
Although there is evidence supporting both hypotheses that possibly interrelate, there is 
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controversy between researchers (Oates, 2002; Obrosova, 2002). The polyol pathway 
has been the target of experimental studies in diabetes and aldose reductase inhibitors 
are currently undergoing phase III clinical trials (Schemmel et al., 2010).      
Imbalances in the ratio of redox co-enzymes may have several consequences in 
cell metabolism. NADPH/ NADP+ ratio changes have a direct effect on the   anti-
oxidant capacity, affecting GSH/GSSG concentrations, inhibiting the reactivation of 
catalase and the pathway involved in the regeneration of thioredoxin. Abundance of 
NADH in mitochondria can increase the proton gradient across mitochondrial 
membranes and consequently potentiate ROS generation from the electron transport 
chain.  
In summary, changes in the NAD+/ NADH equilibrium may facilitate a series of 
reactions requiring oxidation thus inducing reductive stress (“pseudohypoxia”) and 
imbalance of NADP+/ NADPH may affect detoxification pathways. These mechanisms 
have been studied in vascular dysfunction in diabetes but there is little evidence in 
peripheral nerves.  
 
 
1.5.4 Carbonyl Stress and AGEs 
    
The AGE hypothesis proposes that chronic accelerated chemical modification of 
macromolecules by glycation in diabetes alters the structure and function of proteins, 
lipids and nucleotides contributing to pathophysiology and the development of diabetic 
complications. Glycation is the result of non-enzymatic addition of glucose or other 
saccharides to proteins, lipids and nucleotides. Glucose and other glycolytic 
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intermediates can bind to protein amino groups which first form a Schiff’ s base that 
then progresses to an Amadori product which is stable. This results in the irreversible 
formation of AGEs and the subsequent cross linking of proteins damaging their 
structure.  
Dysfunction also arises through the increased production of the carbonyl species 
glyoxal, methylglyoxal, and 3-deoxyglucosone. These products are physiological α-
oxoaldehydes formed by lipid peroxidation, glycation, and degradation of glycolytic 
intermediates (Abordo et al., 1999). Thus, α-oxoaldehydes are produced in the course of 
metabolism under normal conditions by both enzyme and non enzyme catalysed 
reactions. Their detoxification occurs mainly via the glyoxalase system that comprises 
two enzymes, glyoxalase I and II, and uses significant amounts of reduced glutathione. 
Increased production of α-oxoaldehydes or decrease of their detoxification systems 
results in the non enzymatic reaction and modification of various macromolecules. 
Depending on the macromolecule affected, these reactions cause a direct inhibitory 
effect to the affected macromolecules and the formation of AGEs leading to disturbance 
of cell function.  This phase of toxicity is designated carbonyl stress. A second phase of 
toxicity leads to free radical production and oxidative stress (review by Kalapos, 2008).  
AGEs are formed at an early stage in the disease process and the increase in 
their levels is systemic. AGE formation in cells leads to intra- and extracellular cross 
linking of proteins and protein aggregation. AGEs then interact with their receptor, 
RAGE, which is their main receptor appearing in several isoforms and in many cell 
types including neurons.  RAGE alters intracellular signalling and has multiple specific 
downstream signalling targets including mitogen activated protein kinases (MAPK), 
p21 ras, nuclear factor κB (NFκB) and multiple other intermediates thus altering the 
gene expression (Tomlinson & Gardiner, 2008a; Tomlinson & Gardiner, 2008b).  
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1.5.5 Neurotrophic support deficiency and alterations in gene expression 
 
Diminished neurotrophic support (NGF, insulin, C peptide, Insulin Growth 
Factor-1 (IGF1)) may also contribute to neurite and axonal degeneration in diabetic 
neuropathy. Deficiency of neurotrophic factors is implicated in defective interaction 
with surrounding cells and depressed axonal transport. Growth factors initiate signal 
transduction pathways to promote axonal and dentrite survival and regeneration. Genes 
may be upregulated or downregulated by the growth factor-promoted signal to generate 
a response to environmental stimuli or damage. Nevertheless, despite its efficiency in 
experimental diabetes, in phase III clinical trials, NGF administration failed to relieve 
neuropathy in diabetics (Apfel, 2002).  
The activation of MAPK such as c-Jun N terminal kinase and p38, may arise 
from a combination of events (Tomlinson, 1999; Yang et al., 2003; Tomlinson & 
Gardiner, 2008b). Moreover, changes in the expression and activation of protein kinase 
C (PKC) has also been implicated in diabetic neuropathy occurring via the de novo 
synthesis of diacylglycerol (Eichberg, 2002). The main targets of kinases are 
transcription factors and the phosphorylation of these factors may occur post 
translationally leading to altered neuronal phenotype. Finally, the activation of the 
nuclear enzyme, poly(ADP-ribose) polymerase (PARP) contributes to early diabetic 
sensory neuropathy by mechanisms that may include oxidative stress (Ilnytska et al., 
2006).   
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It would be useful to develop a model for diabetic gastrointestinal neuropathy to 
directly manipulate the immediate environment of myenteric or sympathetic ganglia, 
allowing the effects of altered metabolism or treatments to be observed. While in vivo 
studies provide physiological and cellular details of diabetic neuropathy, the complexity 
of the system obscures the details of molecular events under glucose stress. The use of 
simpler in vitro systems is hence very important to map these events. It is generally 
assumed that the mechanisms underlying diabetic distal sensory polyneuropathy also 
account for autonomic neuropathy but much of the work revealing pathological 
mechanisms has been carried out through the study of sensory neurons in vitro. 
Embryonic DRG neurons have mainly been utilised as an in vitro model of diabetic 
sensory neuropathy (Russell et al., 1999;Vincent et al., 2005a), but adult DRG neurons 
do not respond in the same way to high glucose in vitro (Tolkovsky, 2002;Huang et al., 
2003). For example, apoptotic cell death has been reported as the response to high 
glucose in vitro but it is not a feature of diabetes in vivo (Schmidt, 2002; Tolkovsky, 
2002). Furthermore, the effect of high glucose in vitro is greater when the neurons are 
dissociated prior to culture rather when explants are used (Semra et al., 2004). Thus, 
there is a requirement for a model of diabetic gastrointestinal neuropathy that allows the 
detailed study of the changes that occur in vivo. 
Thus, the specific aims of this thesis are: 
1) to establish in vitro models of diabetic gastrointestinal neuropathy and study 
subopulations of adult myenteric neurons in wholemount preparations following 
exposure to stimuli that mimic the diabetic environment; 
2) to use the in vitro models to investigate the ability of therapeutic agents to 
prevent diabetic gastrointestinal neuropathy; 
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3) to investigate the effect of high extracellular glucose on NAD(P)H metabolism 
in living neurons from explants of sympathetic ganglia that either undergo 
degeneration in diabetes or are resistant to change.  
 
Chapter 2: Establishment of the in 
vitro models 
 
2.1 Introduction 
 
A causative role of hyperglycemia for the pathology of diabetic complications, 
including neuropathy, was demonstrated about 20 years ago. The DCCT study for type 
1 diabetes and UK prospective study for type 2 diabetes correlated hyperglycaemic 
blood glucose levels, measured by glycated hemoglobin levels (HbA1c) with diabetic 
complications (The Diabetes Control and Complications Trial Research Group, 
1993;UK Prospective Diabetes Study Group, 1998). Intensified insulin treatment 
reduced the neurological deficits of diabetic polyneuropathy. Patients with intensified 
insulin treatment for 4 years (HbA1c levels of 7%) showed a clinically relevant and 
statistically significant improved nerve function when compared to the conventionally 
treated group with HbA1c levels of approximately 9%. Hence, hyperglycaemia per se 
has been proposed as the pathogenic factor for the onset and progression of diabetic 
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neuropathy. However, hyperglycaemia induces a complex interaction between 
metabolic and vascular abnormalities suggesting multifactorial pathways in the 
pathogenesis of diabetic neuropathy. 
 
2.1.1 AGEs & methylglyoxal  
 
The toxic effect of hyperglycaemic fluctuations has been linked with the 
formation of AGEs. Increased glucose and other sugar derivatives in plasma undergo 
the Maillard reaction, a cascade of non enzymatic reactions with amine substrates of 
proteins, lipids and nucleic acids. The predominant early product of these reactions is 
fructosamine (N6-fructosyl-lysine) that degrades slowly to form more stable advanced 
glycation adducts. Considering the numerous molecules that sugars can attach to via the 
Maillard reaction, there are a wide variety of AGEs recognised using chromatographic 
and immunochemical techniques. Hydroimidazolones, N6-carboxymethyl-lysine 
(CML), N6-(1-carboxylethyl)-lysine (CEL), pyrraline, bis(lysyl) imidazolium cross-
links glyoxal-, methylglyoxal- and 3-deoxyglucosome- derived lysine dimers (GOLD, 
MOLD and DOLD respectively) are among recognised forms of AGEs (Thornalley, 
2002). Some of them fluoresce and have a characteristic brown colour, for example, 
pentosidine and argipyrimidine. Some AGEs however, are short lived and their 
concentration depends on proteolysis and protein turnover (Ahmed & Thornalley, 
2007).  
Additionally, in the cytosol of cells like neurons that accumulate increased 
levels of glucose, concentrations of dicarbonyls increase and they can also lead to AGE 
formation (Brownlee, 2001). Dicarbonyls have low molecular weight and extremely 
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high chemical activity, even at low concentrations. Methylglyoxal is of particular 
importance in diabetes because its biogenesis derives not only as a parallel product of 
the Maillard reaction but also from glycolytic intermediates or from lipid peroxidation 
as well (Thornalley, 2005). Glycolytic intermediates and subsequent triose phosphate 
formation or threonine catabolism can accelerate significantly the formation of 
methylglyoxal. Methylglyoxal can diffuse passively in cell membranes. Its biological 
form is of two kinds; the unbound form that has very short survival and it is particularly 
difficult to quantify; and the bound form which is found on protein residues as a major 
glycation adduct (Turk, 2010). In order to protect the cell from methylglyoxal toxicity, 
its physiological levels are kept low mainly by the glyoxalase system, using reduced 
GSH as a rate limiting factor. Inefficiency of the related scavenger system (for example 
GSH depletion) and alterations in cell metabolism can provoke carbonyl stress 
(Thornalley, 2003a).   
Carbonyl stress is an acute metabolic event characterized by accelerated tissue 
damage. Free amino groups of amino acids, phospholipids, peptides or nucleic acids 
react non enzymatically with the carbonyl group of methylglyoxal to form various 
modified macromolecules or carbonyl adducts. Hydroimidazolones, CEL and MOLD 
are important AGEs, derived from methylglyoxal -induced irreversible modifications of 
deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and amino acids (Turk, 2010).  
Endogenous AGE formation and carbonyl stress can promote the pathology of diabetic 
complications but their impact has not been yet clarified in diabetic gastrointestinal 
neuropathy.   
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 2.1.1.1 Functional effects of AGEs on neurons 
Axonal atrophy and defective axonal transport is a characteristic feature of 
diabetic neuropathy and several lines of evidence have linked impaired cytoskeletal 
function with the formation of AGEs. A significant increase in the amount of 
pentosidine was found in both the cytoskeletal and myelin fractions of sural nerve 
biopsies of diabetic patients (Ryle & Donaghy, 1995). Similar changes occur in sciatic 
nerves of STZ-induced diabetic rats (Ryle et al., 1997).  In contrast, in the same study, 
the cytoskeleton of CNS nerves was more resistant to non enzymatic glycosylation. 
Actin and tubulin in CNS neurons are increasingly glycosylated in vitro (Williams et al., 
1982; Pekiner et al., 1993). The formation of amorphous α and β tubulin aggregates and 
the inhibition of guanosine diphosphate-dependent tubulin polymerisation may 
compromise microtubule formation and neuroaxonal regeneration. Vlassara and 
colleagues found a three fold increase in amino acid glycosylation–(especially lysine) 
from sciatic and femoral nerves of diabetic rats and dogs in comparison to controls 
(Vlassara et al., 1981).  
Functional effects of AGEs in neuronal cells arise also from the modification of 
the peripheral nerve myelin, endoneurial microvessels and extracellular matrix. 
Sugimoto et al. found extensive CML immunoreactivity in biopsies of sural, peroneal 
and saphenous nerve tissue of patients with diabetic neuropathy. CML staining was 
located in the perineurium, axons and Schwann cells of myelinated fibres, in 
unmyelinated fibres, in endothelial cells and pericytes of endoneurial microvessels, and 
in interstitial collagen and basement membranes of the perineurium (Sugimoto et al., 
1997). It has been suggested that glycation of the extracellular matrix proteins of the 
perineurium, laminin and fibronectin, accompanied by a reduction in neurotrophic 
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factors, contributes in neuroaxonal degeneration and failing attempts of the nerve cones 
to regenerate in diabetic neuropathy (King, 2001;Duran-Jimenez et al., 2009).  
Furthermore, extracellular AGEs interact with their receptor, RAGE and this 
interaction activates a cascade of signal transduction pathways that can cause oxidative 
stress (Vincent et al., 2007a). RAGE is expressed predominantly in lung, endothelial 
cells and Schwann cells (Wada & Yagihashi, 2005). In neurons, RAGE mRNA was 
increased in peripheral epidermal axons, sural axons, and sensory neurons within 
ganglia of STZ diabetic rats and this increase was related with pathological changes 
(Toth et al., 2008).  Expression of RAGE has also been demonstrated in enteric neurons 
(Korenaga et al., 2006; Jeyabal et al., 2008).  
 
2.1.1.2 Correlation of AGEs with HbA1c levels 
Higher HbA1c levels were correlated with decreased performance in autonomic 
and sensory neurological tests during DCCT trial (The Diabetes Control and 
Complications Trial Research Group, 1993). This shows that increased glycosylation is 
a significant risk factor to diabetic neuropathy. However, HbA1c measurements can 
only indicate the glycosylation of circulating haemoglobin and cannot indicate 
intracellular glycosylation levels.  
 
 
2.1.2 Oxidative stress and accelerated ageing 
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Oxidative stress has been implicated in neurodegenerative diseases and ageing 
and has also been investigated extensively in diabetes. It has been associated with the 
pathogenesis of diabetes causing destruction of β cells and of the secondary 
complications of diabetes (Rosen et al., 2001). Clinical and experimental evidence 
demonstrates that generation of free radicals is increased in both type 1 and type 2 
diabetes (Traverso et al., 1998). The end products of free radical attack are reliable 
indicators of oxidative stress. Thus, DNA damage, modified proteins and increased lipid 
peroxidation have been documented in various types of cells. Oxidized proteins have 
been reported to be significantly higher in diabetic patients with complications, than in 
those without complications (Rosen et al., 2001). Endothelial cells constitute major sites 
for the production of reactive species (Brownlee, 2001) and in neurons, hyperglycaemia 
is associated with oxidative stress, mitochondrial swelling and deregulation of inner 
membrane potential (Vincent et al., 2002;Vincent et al., 2004a;Vincent et al., 2005a;Yu 
et al., 2006). Contributory factors like endoneurial hypoxia, transition metal imbalances 
and hyperlipidemia are additionally linked with increased free radical generation in 
neurons (Low et al., 1997;Pop-Busui et al., 2006;Vincent et al., 2009).  
Multiple pathways cause excess free radical production (Feldman, 2003;Vincent 
et al, 2004b;Pop-Busui et al., 2006;Figueroa-Romero et al., 2008). Increased metabolic 
flux of glucose through the polyol pathway induces NAD(P)H redox imbalances;  
reactive species can also be generated as a result of auto-oxidation of glucose, glucose 
metabolism, formation of AGEs and the action of AGEs on RAGE. PKC activity is 
regulated through the redox status; mitochondrial functional impairment and swelling 
are associated with oxidative stress. In addition, the sensitivity to oxidative stress due to 
anti-oxidant or reductant deficiencies has been extensively described. For example, 
colons from diabetic patients had decreased amounts of the non-enzymatic anti-oxidant 
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GSH and this correlated with higher HbA1C levels and diabetes duration. There was 
also an increased expression of SOD, possibly as a compensatory mechanism 
(Chandrasekharan et al., 2011). 
In conclusion, oxidative stress plays a significant role in the onset and 
progression of diabetes. Whether oxidative stress has a causative role in diabetic 
gastroenteropathy has received less attention. In addition, it is not known if the 
proposed pathways described above contribute to changes in different neurons within 
the enteric nervous system. This is an important consideration since it is known that 
subpopulations of enteric neurons are affected differently in diabetes (see below). 
Studies in sensory neurons suggest that oxidative stress is a unifying mechanism 
(Vincent et al. 2004b), but this has yet to be examined in the enteric nervous system. 
 
2.1.3 Culture models for the study of diabetic neuropathy 
 
Much of the evidence concerning the mechanisms underlying diabetic 
neuropathy derives from in vitro studies. In vitro studies provide useful disease models 
to map molecular events of pathologic and neuroprotective mechanisms in more detail. 
It is also important to investigate the pathways involved under diabetic conditions 
excluding the vascular abnormalities as a contributing factor and the use of in vitro 
models facilitates this attempt. Thus, the in vitro approach allows the investigation of 
mechanistic questions that are not possible in animal models. Experimental models and 
genetic manipulations to animals then allow the study of the relevance of these 
mechanisms in vivo (Vincent et al. 2005a).  
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Primary cultures from DRG neurons are the most common in vitro model of 
diabetic sensory polyneuropathy (Hattangady & Rajadhyaksha, 2009). Most of the 
significant findings come from studies using primary DRG dissociated neurons from 
normal untreated rodent embryos in which the first step was to examine the defects in 
neuronal metabolism produced by high glucose. It was shown, using electron 
microscopy, that high glucose affected not only neurite outgrowth but also the 
percentage of cultured neurons that die (Russell et al., 1999). Programmed cell death 
was also demonstrated by immunohistochemical techniques examining the activation of 
caspase 3 and Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling 
(TUNEL) staining. Under high glucose concentrations, apoptosis occurred through the 
induction of ROS and mitochondrial degeneration with enlargement and swelling, 
disrupted inner cristae, mitochondrial membrane depolarization and decrease of 
absolute levels of ATP (Russell et al., 2002). 
Using the same model, a series of studies shed light on oxidative stress, 
mitochondrial dysfunction, changes in morphology, anti-oxidant systems, together with 
the time course of changes and feedback mechanisms. Short term hyperglycemia 
induced superoxide formation and lipid peroxidation in 1 h, oxidative stress and 
apoptosis in 2 hrs and by 3-6 hrs, increase of anti-oxidant potential, but insufficient to 
protect DRG (Vincent et al. 2005a). RAGE expression was demonstrated in DRG after 
exposure to ligand but not high glucose. Downstream pathways such as transient 
activation of MAPK and PI3K/Akt, subsequent NADPH oxidase activation and 
oxidative stress were also shown (Vincent et al., 2007a). Intrinsic and extrinsic anti-
oxidants and uncoupling proteins have all been shown to be protective (Vincent et al., 
2004a; Vincent et al., 2005b;Vincent et al., 2007b).  
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However, the extrapolation of the above findings using embryonic cultures may 
be problematic because the developmental stage of neurons can influence the results. A 
study with primary cultures of sympathetic ganglia using neonatal and adult dissociated 
neurons showed that the age of neurons affects the response to high glucose and the 
ability of NGF to protect against the effect of high glucose (Semra et al., 2009). Adult 
rat sympathetic and sensory neurons differ significantly from embryonic neurons. 
Immature neurons have an absolute requirement for NGF for survival and need 30 mM 
glucose for optimal growth. In contrast, adult neurons can survive in the absence of 
NGF and at lower concentrations of glucose (7-10mM). Explants from newborn and 
older human myenteric plexus in culture showed differences in growth patterns, and 
specifically a different degree of neurite outgrowth and glial proliferation (Schafer & 
Mestres, 1997).  
Interestingly, in primary cultures of adult vagal and DRG explants from diabetic 
animals, high glucose induced a regenerative effect, challenging the notion of glucose-
induced cell death (Sango et al., 1991; Sango et al., 2002). When the morphological 
features and the neurite regeneration ability were investigated, no apoptotic cell death 
was found by light and electron microscope techniques or TUNEL staining. In contrast, 
there was enhanced neurite regeneration and upregulated expression of variable growth 
factors. In another study, hyperglycemia did not induce apoptosis of adult DRG neurons 
or Schwann cells but restricted axonal regeneration and Schwann cell proliferation 
(Gumy et al., 2008).  
In vitro studies investigating diabetic gastroenteropathy have used various 
models. Studies from this laboratory, using two sources of adult rat sympathetic 
dissociated neurons, demonstrated that neurons from the prevertebral CG/SMG that 
supplies the upper GI tract are particularly sensitive to high glucose in comparison to 
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neurons from the paravertebral SCG (Semra et al., 2004;Semra et al., 2009).  Using 
explants of the same ganglia it was also found that low levels of oxidative stress 
induced by menadione selectively caused the accumulation of TH that also occurs 
selectively in prevertebral ganglia in vivo (Semra et al., 2006). Enteric neuronal murine 
cell lines have also been used to show that treatment with high glucose increased 
cleaved caspase 3, decreased the survival pathway PI3K/Akt, and that an anti-oxidant 
reversed these responses (Chandrasekharan et al., 2011). Similar results were also found 
using primary cultures of embryonic enteric dissociated neurons. Hyperglycemic insult 
induced apoptosis, decreased Akt phosphorylation and these responses were inhibited 
by Glial cell line-derived neurotrophic factor (Anitha et al., 2006). Recently, dissociated 
enteric neurons from neonatal rats have been used to assess the effect of oxidative stress 
in vitro and hydrogen peroxide was shown to cause neuronal cell death (Korsak et al., 
2012).   
A model introduced by Korenaga et al. (2006) was whole mount preparations of 
longitudinal muscles with adherent myenteric plexus from the duodenum of adult male 
rats exposed to AGEs. AGEs induced RAGE expression in myenteric neurons and 
suppressed the expression of nNOS. However, this study was restricted to the nNOS 
myenteric subpopulation. We aim to use a similar in vitro model to study different 
subpopulations of myenteric neurons that respond differently in diabetes.  The use of a 
wholemount preparation has the advantage of maintaining the normal environment of 
the myenteric neurons and avoiding the disruption associated with dissociation of the 
neurons. In addition, the use of cell lines does not allow the investigation of the 
different subpopulations of neurons that occur within the myenteric plexus in vivo. 
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2.1.4 Heterogeneity of enteric neuronal responses in diabetes  
 
Previous studies from this laboratory using the STZ-induced diabetic rat model 
have shown that subpopulations of myenteric neurons are affected differently in 
diabetes. Changes include alterations in cellular morphology and chemical coding. 
Some enteric neuronal subpopulations exhibit degeneration, some undergo change in 
neurotransmitter content without degeneration while some are unaffected. It has been 
shown previously that the main intrinsic inhibitory motor neurons are particularly 
affected in diabetes resulting in abnormalities in smooth muscle relaxation, 
accompanied by increased excitatory messaging (Chandrasekharan & Srinivasan, 2007). 
In particular, it has been shown that VIP-containing neurons degenerate with 
accumulation of VIP in the cell body, while diabetes causes a reduction in the 
expression of nNOS in myenteric neurons (Shotton et al., 2004; Shotton & Lincoln, 
2006;Shotton et al., 2007). Recently, in this laboratory, the subpopulation of myenteric 
neurons that contains calbindin has been shown to be resistant to change in diabetes 
(Voukali et al. 2011). Yet, it is not known if individual subpopulations are more or less 
susceptible to specific pathways implicated in the development of neuropathy. 
 
Therefore, the aim of this study was to investigate whether the pattern of change 
that occurs in myenteric neurons in diabetes in vivo can be reproduced in vitro using a 
myenteric plexus/muscle preparation from the adult rat ileum. We chose representative 
enteric subpopulations that are differently affected by diabetes. The responses of VIP-, 
nNOS- and calbindin-containing neurons to oxidative stress, carbonyl stress, high 
glucose and AGEs were examined to investigate their potential contribution to the 
development of neuropathy. 
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2.2 Materials and methods 
2.2.1 Culture preparations 
 
Adult male Sprague-Dawley rats (275-350 g, 9-12 weeks old) were killed by 
CO2 asphyxiation. All procedures described were in compliance with Home Office 
regulations. The ileum was dissected, cleaned, and stored in a dissecting buffer of 
Hank’s balanced salt solution (HBSS) containing 10 mM glucose and 1% penicillin-
streptomycin. Approximately 4 cm of the gut were put on a 2 ml stripette, scored gently 
with forceps and the myenteric plexus and the muscle layers were peeled away under a 
dissecting microscope. The myenteric plexus/muscle preparations were then washed in 
antibiotic wash solution (HBSS containing 1% penicillin-streptomycin, 2% gentamycin 
and 2% 5mg mlˉ¹ metronidazole). The tissue was cut into segments approximately 
1cm², stretched and pinned onto Sylgard (VWR, Buffalo Grove, IL, USA). The samples 
were cultured in defined culture medium containing 10 mM glucose (M199, 
supplemented with 1% L-Glutamine, 1% Hepes Buffer, 1% penicillin-streptomycin , 
0.35% Pathocyte-4- bovine serum albumin (BSA), 60 ng mlˉ¹ progesterone, 0.016 mg 
mlˉ¹ putrescine, 400 ng mlˉ¹ l-thyroxine, 38 ng mlˉ¹ sodium selenite, 340 ng mlˉ¹ 
triiodothyronine, 100 μg mlˉ¹ transferrin).  
The myenteric plexus/muscle preparations were exposed to a range of different 
stimuli in order to mimic the diabetic environment: a) for oxidative stress, 1 μM 
menadione sodium bisulfite was added to the medium, b) for hyperglycaemia, the 
medium contained additional glucose to give a final concentration of 30 mM., c) for 
carbonyl stress, a range of different concentrations of methylglyoxal (1, 10, 50, 100 and 
500 μM) were examined and d) for AGEs 250 μg mlˉ¹ BSA-AGE (Biovision Research 
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Products, CA, USA) was added. Control preparations were maintained in 10mM 
glucose in parallel. All preparations were maintained for 24h at 37
o
C gassed with 95% 
O2 and 5% CO2.   
The samples were fixed in 4% paraformaldehyde (PFA) for 18-24h at 4 °C. 
Samples that had not been subjected to culture (in situ preparations) were also included 
in the immunohistochemistry experiments. Myenteric plexus/muscle preparations were 
washed and stored in phosphate buffered saline (PBS) merthiolate (0.05%) at 4 °C 
before processing. All chemicals mentioned above were obtained from Sigma, Poole, 
UK unless stated otherwise.  
 
2.2.2 Immunofluorescence procedures: double staining for VIP, nNOS, or calbindin with 
HuC/D. 
The myenteric plexus/muscle preparations were placed, longitudinal muscle 
uppermost, onto microscope slides and processed for immunohistochemical localisation 
of nNOS, VIP, and calbindin. In order to evaluate the relative frequency of the positive 
cell bodies, anti-Human Neuronal Protein (anti-HuC/D) was used to label all neuronal 
cell bodies in the myenteric plexus. The myenteric plexus/muscle preparations were 
incubated for 1 hour in blocking solution containing 10 % normal horse serum (Gibco-
Invitrogen, Paisley, UK) and 0.1% Triton X100 in PBS merthiolate. Primary antisera 
were diluted in the above blocking solution (rabbit polyclonal anti-nNOS, epitope 
corresponding to amino acids 2-300 mapping at the N-terminus of nNOS, Santa Cruz, 
CA, USA, 1:500, rabbit polyclonal anti-VIP, Immunostar Inc., Hudson, WI, USA, 
1:500, rabbit polyclonal anti-Calbindin D28k, Swant, Bellinzona, Switzerland, 1:1000). 
The myenteric plexus/muscle preparations were incubated with the primary antisera 
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overnight. After being washed in PBS containing 0.1% X100 Triton, the preparations 
were incubated in blocking solution containing 10% normal goat serum (Gibco-
Invitrogen, Paisley, UK) and 0.1% Triton X100 in PBS merthiolate for 1 hour.  Samples 
were then incubated overnight with mouse monoclonal anti-HuC/D (Molecular Probes 
Probes, Eugene, OR, USA) diluted 1:200 in the above solution. Finally, the samples 
were washed, incubated for 1 hour in the dark at room temperature with Alexa 488 
Donkey anti-Rabbit (Molecular Probes, Eugene, OR, USA) and Cy3 Goat anti-Mouse 
(Jackson ImmunoResearch Laboratories, West Grove, PA, USA) diluted 1:100 in PBS 
Triton, washed, mounted and the coverslips sealed. All procedures were carried out at 
room temperature. 
 2.2.3 Analysis and statistics 
The samples were processed in parallel and analysed on a Zeiss fluorescence 
microscope (Carl Zeiss Ltd., Welwyn Garden City, UK). For each sample, a minimum 
of 200 cell bodies positive for HuC/D was assessed for the presence or absence of 
nNOS, VIP or calbindin. The proportion of positive nNOS, VIP or calbindin cell bodies 
were expressed as a percentage of the number of HuC/D-immunoreactive myenteric 
neurons. In addition, the average number of HuC/D-positive neurons per ganglion was 
assessed by counting the number of HuC/D-positive neurons in six ganglia per 
preparation.  
The data were analysed with GraphPad Prism 3 software using one way analysis 
of variance followed by Neumann-Keulls post hoc comparisons, or using an unpaired 
Student’s t test, where P < 0.05 was taken to indicate statistical significance. The 
samples were also photographed using a Canon EOS Elan II digital camera and 
micrograph pictures were produced using Photoshop Elements 8.0 software.  
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2.3 Results 
2.3.1 Effect of culture 
 
Comparisons were made between the immunohistochemical staining of 
preparations that had been fixed immediately (in situ) and those that had been 
maintained for 24h in vitro to examine the effects of culture per se and the results are 
given in Table 2.1A. The number of HuC/D-positive neurons/ganglion was unaffected 
by culture. However, the percentages of HuC/D-positive neurons that contained VIP, 
nNOS or calbindin were all significantly increased following 24h in culture under 
control conditions.  
Before assessing the effects of the stimuli in vitro, preliminary experiments were 
carried out to establish that, at the concentrations used, the stimuli did not affect the 
number of HuC/D-positive neurons per ganglion. The results are given in Table 2.1 B. 
Exposure of myenteric plexus/muscle preparations to oxidative stress, high glucose, 
carbonyl stress (explained below) or AGEs for 24h had no significant effect on the 
number of HuC/D-positive neurons per ganglion.  
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Table 2.1: Characterisation of myenteric plexus in vitro. 
 
A. Effect of Culture 
 
 
In Situ 
 
Control 
Culture 
(10mM glucose) 
 
 
VIP 
(% HuC/D-positive neurons) 
 
3.18  0.18 
(10) 
 
10.13  0.82 
(12) 
 
p < 
0.001 
 
nNOS 
(% HuC/D-positive neurons)  
 
22.87  1.96 
(10) 
 
31.94  2.13 
(10) 
 
p < 0.01 
 
Calbindin 
(% HuC/D-positive neurons) 
 
19.30  2.46 
(10) 
 
30.47  4.03 
(10) 
 
p < 0.05 
 
HuC/D-positive neurons 
(No. per ganglion) 
 
50 1 
(6) 
 
45  3 
(6) 
 
NS 
 
B. Effect of Stimuli in vitro 
(No. HuC/D-positive neurons 
per ganglion) 
 
Control 
Culture 
(10mM glucose) 
 
Plus Stimulus 
 
 
Oxidative Stress 
(1M Menadione) 
 
45  3 
(6) 
 
42  1 
(6) 
 
NS 
 
High Glucose 
(30mM) 
  
40  2 
(6) 
 
NS 
 
Carbonyl Stress 
(10M Methylglyoxal) 
  
43  2 
(6) 
 
NS 
 
Advanced Glycation Endproducts 
(250 g mlˉ¹ BSA-AGE) 
  
42  2 
(6) 
 
NS 
Data have been given as the mean ± SEM and the numbers of separate culture 
preparations used to provide the data are given in brackets.  
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2.3.2 Effects of stimuli on VIP-, nNOS- and calbindin-positive neurons in vitro 
 
In all cases, control preparations (10 mM glucose) were maintained in parallel 
with preparations exposed to the stimuli mimicking aspects of the diabetic environment 
for comparison. 
 
2.3.2.1 Oxidative stress 
Representative micrographs demonstrating immunohistochemical staining for 
HuC/D together with VIP, nNOS or calbindin, with and without exposure to menadione 
to induce oxidative stress, are given in fig. 2.1 A-C. As has been reported previously, 
HuC/D labelled the cell bodies of all myenteric neurons without staining the nerve 
fibres providing a pan-neuronal marker with which numbers of neurons were easy to 
assess (Lin et al., 2002). Double labelling enabled the number of VIP-, nNOS and 
calbindin-containing neurons to be assessed as a percentage of the HuC/D-positive 
neurons and the results are given in fig. 2.2. Relative to control preparations maintained 
for 24h in 10 mM glucose, exposure to menadione caused a significant increase (p < 
0.01) in the proportion of HuC/D-positive neurons expressing VIP and a significant 
decrease (p < 0.01) in the proportion of HuC/D-positive neurons expressing nNOS. 
Calbindin expression was unaffected by exposure to oxidative stress. 
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Figure 2.1: Effect of oxidative stress on myenteric neurons. Photomicrographs show the 
immunoreactivity of VIP (A), nNOS (B) and Calbindin (C) double labelled with the 
neuronal marker HuC/D. Left panels depict staining of control preparations maintained 
for 24h in vitro and right panels depict samples after exposure to menadione to induce 
oxidative stress. Green fluorescence indicates VIP, nNOS or Calbindin labelling and red 
fluorescence HuC/D. The arrows indicate co-localisation with HuC/D (yellow). Scale 
bars represent 50 μm. 
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Figure 2.2: Effect of oxidative stress on the relative number of VIP, nNOS and 
Calbindin immunoreactive cell bodies. Neurons containing VIP, nNOS or calbindin are 
expressed as a percentage of the number of HuC/D-positive neurons. Clear bars 
represent data from controls and black bars represent data from preparations after 
exposure to menadione (Men). Note the significant increase of VIP positive cell bodies 
and decrease of nNOS positive cell bodies following exposure to menadione while 
calbindin-positive neurons were unaffected. Data are expressed as the mean ± SEM, n = 
10, (** p < 0.01, by non paired Student’s t-test). 
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2.3.2.2 Effect of different methylglyoxal concentrations 
Myenteric plexus/muscle preparations were exposed to a range of different 
methylglyoxal concentrations in culture. The higher concentrations of methylglyoxal 
(50 μM, 100 μM, 500 μM) resulted at a significant loss of HuC/HuD positive cell 
bodies (fig. 2.3).  Since diabetes does not cause a significant loss of HuC/HuD positive 
cell bodies (Voukali et al., 2011) a concentration of 10 M was chosen for subsequent 
studies of the effect of methylglyoxal on VIP-, nNOS- and calbindin-containing 
neurons. 
 
2.3.2.3 High glucose, carbonyl stress and AGEs 
The effects of exposure to high glucose levels, methylglyoxal to induce carbonyl 
stress and of AGEs on VIP, nNOS and calbindin are shown in figs. 2.4, 2.5 and 2.6 and 
in the graph given in fig. 2.7 A-C, respectively. In the case of VIP-containing neurons, 
exposure to high glucose and to carbonyl stress caused a significant increase (p < 0.01, 
for both) in the proportion of HuC/D-positive neurons expressing VIP while exposure to 
BSA-AGE had no significant effect (fig. 2.4, 2.7A). In contrast, exposure to high 
glucose and carbonyl stress has no significant effect on nNOS-containing neurons while 
exposure to BSA-AGE resulted in a significant decrease (p < 0.05) in the proportion of 
neurons expressing nNOS (fig. 2.5, 2.7B). The proportion of HuC/D-positive myenteric 
neurons expressing calbindin was unaffected by exposure to high glucose, carbonyl 
stress or BSA-AGE (fig. 2.6, 2.7C). Preliminary control experiments demonstrated that 
exposure to BSA, at the same concentration as that used for BSA-AGE, had no effect on 
any of the subpopulations of myenteric neurons studied.  
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Figure 2.3: Effect of different methylglyoxal (MG) concentrations on the neuronal 
viability in vitro measured with the number of HuC/D positive neurons per ganglion. 
Clear bars represent data from controls and shaded bars represent data from preparations 
after exposure to the various methylglyoxal concentrations.  Note the decrease in 
HuC/D immunoreactive neurons following exposure to higher methylglyoxal 
concentrations. Data are expressed as the mean ± SEM, n = 6, (** p < 0.01, by 
ANOVA). 
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Figure 2.7:  Effects of high glucose (h glu), methylglyoxal (MG) and AGEs on the 
relative number of VIP, nNOS and Calbindin immunoreactive cell bodies. Neurons 
containing VIP, nNOS or calbindin are expressed as a percentage the number of 
HuC/D-positive neurons. Clear bars represent data from controls and black bars 
represent data from preparations after exposure to the stimulus. (A) Note the significant 
increase of VIP positive cell bodies following exposure to high glucose and 
methylglyoxal but not AGE (h glu, n = 9; C, n = 12; MG, n = 7; C, n = 7; AGEs, n = 7; 
C, n=7) (B) Note the significant decrease of nNOS-positive cell bodies occurred only 
following exposure to AGE (h glu, n = 11; C, n = 10, MG, n = 7; C, n = 7, AGEs, n  =5; 
C, n = 6) (C) Calbindin-positive neurons were unaffected by all stimuli (h glu, n = 11; 
C, n = 10; MG, n = 6; C, n = 6; AGE, n = 4; C, n = 5). Data are expressed as the mean ± 
SEM (** p < 0.01, * p < 0.05 by non paired Student’s t-test). 
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2.4 Discussion 
 
 
The results of the present study demonstrate that it is possible to replicate the 
effects of diabetes in vivo in an in vitro model using a myenteric plexus/muscle 
preparation from the adult rat. A number of pathways have been suggested to lead to 
neuropathy in diabetes and in vitro models are required in order to examine each 
pathway separately.  This is the first in vitro study that uses explants of myenteric 
plexus/muscle to investigate different subpopulations of myenteric neurons involved in 
diabetic gastroenteropathy.   The segment of the gut taken was always ileum since it has 
been shown that it is particularly susceptible in diabetes (Shotton et al., 2003).  
Diabetes affects many subpopulations of the intrinsic and extrinsic nerves of the 
gut. Investigating the myenteric plexus has the advantage that it contains a number of 
different subpopulations of neurons that are not all affected in the same way in diabetes. 
We used wholemounts with the mucosal and submucosal layers stripped, in order to 
focus on three representative neuronal subpopulations in the myenteric plexus that show 
differential response to diabetes, the VIP, nNOS and Calbindin-containing neurons.  
Previous studies from this laboratory have demonstrated that STZ-induced 
diabetes in rats causes an increase in the percentage of myenteric neurons containing 
VIP in the ileum (Belai et al. 1985; Shotton et al., 2004;Shotton et al., 2007) . This 
change is associated with failure to release VIP on electrical stimulation and 
degenerative changes in the nerve fibres (Belai et al., 1987). 
In contrast, nNOS expression decreases. For example, the percentage of neurons 
expressing nNOS is significantly decreased in diabetes (Shotton & Lincoln, 2006; 
Shotton et al., 2007). However, there is some conflicting evidence possibly due to the 
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different time course of diabetes and the animal model examined (Adeghate et al., 
2003;Pereira et al., 2008).  There is a general consensus that dysfunction of NOS-
containing neurons and decreased expression of nNOS are important contributing 
factors of impaired NANC smooth muscle relaxation and the gut dysmotility symptoms 
of diabetic gastroenteropathy (Takahashi, 2003). It has been reported, that nNOS 
myenteric neurons are particularly susceptible in diabetes (Cellek et al., 2004) and 
neuropathy in nNOS-containing neurons occurs in two phases. The first phase, with the 
loss of nNOS in the neurons is reversible on insulin replacement. The second phase 
occurring late in diabetes is characterized by neuronal apoptosis and is irreversible on 
insulin replacement (Cellek et al., 2003).  Nevertheless, the mechanism by which the 
nNOS myenteric neurons are altered in diabetic complications is at present unclear. 
The colocalization of nNOS with VIP has been reported in myenteric neurons 
throughout the GI tract in a range of species including rat, mouse, guinea-pig, pig, and 
human (Ekblad et al., 1996; Sang & Young, 1996; Costa et al., 1992; Timmermans et 
al., 1994; Porter et al., 1997;Qu et al., 2008). In the guinea-pig and mouse 90-100% of 
nNOS-immunoreactive neurons are positive for VIP (Costa et al., 1992; Qu et al., 
2008). This overlap was determined in colchicine-treated tissue in order to enhance VIP 
immunoreactivity. Colchicine blocks axonal transport by disruption of microtubules 
causing peptides to accumulate within the cell bodies. However, according to Ekblad et 
al. (1996), colchicine treatment itself alters the expression of neuropeptides and nNOS 
in enteric neurons and extrapolation of data after colchicine treatment may give rise to 
misinterpretation of colocalization data. Double-labelling for VIP and nNOS has not 
been performed on the myenteric plexus of diabetic rats. Therefore it has not been 
determined if the increase observed in VIP occurs in nNOS-containing neurons. 
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In this study we also wished to examine whether resistance to change in diabetes 
could be replicated in vitro. Previously, it has been reported that substance P-containing 
nerves are unaffected in diabetes (Belai et al., 1985). However, it is not possible to 
quantify the number of intrinsic Substance P-containing neurons in the myenteric plexus 
without the use of an axonal transport inhibitor such as colchicine (Domoto et al., 
1984). Therefore, we identified a population of myenteric neurons that were amenable 
to quantitation and were unchanged in diabetes. Calbindin-containing myenteric 
neurons were also unaffected after 12 weeks STZ-induced diabetes and provided a 
subpopulation with which to compare the responses of VIP- and nNOS-containing 
neurons (Voukali et al., 2011).   
Calbindin belongs to a family of calcium binding proteins such as calretinin, 
parvalbumin, calmodulin, S100 etc. Calbindin is found in enterocytes and other types of 
cells and is also dispersed in various types of neurons. It has been extensively used as a 
neuronal marker, since it is localised in distinct neuronal subpopulations in the central 
and peripheral nervous systems and stains the cytoplasm and even the thin processes of 
neurons facilitating studies of neuronal shape and connectivity. The presence of 
calbindin in mammalian ENS was first shown by Buchan and Baimbridge (Buchan & 
Baimbridge, 1988). In rat ileum myenteric plexus calbindin neurons are not involved in 
the control of smooth muscle and they do not colocalise with VIP or nNOS forming a 
distinct subpopulation of neurons (Buchan & Baimbridge, 1988; Mann et al., 1999, 
Furness, 2005, Qu et al., 2008). They can be interneurons connecting the myenteric or 
submucosal plexus or may have sensory function with their afferent fibres leading to 
sympathetic ganglia. About 40% of calbindin-containing rat myenteric neurons are 
cholinergic (Mann et al., 1999). VIP or galanin nerve fibres were shown to terminate on 
calbindin-containing neuronal cell bodies. In other species, including human, the 
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distribution of calbindin in ENS is similar (Walters et al., 1993; Quinson et al., 2001; 
Denes & Gabriel, 2004). 
 
2.4.1 Apoptosis and cell death 
 
Throughout this study we used anti-HuC/D as a pan-neuronal marker. Anti-
HuC/D recognises the neuronal proteins HuC and HuD. HuC/D are human members of 
the embryonic lethal, abnormal vision (ELAV), Drosophila family of proteins (ELAV3 
and ELAV4, respectively). The expression of both is restricted to neurons, where they 
act as mRNA stabilizers and are involved in neuronal differentiation during 
development. Their expression is also maintained in the adult (Schenes-Furry et al., 
2006; Bolognani & Perrone-Bizzozero, 2008). Anti-HuC/D has been used widely as a 
neuronal marker in peripheral nervous system (Lin et al. 2002). It has been reported to 
be preferable to PGP 9.5, tubulin β III isoform and Neuron Specific Enolase for neuron 
staining in the myenteric plexus in wholemounts (Lin et al., 2002, Phillips et al., 2004). 
The application of anti-HuC/D as a histochemical marker is advantageous because it 
reliably labels all neurons. In addition, it provides accurate counts of neurons in ganglia 
because immunostaining of anti-HuC/D is restricted to neuronal perikarya and does not 
include the extrinsic and intrinsic neuronal fibres in wholemount preparations. 
Loss of HuC/D coincided with TUNEL staining in CG/SCG in samples of 
horses with equine grass sickness indicating that the latter stages of apoptosis are 
associated with decreased HuC/D expression (Shotton et al., 2011). Other authors have 
considered absence of HuC/D staining as an indication of cell loss (Izbeki et al., 2008; 
De Mello et al., 2009). 
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Culture per se did not significantly affect the number of HuC/D neurons per 
ganglion indicating that the culture conditions did not result in significant neuronal loss. 
It cannot be excluded that culture altered neuronal metabolism or function. However, 
none of the stimuli investigated in vitro affected HuC/D expression relative to control 
culture preparations at the concentrations used. Thus any changes in VIP, nNOS or 
calbindin expression that were observed in this study could not be attributed to loss of 
HuC/D-positive neurons. In preliminary experiments to test the effect of various 
methylglyoxal concentrations in myenteric ganglia, a dose of 10 μM was selected, 
because higher concentrations induced neuronal loss.  
Previous in vivo studies have reported the loss of myenteric neurons in STZ-
diabetes. Counts of the number of enteric neurons per unit area in the STZ-induced 
diabetic rat have shown a wide range of reduction from 1% to 50% with some regional 
differences in the response (De Mello et al. 2009). On the other hand, in a study in this 
laboratory, quantification of the average number of HuC/D-positive neurons per 
ganglion demonstrated that there was no significant loss of neurons after 12 weeks STZ-
induced diabetes in the ileum (Voukali et al., 2011). These contradictory results may be 
due to the difference in the methodology of quantification since measurement of the 
number of neurons per unit area will be susceptible to influence by the distension of the 
gut that occurs in diabetes  in vivo (Schmidt, 2002). It is possible that the quantification 
of six ganglia was not sufficient to demonstrate a small loss of neurons. However, these 
results do demonstrate that any changes observed in the percentage of HuC/D-positive 
neurons containing VIP or nNOS were due to significant changes in the expression of 
VIP or nNOS rather than alterations in the pan neuronal marker.   
Several groups have reported apoptotic neuronal cell death as a feature of 
diabetic neuropathy in other types of peripheral neurons (Russell et al., 1999; Russell & 
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Feldman, 1999; Srinivasan et al., 2000;Kishi et al., 2002;Schmeichel et al., 2003), but 
the evidence  is controversial (Tolkovsky, 2002). Studies of the counts of the total 
number of neurons did not support the presence of significant neuronal cell death 
(Schmeichel et al., 2003;Guo et al., 2004). For example, in the study of Guo et al. 
neuronal counts in sensory, autonomic and myenteric ganglia demonstrated the 
reduction up to 2%.  Activation of caspase 3 was proved to occur without evidence of 
DNA fragmentation and consequently caspase 3 activation does not necessarily imply 
apoptotic cascade (Cheng & Zochodne, 2003; Guo et al., 2004).  Thus, neuronal cell 
death is not a prominent feature of sensory and autonomic neurons in diabetes in vivo 
(Schmidt et al., 1993; Schmidt et al. 1997; Schmidt, 2001; Zochodne et al., 2001). 
Apoptotic stresses are induced, but the final execution of apoptosis is prevented by the 
induction of counter regulatory elements (Kamiya et al., 2005). A slow progression of 
the disease with an axonal dying back phenomenon of axonal loss and neuronal atrophy 
takes place rather than apoptosis.  
 
2.4.2 Effect of culture per se 
 
All results were expressed as a percentage of HuC/D-positive neurons. Under 
control conditions, there was a significant increase in the percentage of myenteric 
neurons expressing VIP, nNOS and calbindin after 24h in culture, relative to myenteric 
plexus/muscle preparations that had not been exposed to culture. These results imply a 
direct effect of axotomy and culture.  
An increase of VIP and nNOS in myenteric and submucous neurons after culture 
has been reported previously (Lin et al., 2003; Lin et al., 2004). Interestingly, in the 
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study of Lin et al., the increased expression of VIP-containing neurons occurred within 
the nNOS-containing myenteric neurons. Culture-induced changes in VIP synthesis 
within nNOS neurons were also explained as a need to enhance intestinal inhibition or 
an attempt to control excessive proliferation of smooth muscle cells during culture. 
Increased expression of VIP within the nNOS myenteric neurons has been found in 
several pathophysiological situations such as axotomy and colchicine treatment, 
hypertrophy of smooth muscle and in Crohn’ s disease (Ekblad et al., 1996;Belai et al., 
1997; Ekblad et al., 1998). These alterations in chemical coding are referred as “cell 
body reaction”, a response to injury or stressful conditions, to promote regeneration and 
survival (Zigmond & Sun, 1997). These changes reflect the shift from synaptic 
transmission to regeneration. 
VIP, apart from its function as a neuromodulator, promotes neuronal survival 
and some authors identify VIP as a neurotrophic factor (Klimaschewski, 1997).  
Increased expression of nNOS is controversial in terms of survival and neuroprotection. 
Exogenous supplement of VIP and a NO donor improved the survival of myenteric 
cultures (Sandgren et al., 2003; Arciszewski & Ekblad, 2005). Hence, our results 
underline the role of calbindin, nNOS and VIP in neuronal plasticity. Whether VIP 
protects specifically the nNOS-containing myenteric subpopulation or NO and VIP act 
in collaboration are significant questions yet to be answered. Therefore, in the present 
study, the effects of all stimuli in vitro were assessed relative to preparations maintained 
in culture under control conditions in parallel throughout.  
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2.4.3 Effect of oxidative stress and diabetic stimuli 
           
None of the stimuli investigated here caused a significant loss of HuC/D-
positive neurons per ganglia. Recently, a significant loss of enteric neurons has been 
reported when dissociated enteric neurons were exposed to hydrogen peroxide in vitro 
which could be prevented by pre-incubation with neurotrophin-3 (Korsak et al., 2012). 
It is possible that myenteric neurons in wholemount preparations are better able to 
survive oxidative stress in culture than dissociated neurons since they have undergone 
less disruption and the normal supportive environment is maintained.   Oxidative stress 
was induced by menadione in this study. Menadione is a quinone that undergoes a redox 
cycle resulting in the production of superoxide radicals and hydrogen peroxide (Briere 
et al., 2004). It can interfere with oxidative phosphorylation, diverting electrons from 
complex 1 (Chiou et al. 2003), inducing mitochondrial membrane depolarisation and 
disrupting calcium homeostasis activating apoptotic factors (Gerasimenko et al., 2002). 
Only oxidative stress produced the same pattern of change in vitro that was 
observed in diabetes with a significant increase in the percentage of VIP-containing 
neurons and a significant decrease in nNOS-containing neurons. Furthermore, we 
demonstrated that resistance to change in diabetes was also reflected by resistance to 
oxidative stress in vitro since calbindin-containing neurons were unaffected under both 
conditions. Thus, oxidative stress appears to be a common element in neuropathic 
changes in myenteric neurons in diabetes.  
A number of pathways have been suggested to lead to oxidative stress in 
diabetes including mitochondrial dysfunction induced by high glucose (Leinninger et 
al., 2006), carbonyl stress due to increased production of carbonyl species such as 
methylglyoxal (Thornalley, 2005), and activation of the RAGE receptor by AGEs (Yan 
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et al., 1994). When the effects of high glucose, methylglyoxal and AGEs were 
examined individually, an interesting differential pattern emerged. Exposure to high 
glucose and methylglyoxal caused an increase in the percentage of VIP-containing 
neurons but had no effect on nNOS-containing neurons. In contrast, exposure to AGEs 
decreased the percentage of nNOS-containing neurons but had no effect on VIP 
expression. Thus, the relative contribution of different pathways to change in diabetes 
appears to differ depending on the subpopulation of neurons involved. A decrease in the 
expression of nNOS in myenteric neurons on exposure to AGEs in vitro has been 
reported previously (Korenaga et al. 2006). Furthermore, vulnerability to AGEs in a 
neuronal cell line only occurred when the cells were induced to express nNOS (Cellek 
et al., 2004). RAGE expression has been demonstrated in myenteric ganglia (Jeyabal et 
al. 2008; Korenaga et al. 2006). However, it remains to be determined if RAGE is 
selectively expressed in nNOS-containing neurons. We were unable to answer such a 
question because of technical difficulties. Also, activation of RAGE in sensory neurons 
induces oxidative stress that can be prevented by -lipoic acid (Vincent et al. 2007a). 
In studies of the guinea-pig and mouse ileum, 90-100% of nNOS-containing 
neurons have been reported also to contain VIP (Costa et al., 1992; Qu et al., 2008). 
This raises the question as to whether high glucose/MG were acting on the same 
population of nNOS-containing myenteric neurons to cause an increase in VIP together 
with a decrease in nNOS. Alternatively, high glucose and MG could have been acting 
on a different subpopulation of nNOS-containing neurons from that at which AGE 
exerted its effects. It should be noted that the above colocalization studies were 
performed using colchicine to enhance VIP-immunoreactivity. In a study of myenteric 
neurons in the rat small intestine, it has been reported that, in the absence of colchicine, 
the majority of nNOS-containing neurons do not contain VIP. Colchicine treatment 
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resulted in an increase in VIP-containing neurons together with a decrease in nNOS-
containing neurons and an increase in the colocalization of nNOS with VIP. The authors 
concluded that the level of colocalization observed after colchicine treatment may not 
reflect the normal condition (Ekblad et al., 1996). In a recent study of the myenteric 
plexus of a rat model of Parkinson’s disease, Colucci et al., (2012) reported a decrease 
in nNOS-containing neurons and an increase in VIP-containing neurons in the absence 
of changes in the intrinsic excitatory motor neurons that contain ACh in the distal ileum 
and proximal colon. This is similar to the pattern observed in the STZ-diabetic rat. 
Using triple labelling for nNOS, VIP and HuC/D in the absence of colchicine, Colucci 
et al. demonstrated that the increase in VIP coincided with an increase in the percentage 
of nNOS-containing neurons that also contain VIP. The authors concluded that there 
were two subpopulations of nNOS-containing neurons that were affected differently in 
Parkinson’s disease. They proposed that, decreased nNOS expression occurred in a 
specific population of neurons that selectively expressed nNOS under normal 
conditions. However, VIP expression was induced in a separate population of nNOS-
containing neurons that maintained their expression of nNOS (Colucci et al., 2012). The 
presence of two populations could explain how the changes in nNOS and VIP 
expression reported here occurred in response to different diabetic stimuli. However, 
triple labelling studies are required to confirm if this is the case in STZ-induced diabetes 
and the in vitro model.               
In addition to being resistant to oxidative stress and diabetes, calbindin-
containing neurons were unaffected by exposure to high glucose, methylglyoxal and 
AGEs in vitro. Although they do not prove a direct link between calbindin and 
neuroprotection, these findings imply that calbindin seems to confer to neurons a greater 
resistance to diabetic stimuli.  It has been shown that calbindin-positive hippocampal 
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neurons are better able to buffer acute elevation of intracellular calcium (Mattson et al., 
1991). Alexianu et al. showed that absence of calbindin could represent a factor 
explaining different susceptibility of motor neurons in Amyotrophic Lateral Sclerosis 
that die from oxidative stress. Motor neurons affected late in the disease process do 
contain calbindin and/or parvalbumin, but motor neurons that degenerate early do not 
(Alexianu et al., 1994). In line with this evidence, it was found that calbindin-containing 
dopaminergic neurons in the midbrain were completely spared after paraquat-induced 
degeneration and showed no overt signs of lipid peroxidation (McCormack et al., 2006). 
Also, calbindin-containing neurons from rat cortical cultures exposed to xanthine 
oxidase were spared, suggesting that calbindin is protective against oxidative stress 
(Hugon et al., 1996).               
Calbindin maintains a significant intracellular role in regulating the excitability 
of nerve cells. The role of calbindin, as a calcium buffering protein, is to bind calcium 
ions with high affinity. It is found in high concentrations in neurons and thus it has high 
buffering capacity (Baimbridge et al., 1992). Calbindin interacts with calcium-
dependent processes such as the release of neurotransmitters and influences the activity 
of calcium channels.  It is present in enteric neurons with specific electrophysiological 
properties (AH neurons) and where various types of calcium channels are present 
(Naidoo et al., 2010).  It has been described that calbindin, as a calcium binding protein, 
can alter the duration of action potentials; can promote neuronal bursting activity; can 
allow for a greater contribution of calcium entry to the overall membrane depolarization 
(Baimbridge et al., 1992). Finally, calbindin can protect the cells against the damaging 
effects of excessive calcium influx during prolonged periods of high activity slowing 
down calcium transients and making up a passive system that limits a stimulated rise in 
intracellular free calcium concentration.  
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The protective role of calbindin in enteric neurons in vitro has not been studied 
before. The presence of calbindin in myenteric neurons may help to attenuate the 
degrading consequences of elevated intracellular calcium and to be protective against 
glucose toxicity. Calcium dyshomeostasis and impaired mitochondrial calcium 
buffering is a common feature in diabetes (Huang et al., 2002b; Verkhratsky & 
Fernyhough, 2008;Fernyhough & Calcutt, 2010). The disruption of intracellular calcium 
metabolism may occur due to impairment of calcium transport and persistent elevated 
cytosolic calcium concentrations due to mitochondrial injury. Some studies have 
reported changes in the expression of calcium binding proteins in neurodegenerative 
disease, but the data are rather inconsistent (Heizmann & Braun, 1992). In this study, 
the immunoreactivity of calbindin remained in similar values whether exposed to 
stimuli or not, in contrast to the other neuronal myenteric subpopulations.  
 
2.4.4 Conclusion 
 
          As far as we are aware, this is the first study that has reproduced the effects of 
diabetes in an in vitro model in terms of both vulnerability and resistance in discrete 
subpopulations of myenteric neurons in the same plexus. The results presented here 
provide evidence that oxidative stress plays an important role in diabetes-induced 
changes but that the pathway by which oxidative stress occurs differs in different 
populations of myenteric neurons. The in vitro models established in this study could 
provide a useful tool with which to investigate the mechanisms underlying the 
development of neuropathy in diabetes that lead to abnormal control of gut motility.  
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Chapter 3: Study of therapeutic 
agents for diabetic neuropathy 
 
3.1 Introduction 
 
 
The management of the gastrointestinal symptoms of diabetic neuropathy 
mainly relies on various drugs acting on gut motility (Ziegler, 2001; Shakil et al., 2008). 
For gastroparesis, several specific therapies directed at the presenting symptoms, such 
as metoclopramide, a 5-HT3 and D2 receptor antagonist; erythromycin, a motilin 
receptor agonist; acetylcholine release inhibitors and, in some cases, gastric electric 
stimulation are used. For diarrhea, the relief is directed towards the correction of fluid 
and electrolyte imbalances and sometimes towards the prescription of antibiotics. For 
constipation that may alternate with diarrhea the use of laxatives is advised.   
In fact, the optimal control of blood glucose levels is the most effective strategy 
to prevent neuropathy in diabetes including gastroenteropathy. The benefit of 
maintaining normoglycaemia has been consistently demonstrated. The DCCT 
multicentre study showed that the prevention of the appearance and the progression of 
the symptoms of neuropathy can be sustained for many years (The Diabetes Control and 
Complications Trial Research Group, 1993; Parry, 1999). However, strict glycaemic 
control can result in regular episodes of hypoglycaemia that may insult the cognitive 
abilities and cause painful neuropathy. Furthermore, it is not easy, even for the most 
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determined patient, to keep their blood glucose levels well regulated. For this reason, 
additional approaches have been investigated that counteract the metabolic 
consequences of hyperglycaemia that may lead to neurodegeneration. This chapter will 
focus on agents that act against oxidative stress and/or carbonyl stress.  
 
 
3.1.1 Pathogenesis oriented treatments: In vivo studies & clinical trials 
3.1.1.1  α-Lipoic acid  
α-Lipoic acid has been characterised as a “universal” anti-oxidant since it can 
act in both an aqueous and a lipid environment (Packer et al., 1995). Treatment with α-
lipoic acid has been investigated in experimental diabetes. STZ-induced diabetic rats, 
injected intraperitoneally with different doses of α-lipoic acid five times per week, 
demonstrated improved nerve blood flow, distal nerve conduction velocity and reduced 
oxidative stress, indicated by GSH levels (Nagamatsu et al., 1995). Another study 
showed a beneficial action of α-lipoic acid on neurovascular function and nerve 
conduction velocity in STZ-diabetic rats (Cameron et al., 1998). In a following study 
(Kishi et al., 1999), the administration of α-lipoic acid intraperitoneally enhanced 
glucose uptake in a dose dependent manner.  
However, Stevens et al. highlighted the selective and complex action of α-lipoic 
acid. Administration of α-lipoic acid as recommended by Nagamatsu et al. improved 
selectively sensory nerve conduction velocity but not motor nerve conduction velocity. 
It restored some energy metabolites [(Na, K)ATPase activity, NAD+: NADH ratios and 
myoinositol content] and prevented the decrease of endogenous anti-oxidant enzymes 
activity. On the other hand, it exaggerated aldose reductase pathway metabolites 
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(Stevens et al., 2000). With parallel dietary and intraperitoneal administration, Coppey 
et al. found that motor nerve conduction velocity was improved in STZ-diabetic rats but 
the increase in serum triglyceride and free fatty acids could not be prevented (Coppey et 
al., 2001). In the study of Yorek et al., combination therapy of α-lipoic acid with an 
aldose reductase inhibitor, fidalrestat, normalised oxidative stress markers and nerve 
conduction velocities at lower doses (Yorek et al., 2004). In the case of enteric nerves, 
α-lipoic acid treatment, on its own, was unable to prevent diabetes-induced changes in 
VIP- or NA-containing nerves (Shotton et al., 2003). However, in combination with 
evening primrose oil to supplement γ-linolenic acid, α-lipoic acid did prevent changes in 
VIP-containing nerves (Shotton et al., 2004).    
These positive results in experimental diabetes prompted the initiation of a series 
of clinical trials of α-lipoic acid in diabetic patients with neuropathy. Ziegler et al. 
(2004; 2011) have performed meta-analysis of the results of several of these clinical 
trials. The trials were selected on the basis that they were all randomised, double-
masked placebo controlled trials on diabetic patients with symptomatic polyneuropathy. 
-lipoic acid was administered intravenously (600 mg per day on weekdays over three 
weeks) and the total symptom score for neuropathy was assessed daily on weekdays. 
The results from four trials were analyzed: The alpha-lipoic acid in diabetic neuropathy 
(ALADIN I and ALADIN III) trials were on outpatients from diabetic centres 
throughout Germany. The symptomatic diabetic trial (SYDNEY) consisted of in-
patients in a Moscow hospital. The neurological assessment of thioctic acid in diabetic 
neuropathy (NATHAN I) trial investigated outpatients in diabetic centres in the USA, 
Canada and Europe. The outcomes of the SYDNEY and ALADIN I trials demonstrated 
significant beneficial effects on neuropathic symptoms compared with placebo. The 
NATHAN I and ALADIN I also observed some beneficial effects but these trends did 
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not reach statistical significance. The oral use of α-lipoic acid (600 mg) is now 
considered helpful in improving sensory neuropathic symptoms, after only 1 week of 
administration. Clinical trials testing the efficacy of α-lipoic acid on the treatment of 
autonomic neuropathy including enteropathy (600, 800 mg intravenously and orally), 
also demonstrate encouraging outcomes and improvement of neuropathic symptoms 
(Ziegler et al., 1997; Tankova et al., 2004). So far, α-lipoic acid was only compared to 
placebo. Thus, its efficacy over other commonly prescribed oral treatments has not been 
yet investigated (Tang et al., 2007). However, it is well tolerated, with moderate adverse 
events, and this is a strong benefit compared with other treatments.  
 
3.1.1.2 Nicotinamide 
Nicotinamide is one of the two principal forms of vitamin B3 and a precursor of 
NAD+ and NADP+, coenzymes involved in many redox reactions in the cell 
(Niacinamide.Monograph, 2002). Nicotinamide is not only an essential nutrient for 
cellular function. It also has a protective ability that prevents NAD+ depletion during 
DNA repair by inhibiting PARP. Interestingly, nicotinamide has been utilised to prevent 
experimental and clinical diabetes. Nicotinamide supplementation was protective 
against the effects of STZ in rats, lowering damage due to lipid peroxidation (Melo et 
al., 2000) but the European Nicotinamide Diabetes Intervention Trial showed that it was 
ineffective in the prevention of type 1 diabetes (Gale et al., 2004).  
PARP is activated as a downstream effector of oxidant induced DNA damage. 
Excessive ROS production triggers DNA single strand breakage. By the synthesis of a 
poly(ADP-ribose) chain on damaged DNA, PARP acts as a signal to initiate DNA 
repair. Its overactivation initiates an energy consuming cycle: PARP transfers the ADP-
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ribose moieties from NAD+ to nuclear proteins leading to the rapid depletion of the 
intracellular pools of NAD+ and energy failure. However, it is worth emphasizing that 
in diabetes the levels of ATP and energy substrates are not decreased (Gibson et al., 
2006; Kishi et al., 1999). PARP also begins a downstream regulation of various 
transcription factors including NFκB.  
The role of PARP has been studied extensively in diabetic neuropathy. 
Obrosova et al. reported that PARP activation is an important mechanism in diabetic 
neuropathy (Obrosova et al., 2004, Obrosova et al., 2005). Inhibitors of PARP can 
alleviate neuropathy, increase nerve conduction velocity and improve nerve function 
(Ilnytska et al., 2006; Gibson et al., 2006).  
In experimental diabetic neuropathy, nicotinamide, used as a weak PARP 
inhibitor, reversed impairments in endoneurial blood flow, corrected increased lipid 
peroxidation in sciatic nerve and attenuated functional and behavioural deficits of 
diabetic sensory neuropathy (Stevens et al., 2007).  In addition, nicotinamide prevented 
the NAD+ depletion of the diabetic sciatic nerve (Negi et al., 2010).  
 
 
3.1.1.3 Aminoguanidine  
Aminoguanidine or pimagedine has been proposed to act as a carbonyl 
scavenger that inhibits the formation of AGEs (Thornalley, 2003b). Early studies of 
aminoguanidine in experimental diabetic neuropathy showed that oral or intravenous 
administration improves nerve function. Nerve ischemia and conduction velocity 
deficits of sciatic-tibial and caudal nerves were ameliorated after 24 weeks of 
aminoguanidine treatment in a dose dependent manner (Kihara et al., 1991). In another 
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study, the beneficial effect of aminoguanidine on nerve conduction velocity did not 
depend on the reduction of aldose reductase metabolites (Cameron et al., 1992). Instead, 
the improvement of nerve conduction velocity occurred through inhibition of AGEs 
formation, and was accompanied by a partial effect on reduced myelinated fiber size 
and axonal atrophy in diabetes (Yagihashi et al., 1992; Miyauchi et al., 1996).  
Treatment with aminoguanidine also partially corrected the enlargement of sural nerve 
microvessels and the expansion of their vascular and luminal areas (Sugimoto & 
Yagihashi, 1997).  Additionally, other studies reported a partial correction of Na+, K-
(ATP)ase activity loss (Wada et al., 1999). 
An additional action of aminoguanidine as an NOS inhibitor has also been 
investigated. It was suggested that the mechanism of treatment of aminoguanidine on 
peripheral somatic nerves during diabetes involves improved NO action. However, 
aminoguanidine treatment does not affect NO production in the vasa nervorum of 
peripheral nerves (Cameron & Cotter, 1996). These findings were also supported by the 
study of Dewhurst and colleagues (1997). This study showed that inhibiting NOS with 
NG-nitro-L-arginine methyl ester, reduced the sciatic endoneurial blood flow, but 
stimulating the synthesis of NO, with L-arginine, enhanced endoneurial blood flow 
(Dewhurst et al., 1997).  
Some studies investigating experimental diabetic neuropathy and other diabetic 
complications yielded conflicting results of the efficacy of aminoguanidine (Azal et al., 
2002; Unlucerci et al., 2001). The study of Birrell and colleagues using primates in 
chronic aminoguanidine treatment, did not find any improvement on motor nerve 
conduction velocity, morphometric analysis of nerve fibres or autonomic dysfunction 
(Birrell et al., 2000). However this study has been criticized of using the very small 
dose of 10 mg/kg compared with 25 or 50 mg/kg that have been administrated in rats 
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(Cameron et al., 2005). In experimental diabetic autonomic neuropathy, the chronic 
administration of aminoguanidine did not prevent the frequency or the appearance of 
neuroaxonal dystrophy in sympathetic ganglia (Schmidt et al., 1996). Similarly, 
aminoguanidine was unable to prevent diabetes-induced changes in NA-containing 
nerves within the ileum. However, changes in the intrinsic nNOS- and VIP-containing 
nerve fibres in the ileum in diabetes were partially prevented by aminoguanidine 
treatment (Shotton et al., 2007).   
Double-blinded, multiple-dose (low and high doses of 50–300 or 100–600 
mg/day), placebo-controlled, randomized clinical trials of chronic aminoguanidine 
treatment in overt diabetic nephropathy (ACTION) were also performed: ACTION I 
was conducted in patients with type 1 diabetes mellitus and ACTION II in patients with 
type 2 diabetes mellitus (Freedman et al., 1999;Thornalley, 2003b). Patients with 
combined high and low aminoguanidine dose showed a non significant alleviation of 
nephropathy with lower levels of triglycerides, low density lipoproteins (LDL) 
cholesterol and urinary protein. In ACTION II, the External Safety Monitoring 
Committee recommended the early termination of the ACTION II trial due to safety 
concerns and lack of efficacy. Gastrointestinal disturbance, abnormalities in liver 
function tests, flu-like symptoms, and a rare vasculitis were the reported side effects of 
the drug.  
 
3.1.1.4 Thiamine  
Thiamine belongs to the B1 vitamin complex and is an essential micronutrient 
absorbed from the diet (Thiamine Monograph, 2003). Once transported into the cell, 
thiamine is phosphorylated to thiamine pyrophosphate. Thiamine pyrophosphate is a 
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cofactor of a series of enzymes and fundamental for the intracellular metabolism of 
glucose. In 1987, it was reported that diabetic patients have low blood thiamine levels 
(Saito et al., 1987) that is not due to the diet of diabetics (Ba, 2008;Vindedzis et al., 
2008), but from impaired metabolism and clearance of thiamine in the diabetic kidney 
(Thornalley et al., 2007;Rabbani & Thornalley, 2011). Thiamine, and/or its derivative 
benfotamine, increases the disposal of excess triosephosphates formed in 
hyperglycaemia thus preventing methylglyoxal-induced carbonyl stress and subsequent 
formation of AGEs (Berrone et al., 2006). These findings have led to the therapeutic 
potency of thiamine in diabetes being examined.  
Double-blind, randomized, controlled clinical trials of thiamine in diabetic 
patients with neuropathy have reported benefits with no specific adverse effects. 
Administration of benfotiamine, a lipophilic derivative of thiamine with better 
bioavailability (Benfotiamine Monograph, 2006), in a combination therapy with 
vitamins B6 and B12, improved nerve conduction velocity in the peroneal nerve and 
induced a trend of improvement of the vibration perception threshold of patients with 
diabetic polyneuropathy (Stracke et al., 1996). In another clinical trial, thiamine and 
pyridoxine administration alleviated the pain, numbness and paresthesia symptoms of 
diabetic peripheral sensory neuropathy (Abbas & Swai, 1997). In a randomized, 
placebo-controlled, double-blind, two-centered pilot study testing benfotiamine, type 1 
and 2 diabetic patients showed improvement on the total neuropathy score, a decrease in 
pain, a self assessed improvement of their condition, but no effect in the tuning fork test 
(Haupt et al., 2005). Thiamine was effective also in clinical trials of diabetic 
nephropathy (Rabbani et al., 2009; Rabbani & Thornalley, 2011).  
Although clinical trials of B1 vitamin remain at a preliminary level, evidence 
from experimental diabetes is in line with the discussed effects in humans. 
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Benfotiamine suppressed the development of diabetic neuropathy in vivo (Stracke et al., 
2001). Specifically, motor nerve conduction velocity was improved and was nearly 
normalized after six months. In addition, AGEs were significantly reduced in peripheral 
nerve tissue. A high dose of benfotiamine (70 mg/kg) prevented AGEs accumulation in 
kidney, retina and plasma of STZ-treated rats (Karachalias et al., 2003). Thiamine 
corrected dyslipidemia normalizing cholesterol and triglycerides (Babaei-Jadidi et al., 
2004). Thiamine was protective in ameliorating detrusor contractility and inhibiting the 
progression of diabetic cystopathy (Yenilmez et al., 2006).  
 
A number of mechanisms have been proposed for the development of 
neuropathy in diabetes, including carbonyl stress, many of which converge at the level 
of oxidative stress (Baynes & Thorpe, 1999; Brownlee, 2001; Pop-Busui et al., 2006). 
In the previous chapter, data using in vitro models were presented that provided 
evidence that exposure of a wholemount myenteric plexus preparation from the ileum of 
adult rats to oxidative stress did mimic the changes that occur in diabetes in vivo but 
that the stimulus leading to oxidative stress in diabetes may differ depending on the 
individual nerve population studied. This model also provides a tool with which to 
examine the ability of potential therapeutic agents to prevent diabetes-induced changes 
in myenteric neurons and to investigate further the role of oxidative or carbonyl stress. 
Therefore, the aims of this study were to examine the effects of several agents 
on the changes induced in VIP- or nNOS-containing neurons in vitro. The effects of -
lipoic acid, an anti-oxidant;  nicotinamide, a PARP inhibitor; aminoguanidine, a 
carbonyl scavenger; and thiamine, an inhibitor of carbonyl stress induced by high 
glucose, on the responses to oxidative stress, carbonyl stress, high glucose or AGEs 
were investigated.   
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3.2 Materials and methods 
 
3.2.1 Culture preparations 
 
Adult male Sprague-Dawley rats (275-350 g) were killed by CO2 asphyxiation 
and the ileum was dissected, cleaned, and stored in a dissecting buffer of HBSS 
containing 10 mM glucose and 1% penicillin-streptomycin. Approximately 4 cm of the 
gut were put on a 2 ml stripette, scored gently with forceps and the myenteric plexus 
and the muscle layers were peeled away under a dissecting microscope. The myenteric 
plexus/muscle preparations were then washed in antibiotic wash solution (HBSS 
containing 1% penicillin-streptomycin, 2% gentamycin and 2% 5mg mlˉ¹ 
metronidazole). The tissue was cut into segments approximately 1 cm ², stretched and 
pinned onto Sylgard (VWR, Buffalo Grove, IL, USA). The samples were cultured in 
defined culture medium containing 10 mM glucose (M199, supplemented with 1% L-
Glutamine, 1% Hepes Buffer, 1% penicillin-streptomycin , 0.35% Pathocyte-4-BSA, 60 
ng mlˉ¹ progesterone, 0.016 mg mlˉ¹ putrescine, 400 ng mlˉ¹ l-thyroxine, 38 ng mlˉ¹ 
sodium selenite, 340 ng mlˉ¹ triiodothyronine, 100 μg mlˉ¹ transferrin).  
As described in the previous chapter, for oxidative stress, 1 μM menadione 
sodium bisulfite was added to the medium, for hyperglycaemia, the medium contained 
additional glucose to give a final concentration of 30 mM., for carbonyl stress, 10 μM 
methylglyoxal and for AGEs 250 μg mlˉ¹ BSA-AGE (Biovision Research Products, CA, 
USA) was added. Control preparations were maintained in 10mM glucose in parallel. 
All preparations were maintained for 24h at 37
o
C gassed with 95% O2 and 5% CO2.   
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Additional experiments were carried out to examine the ability of different 
inhibitors to prevent changes caused by the stimuli. The anti-oxidant α-lipoic acid was 
tested in the concentration of 100 μM.  α-lipoic acid was prepared as previously 
described (Vincent et al., 2005a) and added to media containing high glucose, 
methylglyoxal or BSA-AGE at the start of the experiment. The carbonyl scavenger 
aminoguanidine (100 and 500 μM) or two forms of vitamin B, thiamine pyrophosphate 
(Vitamin B1, 100 μM) or nicotinamide (Vitamin B3, 100 μM) were added in the media 
containing high glucose, methylglyoxal or menadione at the start of the experiment. The 
preparations were maintained for 24h at 37 °C gassed with 95% O2 and 5% CO2. 
The samples were fixed in 4% PFA for 18-24h at 4 °C. Myenteric plexus/muscle 
preparations were washed and stored in PBS merthiolate (0.05%) at 4 °C before 
processing. All chemicals mentioned above were obtained from Sigma, Poole, UK 
unless stated otherwise.  
 
3.2.2 Immunofluorescence procedures: double staining for VIP or nNOS  with HuC/D 
 
The myenteric plexus/muscle preparations were placed, longitudinal muscle 
uppermost, onto microscope slides and processed for immunohistochemical localisation 
of nNOS and VIP. In order to evaluate the relative frequency of the positive cell bodies, 
anti-HuC/D was used to label all neuronal cell bodies in the myenteric plexus. The 
myenteric plexus/muscle preparations were incubated for 1 hour in blocking solution 
containing 10 % normal horse serum (Gibco-Invitrogen, Paisley, UK) and 0.1% Triton 
X100 in PBS merthiolate. Primary antisera were diluted in the above blocking solution 
(rabbit polyclonal anti-nNOS, Santa Cruz, CA, USA, 1:500, rabbit polyclonal anti-VIP, 
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Immunostar Inc., Hudson, WI, USA, 1:500). The myenteric plexus/muscle preparations 
were incubated with the primary antisera overnight. After being washed in PBS 
containing 0.1% X100 Triton, the preparations were incubated in blocking solution 
containing 10% normal goat serum (Gibco-Invitrogen, Paisley, UK) and 0.1% Triton 
X100 in PBS merthiolate for 1 hour.  Samples were then incubated overnight with 
mouse monoclonal anti-HuC/D (Molecular Probes Probes, Eugene, OR, USA) diluted 
1:200 in the above solution. Finally, the samples were washed, incubated for 1 hour in 
the dark at room temperature with Alexa 488 Donkey anti-Rabbit (Molecular Probes, 
Eugene, OR, USA) and Cy3 Goat anti-Mouse (Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA) diluted 1:100 in PBS Triton, washed, mounted and the 
coverslips sealed. All procedures were carried out at room temperature. 
 
3.2.3 Analysis and statistics 
 
The samples were processed in parallel and analysed on a Zeiss fluorescence 
microscope (Carl Zeiss Ltd., Welwyn Garden City, UK). For each sample, a minimum 
of 200 cell bodies positive for HuC/D was assessed for the presence or absence of 
nNOS or VIP. The proportion of positive nNOS or VIP cell bodies were expressed as a 
percentage of the number of HuC/D-immunoreactive myenteric neurons.  
The data were analysed with GraphPad Prism 3 software using one way analysis 
of variance followed by Neumann-Keulls post hoc comparisons, or using an unpaired 
Student’s t test, where P < 0.05 was taken to indicate statistical significance.  
The samples were also photographed using a Canon EOS Elan II digital camera 
and micrograph pictures were produced using Photoshop Elements 8.0 software.  
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3.3 Results 
3.3.1  -lipoic acid 
 
When added to control media, -lipoic acid did not cause any significant 
changes in the number of nNOS or VIP immunoreactive neuronal cell bodies.  
Furthermore, it was established that the solution required to dissolve -lipoic acid for in 
vitro experiments (Vincent et al. 2005a), had no effect on its own on myenteric neurons. 
Exposure to 10 μM methylglyoxal for 24h to induce carbonyl stress caused a significant 
increase in the relative number of VIP-positive neurons (p<0. 01). Exposure to BSA-
AGE caused a decrease of the nNOS-containing neurons (p<0. 05).  Addition of 100 
μM -lipoic acid completely prevented the increase in VIP-containing neurons induced 
by carbonyl stress and the decrease in nNOS-containing neurons induced by BSA-AGE 
(fig. 3.1). Representative micrographs are provided in fig. 3.2. Although the data are not 
presented here, it should be noted that previous studies from this laboratory by H.R. 
Shotton demonstrated that -lipoic acid also prevented the increase in VIP-containing 
neurons induced by high glucose (see Voukali et al., 2011). 
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Figure 3.1:  Effect of α-lipoic acid (LA) on the action of methylglyoxal (MG) and 
BSA-AGE (AGE) in myenteric plexus/muscle preparations. Neurons containing VIP or 
nNOS are expressed as a percentage the number of HuC/D-positive neurons. Clear bars 
represent data from controls (C), black bars represent data from preparations in the 
presence of a stimulus (MG or AGE). Hatched bars represent data from preparations 
incubated with both the stimulus and LA) -Lipoic acid prevented the increase in VIP-
containing neurons induced by methylglyoxal (MG, n = 5; +LA, n = 6; C, n = 6, LA, 
n=6). (C) α-Lipoic acid prevented the decrease in nNOS-containing neurons induced by 
BSA-AGE (AGE, n = 5; +LA, n = 6; C, n = 6, LA, n=5).   Data are expressed as the 
mean ± SEM. (* p < 0.05 and ** p < 0.01 by ANOVA/ Neumann Keuls post hoc 
comparisons).  
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Figure 3.2: Inhibition of changes induced by methylglyoxal (MG) and BSA-AGEs 
(AGE) by α-lipoic acid (LA) in vitro on myenteric neurons. Photomicrographs show the 
immunoreactivity of VIP (A, B) and nNOS (C, D) double labelled with the neuronal 
marker HuC/D. A and C depict staining of preparations maintained for 24h in vitro after 
exposure to methylglyoxal or BSA-AGE and B and D depict samples after co-
incubation with α-lipoic acid. Green fluorescence indicates VIP or nNOS labelling and 
red fluorescence HuC/D. The arrows indicate co-localisation with HuC/D (yellow). 
Note the considerable decrease in VIP staining in B compared with A and the increase 
in nNOS staining in D compared with C. Scale bars represent 50 μm. 
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3.3.2 Nicotinamide 
 
Preliminary experiments established that nicotinamide (100 µM) had no 
significant effect on the expression of VIP or nNOS in control preparations. Exposure to 
high glucose, methylglyoxal and oxidative stress resulted in a significant increase in the 
relative number of VIP-containing neurons (p<0.01 for all) and oxidative stress caused a 
significant decrease in the relative number of nNOS-containing neurons (p< 0.01). All 
these changes were prevented by nicotinamide such that VIP and nNOS expression was 
similar to control preparations (fig. 3.3) Representative micrographs are provided for 
VIP (fig. 3.4) and nNOS (fig. 3.5). 
 
 
3.3.3 Aminoguanidine 
 
Preliminary experiments were carried out using aminoguanidine at a 
concentration of 100 µM according to Thornalley (2003b). However, at this 
concentration aminoguanidine was not effective as a carbonyl scavenger in preventing 
changes induced by methylglyoxal and all further experiments used a concentration of 
500 µM. At this concentration, aminoguanidine had a significant effect on the 
expression of VIP and nNOS in preparations maintained under control culture 
conditions of 10 mM glucose. Exposure to aminoguanidine resulted in a significant 
increase (p<0.05) in the relative number of VIP-containing neurons and a significant 
decrease (p<0.01) in the relative number of nNOS-containing neurons (fig. 3.6). The 
results from experiments examining the effect of aminoguanidine on changes induced  
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Figure 3.3: Effect of nicotinamide (B3) on the responses to high glucose (h glu), 
methylglyoxal (MG) and oxidative stress induced by menadione (Men) in myenteric 
plexus/muscle preparations. Clear bars represent data from controls (C), black bars 
represent data from preparations in the presence of a stimulus and hatched bars 
represent data after co-incubation of the stimulus with nicotinamide. (A) Nicotinamide 
prevented the increase in VIP-containing neurons induced by high glucose (h glu, n = 7; 
+ B3, n = 8; C, n = 9) and methylglyoxal (MG, n = 7; +B3, n = 9; C, n = 9). (B) 
Nicotinamide prevented the increase in VIP-containing neurons induced by menadione 
(Men, n = 9; +B3, n = 9; C, n = 9) and the decrease in nNOS-containing neurons 
induced by menadione (Men, n = 10; +B3, n = 6; C, n = 7). Data are expressed as the 
mean ± SEM. (* p < 0.05 and ** p < 0.01 compared to controls by ANOVA/ Neumann 
Keuls post hoc comparisons). 
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Figure 3.4: Inhibition of changes induced by high glucose (h glu) and methylglyoxal 
(MG) on VIP-containing myenteric neurons by aminoguanidine (AG), thiamine 
pyrophosphate (B1) and nicotinamide (B3) in vitro. Photomicrographs show the 
immunoreactivity of VIP double labelled with the neuronal marker HuC/D. Green 
fluorescence indicates VIP labelling and red fluorescence HuC/D. The arrows indicate 
co-localisation with HuC/D (yellow). (A) Staining of preparations maintained for 24h in 
vitro after exposure to high glucose. (B) Samples after exposure to methylglyoxal. (C) 
and (D) show the staining of preparations after co-incubation of high glucose or 
methylglyoxal with aminoguanidine. Note the decrease of VIP staining correspondingly 
compared with (A) and (B). (E) and (F) show the staining of preparations after co-
incubation of high glucose or methylglyoxal with thiamine pyrophosphate. Note the 
decrease of VIP staining in (F) compared with (B), but not in (E) compared with (A). 
(G) and (H) show the staining of preparations after co-incubation of high glucose or 
methylglyoxal with nicotinamide. Similarly to the effect of aminoguanidine, note the 
significant decrease of VIP staining correspondingly comparing A and B. Scale bar 
represents 50 μm. 
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Figure 3.6: Effect of 500 μM aminoguanidine (AG) on VIP- and nNOS-containing 
neurons in preparations maintained under control conditions of 10 mM glucose. Clear 
bars represent data from untreated controls (C) and shaded bars represent data after 
incubation with aminoguanidine (+AG). Aminoguanidine on its own induced increase 
in VIP-containing neurons (C, n=5, +AG, n=6) and decrease in nNOS-containing 
neurons (C, n=6, +AG, n=6). Data are expressed as the mean ± SEM. (* p < 0.05 and ** 
p < 0.01 by unpaired t-test). 
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by high glucose, methylglyoxal and oxidative stress in VIP-containing neurons and by 
oxidative stress in nNOS-containing neurons are given in fig. 3.7. Exposure to high 
glucose and methylglyoxal caused a significant increase in the relative number of VIP-
containing neurons (p<0.01 for both) that was prevented by aminoguanidine. Exposure 
to menadione to induce oxidative stress caused a significant increase in VIP-containing 
neurons (p<0.01) and a significant decrease in nNOS-containing neurons (p<0.01). Both 
changes were prevented by aminoguanidine (fig. 3.7). Representative micrographs are 
provided for VIP (fig. 3.4) and nNOS (fig. 3.5).    
 
3.3.4 Thiamine pyrophosphate 
 
Preliminary experiments established that 100 µM thiamine pyrophosphate had 
no effect on the expression of VIP or nNOS in control preparations. Both high glucose 
and methylglyoxal caused a significant increase in the relative number of VIP-positive 
neurons, compared to control values (p<0. 01).  The addition of thiamine pyrophosphate 
did prevent the increase in VIP-containing neurons induced by methylglyoxal but had 
no effect on the increase induced by exposure to high glucose (fig. 3.8). Oxidative stress 
induced by menadione caused a significant increase in the relative number of VIP-
positive neurons (p<0. 01) and a significant decrease in nNOS-positive neurons 
(p<0.01).  Thiamine pyrophosphate did not prevent the changes induced by oxidative 
stress in either VIP- or nNOS-containing neurons (fig. 3.8).  Representative 
micrographs are provided in fig. 3.4.  
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Figure 3.7: Effect of 500 μM aminoguanidine (AG) on the responses to high glucose (h 
glu), methylglyoxal (MG) and oxidative stress induced by menadione (Men) in 
myenteric plexus/muscle preparations. Clear bars represent data from controls (C), 
black bars represent data from preparations in the presence of a stimulus and hatched 
bars represent data after co-incubation of the stimulus with aminoguanidine. (A) 
Aminoguanidine prevented the increase in VIP-containing neurons induced by high 
glucose (h glu, n = 8; + AG, n = 8; C, n = 7) and methylglyoxal (MG, n = 6; +AG, n = 
6; C, n = 5. (B) Aminoguanidine prevented the increase in VIP-containing neurons 
induced by menadione (Men, n = 4; +AG, n = 5; C, n = 5) and the decrease in nNOS-
containing neurons induced by menadione (Men, n = 6; +AG, n = 6; C, n = 6). Data are 
expressed as the mean ± SEM. (* p < 0.05 and ** p < 0.01 compared to controls by 
ANOVA/ Neumann Keuls post hoc comparisons).  
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Figure 3.8: Effect of thiamine pyrophosphate (B1) on the responses to high glucose (h 
glu), methylglyoxal (MG) and oxidative stress induced by menadione (Men) in 
myenteric plexus/muscle preparations. Clear bars represent data from controls (C), 
black bars represent data from preparations in the presence of a stimulus and hatched 
bars represent data after co-incubation of the stimulus with thiamine pyrophosphate. (A) 
Thiamine pyrophosphate only prevented the increase in VIP-containing neurons 
induced by methylglyoxal (MG, n = 7; +B1, n = 6; C, n = 9). It did not prevent the 
effect of high glucose (h glu, n = 7; + B1, n = 6; C, n = 9) (B) thiamine pyrophosphate 
did not prevent the increase in VIP-containing neurons induced by menadione (Men, n 
= 9; +B1, n = 7; C, n = 7), or the decrease in nNOS-containing neurons induced by 
menadione (Men, n = 8; +B1, n = 11; C, n = 8). Data are expressed as the mean ± SEM. 
(* p < 0.05 and ** p < 0.01 compared to controls by ANOVA/ Neumann Keuls post hoc 
comparisons). 
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3.4 Discussion 
 
 
Four agents were investigated for their ability to prevent the changes induced in 
myenteric neurons in vitro in response to diabetic stimuli described in the previous 
chapter. All the agents used have been investigated clinically for the treatment of 
diabetic neuropathy primarily involving the sensory nervous system. The agents 
differed in their proposed sites of action acting in the prevention of oxidative stress or 
its consequences or by scavenging carbonyl species or preventing their production. 
Thus, a comparison of their effects also potentially provides a means with which to 
assess the relative roles of oxidative stress and carbonyl stress in the effects of acute 
exposure to high glucose. 
 
3.4.1 Oxidative Stress 
3.4.1.1. -Lipoic acid 
In this study, the anti-oxidant, -lipoic acid, did not influence the changes 
induced in VIP and nNOS positive neurons by culture per se. However, it did prevent 
the increase in the relative number of VIP-containing neurons on exposure to 
methylglyoxal and the decrease in the relative number of nNOS-containing neurons on 
exposure to AGE. Previously, in this laboratory, α-lipoic acid has also been shown to 
prevent the increase in VIP-containing neurons induced by exposure to high glucose 
(see Voukali et al., 2011).   
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The pharmacological properties of -lipoic acid mainly concern its reductive 
power and high reactivity with ROS, along with its metal chelating activity. Its 
mechanism of action is complex as -lipoic acid is considered a metabolic anti-oxidant 
in two ways: firstly because of its role in oxidative metabolism and secondly due to its 
effect on signal transduction and gene regulation, inhibiting NF-κB and Activator 
Protein 1 activation  (Packer et al., 1997). -Lipoic acid is an essential cofactor of 
multienzyme complexes controlling key reactions of energy metabolism, as it is 
involved in oxidative decarboxylation of pyruvate in the formation of acetate (Reed et 
al., 1951; Loffelhardt et al., 1995). It is located both in aqueous and membrane domains 
because it is soluble both in water and fats, which is a unique feature among anti-
oxidants (Packer et al., 1995). It is synthesised de novo or readily absorbed from the diet 
and enters the cell via a fatty acid carrier. Once inside the cell, it is converted to 
dihydrolipoic acid (Packer, 1994; Singh & Jialal, 2008;Shay et al., 2009). It interacts 
with other endogenous anti-oxidants since it is capable of regeneration of vitamins E 
and C. It has also been shown to induce an increase in intracellular levels of glutathione 
in a variety of cell types including neuroblastoma cells (Han et al., 1997).   
-Lipoic acid prevented the reduction in nNOS-containing myenteric neurons 
induced by BSA-AGE in the present study. These findings demonstrate that the 
mechanism underlying AGE-induced reduction of nNOS in myenteric neurons occurs 
via oxidative stress. Similarly, activation of RAGE induces oxidative stress in sensory 
neurons that can be prevented by -lipoic acid (Vincent et al. 2007a). In endothelial 
cells, -lipoic acid reduced AGE-related NF-κB transcription and expression and 
prevented the depletion of glutathione and ascorbic acid levels (Bierhaus et al., 1997). 
-Lipoic acid also inhibited the increase of VIP induced by high glucose 
(Voukali et al., 2011). Short term exposure of sensory neurons to high glucose in vitro 
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induced oxidative stress which was similarly inhibited by -lipoic acid (Vincent et al. 
2005a; Vincent et al. 2005b). Moreover, -lipoic acid reduced lipid peroxidation 
induced by exposure to high glucose of both sciatic nerve and brain in vitro in a dose 
dependent manner (Nickander et al., 1996). A study on the effect of the carbonyl 
species, methylglyoxal, in hepatocytes in vitro reported that exposure to methylglyoxal 
results in increased production of ROS and depletion of glutathione and thus provided 
evidence that the cytotoxic effects of methylglyoxal involve the development of 
oxidative stress (Shangari & O’Brien, 2004). The results presented here indicate that 
this is also likely to be the case in the present study on myenteric neurons. Exposure to 
methylglyoxal caused an increase in VIP-containing neurons that was prevented by the 
anti-oxidant α-lipoic acid.  
 
3.4.1.2  Nicotinamide 
Activation of the nuclear enzyme PARP has been proposed to mediate the 
cellular damage that occurs as a consequence of oxidative stress. Thus, PARP inhibitors 
have been investigated for their ability to prevent diabetic neuropathy due to oxidative 
stress (Obrosova et al. 2004; Stevens et al. 2007). Nicotinamide is a PARP inhibitor 
and, in the present study, nicotinamide prevented the increase in VIP-containing 
neurons that occurred on exposure to high glucose and methylglyoxal.  
Nicotinamide has been shown to prevent many of the consequences of PARP 
activation. It prevents the depletion of ATP and NAD that occurs in central neurons 
following cerebral ischaemia in vivo (Yang et al., 2002). In vitro, nicotinamide reduced 
cell injury induced by oxygen-glucose deprivation and reoxygenation of cortical 
neurons, a model of ischaemia/reperfusion. Markers of cell injury included lactate 
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dehygrogenase release, increased calcium influx, caspase-3 activation and nuclear 
condensation (Shen et al., 2004). In STZ-diabetic rats, administration of nicotinamide 
treatment prevented the reduction of NAD levels and the increased immunoreactivity 
for poly (ADP-ribose) induced in the sciatic nerve by diabetes (Negi et al., 2010). In the 
sciatic nerve, activation of PARP occurs in the nuclei of endothelial cells and Schwann 
cells (Obrosova et al., 2004). Exposure of human Schwann cells to high glucose in vitro 
causes increase in the levels of poly (ADP-ribosyl)ated proteins without changing the 
levels of PARP itself, an effect that can be prevented by nicotinamide (Stevens et al., 
2007). In functional studies, nicotinamide treatment has been shown to prevent or 
reverse sensory and motor nerve deficits in STZ-diabetic rats (Negi et al., 2010). To 
date, the effect of nicotinamide on autonomic neuropathy in diabetes has not been 
reported. However, another PARP inhibitor, 3-aminobenzamide, has been shown to 
partially correct impaired relaxation responses in the gastric fundus from diabetic rats, 
largely due to an improvement in nitrergic transmission (Gibson et al., 2006). 
In the present study, nicotinamide prevented the increase in the relative number 
of VIP-containing neurons induced by exposure to high glucose and methylglyoxal, but 
there is evidence that nicotinamide can also act as an anti-oxidant. It prevents the 
increased production of ROS induced in cortical neurons by hypoxia/reoxygenation 
(Shen et al., 2004). Nicotinamide also prevents lipid peroxidation in the sciatic nerve of 
STZ-diabetic rats and the increased levels of 4-hydroxynonenal adducts (marker for 
oxidative stress) in Schwann cells exposed to high glucose (Stevens et al., 2007). Using 
cultures of embryonic rat DRG neurons nicotinamide markedly inhibited the increased 
levels of apoptosis induced by both high glucose and hydrogen peroxide-mediated 
oxidative stress (Vincent et al., 2005b). Therefore, in the present study, the effect of 
nicotinamide on changes induced in myenteric neurons by oxidative stress on exposure 
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to menadione was also investigated. The effect of nicotinamide was examined at the 
same concentration (100 M) that prevented the increase in VIP-containing neurons 
induced by high glucose and methylglyoxal and was the same as the concentration of -
lipoic acid investigated here. At this concentration, nicotinamide prevented both the 
increase in VIP-containing neurons and the decrease in nNOS-containing neurons 
resulting from menadione-induced oxidative stress. In the study of embryonic DRG 
neurons in vitro, much higher concentrations of nicotinamide (10-25 mM) were 
required to prevent apoptosis induced by high glucose and only moderate inhibition of 
superoxide production was achieved at lower concentrations (0.5-1 mM). Thus the 
authors concluded that the primary mechanism by which nicotinamide prevents 
neuronal cell death is via the inhibition of PARP (Vincent et al., 2005b). In the present 
study, neuronal cell death was not a feature of the response to high glucose or 
methylglyoxal (see Chapter 2). From the results presented here, it appears more likely 
that the prevention of the effects of high glucose and methylglyoxal on adult VIP-
containing myenteric neurons by nicotinamide is by its ability to act as an anti-oxidant 
and that the changes observed in the myenteric plexus preparation may not occur via the 
activation of PARP.   
 
3.4.2 Carbonyl Stress   
3.4.2.1 Aminoguanidine 
Aminoguanidine was studied in an attempt to distinguish between the relative 
contributions of oxidative stress and carbonyl stress to the increase in VIP expression 
induced by high glucose. In an in vitro study using primary cultures of endothelial cells, 
the effects of exposure to methylglyoxal and high glucose concentrations were 
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investigated (Dhar et al., 2010). Incubation with high glucose and methylglyoxal 
resulted in increased levels of methylglyoxal within endothelial cells. Both 
methylglyoxal and high glucose had similar effects on endothelial cells, reducing the 
production of NO, the levels of glutathione and increasing the activity of the NADPH 
oxidase. All these changes were attenuated by the carbonyl scavenger aminoguanidine.  
The authors proposed that methylglyoxal could act as the mediator between 
hyperglycaemia and endothelial dysfunction (Dhar et al., 2010).  
Initially, in the present study, the effect of aminoguanidine was examined at the 
same concentration (100 M) as was used for -lipoic acid and nicotinamide. However, 
preliminary experiments revealed that, at this concentration, aminoguanidine was not 
effective in preventing the response to the carbonyl species methylglyoxal. Therefore a 
higher concentration of 500 M that was effective against methylglyoxal was used 
thereafter. Unlike -lipoic acid and nicotinamide, aminoguanidine had a significant 
effect on the expression of both VIP and nNOS in myenteric neurons maintained under 
control conditions of 10 mM glucose producing an increase in the relative number of 
VIP-containing neurons and a decrease in the number of nNOS-containing neurons. 
However, aminoguanidine had an opposite effect on preparations exposed to diabetic 
stimuli, lowering VIP expression and, in the case of oxidative stress, raising nNOS 
expression to levels observed in untreated control culture preparations. Thus, in the 
presence of diabetic stimuli, aminoguanidine was protective and prevented the effects of 
both high glucose and methylglyoxal. The mechanism by which aminoguanidine alters 
the expression of VIP and nNOS in control culture preparations is not known but a 
similar differential effect of aminoguanidine on nNOS-containing nerve fibres in control 
and STZ-diabetic rats has been reported. Aminoguanidine caused a significant increase 
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in the thickness of nNOS-containing nerve fibres in control rats but prevented the 
increase in fibre thickness caused by diabetes (Shotton et al., 2007).   
Aminoguanidine is a nucleophilic hydrazine compound, available as 
hydrochloride salt. The hydrazine group of aminoguanidine is the most reactive group 
with α-oxoaldehydes. The derivative of this interaction is a triazine product (Thornalley 
et al., 2000; Abdel-Rahman & Bolton, 2002; Thornalley, 2003b). The primary action of 
aminoguanidine is the inhibition of the formation of AGEs by scavenging dicarbonyls 
and reducing their concentrations in the cell (Brownlee et al., 1986). Other potential 
therapeutic actions of aminoguanidine are the inhibition of competitive enzymes such as 
inducible nitric oxide synthase, histaminase and semicarbazide-sensitive amine oxidase, 
a minor source of methylglyoxal (Thornalley, 2003b). In higher concentrations than 
those able to react with α-oxoaldehydes, aminoguanidine reacts with pyruvate and 
glucose with a potent pro-oxidant effect (>60 mM) (Suji & Sivakami, 2006). It has also 
been reported to be an aldose reductase inhibitor and chelator of metal ions (Cameron et 
al., 1992; Price et al., 2001). Finally, aminoguanidine can also act as an anti-oxidant, 
preventing the formation of ROS and lipid peroxidation in retinal Müller cells exposed 
to hydrogen peroxide (Giardino et al., 1998).      
In the present study, aminoguanidine prevented the changes in both VIP- and 
nNOS-containing neurons induced by oxidative stress indicating that it is also able to 
act as an anti-oxidant in myenteric plexus preparations. Thus, aminoguanidine was not 
sufficiently speciﬁc as a carbonyl scavenger to differentiate the contribution of carbonyl 
stress and oxidative stress to the responses to high glucose.  
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3.4.2.2  Thiamine  
 
Thiamine pyrophosphate, the phosphorylated active form of thiamine was added 
to myenteric neurons to evaluate its potential in inhibiting the effects induced by 
diabetic stimuli. Unlike all the other agents studied here, thiamine did not act as an anti-
oxidant since it did not prevent the increased expression of VIP or the decreased 
expression of nNOS in myenteric plexus preparations exposed to menadione. However, 
thiamine did prevent the increase in VIP-containing neurons induced by methylglyoxal.  
Thiamine has been reported to prevent lipid peroxidation of liver microsomes and the 
free radical oxidation of oleic acid in a cell free system thus a direct anti-oxidant action 
of thiamine was proposed (Lukienko et al., 2000). The thiamine derivative, 
benfotiamine, prevented oxidative stress due to a variety of stimuli in kidney cell lines 
and a direct anti-oxidant action of benfotiamine was observed in a cell-free assay. 
However, thiamine was unable to act as an anti-oxidant in either system (Schmid et al., 
2008). Thus, there is little evidence for thiamine being able to act as an anti-oxidant in 
intact cells. It has been suggested that the presence of the pyrophosphate group on 
thiamine limits its anti-oxidant capacity (Suji & Sivakami, 2007). Thiamine has been 
reported to prevent hepatocyte cell death induced by carbonyl stress but not oxidative 
stress (Mehta et al., 2008). This is similar to the pattern observed here where thiamine 
prevented the response of VIP-containing neurons to methylglyoxal but not to 
menadione.  
In the present study, thiamine did not prevent the response of VIP-containing 
neurons to high glucose while preventing the response to methylglyoxal. This is unlike 
studies of endothelial cells where thiamine or benfotiamine have been shown to protect 
against the effects of high glucose. The effects of high glucose on endothelial cells such 
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as impaired cell replication and migration, aldose reductase aberrant expression and 
apoptosis were countered when thiamine or benfotiamine were incubated together with 
high glucose (La et al., 1996;Ascher et al., 2001;Berrone et al., 2006;Beltramo et al., 
2009). Benfotiamine also prevented the activation of three major pathways involved in 
hyperglycaemia-induced vascular damage: the hexosamine pathway, the intracellular 
AGE formation pathway and the diacylglycerol-PKC pathway in both endothelial cells 
exposed to high glucose in vitro and the retina from STZ-diabetic rats (Hammes et al., 
2003).   
It has been proposed that thiamine or benfotiamine prevents hyperglycaemic 
damage by increasing the activity of transketolase. Increased transketolase activity has 
been demonstrated in the renal glomeruli and retina of diabetic rats (Babaei-Jadidi et al., 
2003), and in human red blood cells bovine aortic endothelial cells exposed to high 
glucose (Thornalley et al., 2001;Hammes et al., 2003). Transketolase is the rate limiting 
enzyme of the non oxidative branch of the pentose phosphate pathway, dependent on 
substrate and product concentration and on NADP+/NADPH ratio. Thiamine 
pyrophosphate acts as a coenzyme for transketolase and its activity in erythrocytes is 
often used as a marker for a deficit in thiamine. Transketolase, containing a tightly 
bound thiamine pyrophosphate as its prosthetic group, is able to shift excess fructose-6-
phosphate and glyceraldehyde- 3-phosphate (triosephosphates) from glycolysis into the 
pentose-phosphate shunt, thus preventing an accumulation of triosephosphates. This has 
the effect of preventing the formation of methylglyoxal and intracellular AGEs 
(Thornalley et al., 2001). As fas as we are aware, transketolase activity has not been 
measured in neurons. Whether differences between the endogenous levels of 
transketolase activity in endothelial cells and neurons accounts for the finding thiamine 
or benfotiamine prevents the effect of high glucose in endothelial cells but not in 
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myenteric neurons remains to be determined. However, the results presented here do not 
provide any evidence that the response of VIP-containing neurons to high glucose 
involves carbonyl stress. 
         The activation of transketolase by thiamine and subsequent prevention of the 
intracellular production of methylglyoxal could not be the mechanism for the prevention 
of the effect of carbonyl stress demonstrated here since carbonyl stress was induced by 
the exogenous application of methylglyoxal. Some years ago, it was reported that 
thiamine deficiency in rats results in a marked decrease in glyoxalase activity in the 
liver but it was not established whether this was due to a decrease in protein expression 
or a lack of its cofactor glutathione (Salem, 1954). More recently, it has been shown 
that the susceptibility of hepatocytes to glyoxal is dependent on cell thiamine content. 
Thiamine-deficient cells were unable dispose of glyoxal. In addition, glyoxal caused a 
depletion of glutathione in control hepatocytes that could be prevented by thiamine 
(Shangari et al., 2007). It is possible that in these myenteric plexus preparations, 
thiamine was preventing the effect of carbonyl stress by preserving the activity of 
glyoxalase and disposal of methylglyoxal.   
 
       
3.4.5 Conclusion 
 
         In conclusion, oxidative stress appears to be produced by all the diabetic stimuli 
since agents that were able to act as anti-oxidants also inhibited the effects of high 
glucose, methylglyoxal and AGEs. Aminoguanidine did not act exclusively as a 
carbonyl scavenger and could not be used to investigate the role of carbonyl stress in the 
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effect of high glucose. Thiamine was the only agent examined that did not act as an 
anti-oxidant and it prevented the effect of the carbonyl species, methylglyoxal but not 
the effect of high glucose. Therefore, the effect of high glucose on VIP-containing 
neurons did not appear to involve the production of carbonyl stress. This study was 
confined to the investigation of acute effects. It does not exclude the possibility that 
long term exposure to high glucose does lead to the production of carbonyl species and 
AGEs that subsequently affect myenteric neurons in vivo.     
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Chapter 4: Effect of Acute High 
Glucose on Different Populations 
of Living Sympathetic Neurons  
 
4.1 Introduction 
4.1.1 The Pyridine Nucleotides – NAD and NADP 
4.1.1.1 Biological roles of NAD and NADP 
The pyridine nucleotides NAD and the phosphorylated form NADP can  both 
exist in oxidised (NAD+ or NADP+) or reduced (NADH or NADPH) states. NADP+ 
structurally differs from NAD+ only by the additional 2’ phosphate on the adenosine 
ribose moiety. NAD+ and NADH or NADP+ and NADPH accept or donate a hydride in 
numerous reactions involving hydride transfer enzymes or oxidoreductases where the 
oxidized and reduced forms of pyridine nucleotides are interconverted dynamically. The 
NAD+/NADH couple is used in substrate oxidation. In contrast, the NADP+/NADPH 
couple is used in substrate reduction due to its more reduced state (Houtkooper et al., 
2010).  Pyridine nucleotides are water soluble and usually free to diffuse away after 
reaction.  
 126 
Pyridine nucleotides can act as coenzymes in a wide range of intracellular 
reactions. In the case of NAD, it has long been recognized that it has a major role in 
energy metabolism. It acts as an electron acceptor in glycolysis and, as NADH, is the 
major electron source for the electron transport chain in oxidative phosphorylation 
(Skala et al., 2007b; Ying, 2008). NAD
+
 also plays a role in regulatory and signalling 
pathways. These include: ADP-ribosylation reactions; gene transcription via its action 
on the Sir2 family of histone deacetylases; and acting as a precursor to the calcium 
mobilizing molecule cyclic ADP-ribose. In addition, depletion of NAD
+
 following 
activation of PARP-1 mediates cell death (Pollak et al., 2007; Ying, 2008). Apart from 
its role in reductive synthesis, NADPH plays a key role in cellular anti-oxidant defence. 
For example, NADPH is required for the recycling of the major intracellular anti-
oxidant, glutathione, from GSSG by glutathione reductase (Wu et al., 2004;Pollak et al., 
2007;Ying, 2008). However, NADPH is also a substrate for NADPH oxidase. This 
enzyme was initially studied in phagocytes where the activation of NADPH oxidase is a 
major generator of superoxides used in host defence. Since then NADPH oxidases have 
been identified in various tissues and cell types and activation has been implicated in a 
range of pathological conditions (Ying, 2008;Kakehi & Yabe-Nishimura, 2008).  
 
4.1.1.2 Cellular concentrations and redox ratio 
Estimates of total cellular pyridine nucleotide are commonly in the 
submillimolar range. The relative concentrations of these coenzymes differ in different 
cell compartments and this has a direct effect on metabolic pathways within those 
compartments (Krebs, 1967; Pollak et al., 2007). Intracellular levels of NAD (NAD+ 
plus NADH) are significantly higher than NADP (NADP+ plus NADPH) (Pollak et al., 
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2007; Ying, 2008). The majority of NAD is mitochondrial whereas the majority of 
NADP is cytosolic. Under physiological conditions, NAD+ is far more abundant than 
NADH and in contrast, the levels of NADPH are much higher than those of NADP+. 
Thus, total NADPH cellular levels are about 2-3 times higher than those of NADH. 
However, this may vary with cell type. Cells with high metabolic demand, such as 
neurons and heart cells have many more mitochondria containing NAD and NADPH 
levels are lower in cerebral and cardiac tissues than the liver (Wakita et al., 1995; Kann 
& Kovacs, 2007; Pollak et al., 2007; Ido, 2007; Ying, 2008). 
The cell has the capacity to regulate the ratios NAD+/NADH and 
NADP+/NADPH, the balance of which determines the cellular redox state, thus 
influencing cell function (Krebs, 1967). If any component of these couples increases, it 
does so at the expense of the other component of the system. Almost all metabolic 
pathways rely on pyridine nucleotides (energy metabolism and biosynthesis, 
antioxidation, calcium regulation, cell death and gene expression). Therefore, 
information on the value of the redox ratio is important, because it reflects the metabolic 
behaviour of oxidizable and reducible substrates. 
Normally, the cytosolic ratio of free NADP+/NADPH is about 0.02 whereas the 
ratio  of free NAD+/NADH is about 700, this is due to the majority of NADH being 
protein bound. Thus, in the cytosol, any oxidative reactions involving NAD will 
proceed by the conversion of NAD+ to NADH whereas the reducing capacity of the 
cytosol relies almost completely on the NADPH pool. In mitochondria where NAD 
dominates, the relationship shifts markedly towards the reduced form such that the 
NAD+/NADH ratio is about 7-8 (Ido, 2007;Pollak et al., 2007).       
Mitochondrial and cytosolic redox ratios will be the complicated end result of all 
the pathways in which pyridine nucleotides act as coenzymes, for instance the 
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glycolytic pathway; the mitochondrial pyruvate transporter and pyruvate dehydrogenase 
complex; the citric acid cycle; the respiratory chain where NADH is one of the major 
electron donors; and antioxidation systems where NADPH is a key component 
(Houtkooper et al., 2010). The resultant ratios can then influence cell metabolism. For 
example, in the cytosol, redox ratio determines the rate of glycolysis (Wahlberg et al., 
2000). In mitochondria, it determines the magnitude of the free energy changes of 
oxido-reductions like the transfer of the electrons from NADH to flavoproteins in the 
electron transport chain (Krebs, 1967).  
The ratios of NAD+/NADH and NADP+/NADPH can also modulate the 
opening of mitochondrial transition pores controlling the transport of small molecules 
across the mitochondrial membranes. NAD(P)+/NAD(P)H in the subcellular 
compartments are in direct contact and, in order to maintain ratios homeostasis, redox 
shuttles allow the transfer of the reducing equivalents across membranes which in 
general are impermeable toward the various nucleotides (Pollak et al., 2007).   
 
4.1.1.3 Pyridine nucleotides in diabetes 
 High intracellular glucose levels have been proposed to lead to alterations in the 
levels of NADH and NADPH and thus to a change in the redox balance of the cell. In 
the cytosol, the polyol pathway is activated by high glucose. The first step in this 
pathway is the conversion of glucose to sorbitol by aldose reductase during which 
NADPH is converted to NADP+. Sorbitol is then converted to fructose by sorbitol 
dehydrogenase via the reduction of NAD+ to NADH. The oxidation of glucose by 
glycolysis also occurs in the cytoplasm resulting in production of NADH and pyruvate. 
Following transport of pyruvate into mitochondria, further NADH is produced by the 
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TCA cycle providing electrons for the electron transport chain and oxidative 
phosphorylation (Wahlberg et al., 2000; Brownlee, 2001; Ido, 2007). Together these 
pathways will lead to an increase in NADH and a decrease in NADPH.            
Therefore, altered glucose catabolism leads to the reduction of the ratios of 
NAD+/NADH and NADPH/NADP+ in the cytosol and mitochondria, and this is 
described as “the reduction stress hypothesis” or pseudohypoxia. The fluctuations of 
free NADH and NADPH levels may lead to fundamental biochemical changes in 
metabolism and play a significant role in the development of diabetic complications. 
(Wahlberg et al., 2000). Imbalance of NADP+/ NADPH can also affect antioxidation 
pathways, such as GSH recycling from GSSG, inhibition of the reactivation of catalase 
and inhibition of the regeneration of thioredoxin (Ido et al., 1997; Ido, 2007).  
It is generally accepted that mitochondria are the major source of ROS in cells. 
However, more recently it has been proposed that ROS produced by a non-
mitochondrial enzyme-NADPH oxidase, are responsible for neuronal cell death in 
excitotoxicity (Brennan et al., 2009).  Activation of NADPH oxidase has been 
implicated in oxidative stress in diabetes and the development of diabetic complications 
predominantly affecting the vasculature and kidney (Nitti et al., 2007; Kakehi & Yabe-
Nishimura, 2008;Sedeek et al., 2012).  
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4.1.2 The intrinsic fluorescence of NAD(P)H and multiphoton microscopy imaging 
 
A particular NAD(P)+/NAD(P)H ratio, localised in one particular subcellular 
compartment may be calculated from the concentrations of certain oxidized or reduced 
substrates participated in a dehydrogenase reaction. Thus, NAD+/NADH and 
NADP+/NADPH are reflected by several sets of metabolites (for example lactate and 
pyruvate, β-hydroxybutyrate and acetoacetate). The concentration of these metabolites 
has been used to indicate the NAD redox state in mitochondria and the cytosol (Krebs, 
1967; Tischler et al., 1977;Houtkooper et al., 2010). The problem with the metabolite 
indicator methods is that it is difficult to calculate the overall reduced forms of pyridine 
nucleotides because these methods do not differentiate free nucleotides from those that 
bind to proteins.  
This methodological difficulty is now overcome by advanced technologies of 
imaging and microscopy. Multiphoton microscopy and FLIM enable more exact and 
dynamic estimates of the intracellular distribution of pyridine nucleotides. By these 
techniques, the researchers are now able to image intracellular pyridine nucleotides and 
distinguish between protein-bound and free nucleotides in living cells, based on the 
fluorescence properties of the reduced pyridine nucleotides.  
Changes in the oxidation-reduction levels can be continuously recorded through 
the fluorescence yield of the reduced forms of pyridine nucleotides since the oxidized 
forms do not fluoresce (Chance & Thorell, 1959). Imaging of intrinsic fluorescence has 
been a useful tool to study the NADH:NAD+ ratio and cellular energy metabolism 
(Chance et al., 1962). NADPH fluorescence is weaker than that of NADH and is 
constant with respect to metabolic perturbations (Kumar et al., 2007). However, it is 
common to refer NAD(P)H in fluorescence studies because the spectra of NADH and 
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NADPH are indistinguishable. NAD(P)H are poor fluorophores compared with artificial 
probes (Piston & Knobel, 1999). Nevertheless, NAD(P)H is present in submillimolar 
amounts in the cell so it is possible to measure the native fluorescence using microscopy 
particularly in highly metabolic cells.  
Initially, methods for imaging NAD(P)H in high resolution involved one-photon 
excitation (confocal microscopy) at near UV wavelengths. Absorption of a single 
photon delivers sufficient energy for the fluorophore molecule to reach the excited state, 
from which it returns to the ground state by emitting a photon of fluorescence 
(Lichtman & Conchello, 2005). Normally, native NAD(P)H fluorescence is excited with 
light of about 360 nm and emits at about 550 nm wavelength. With confocal laser 
scanning microscopy, the microscope uses a laser beam to supply the energy for 
excitation, uniformly focused within a small spot on the specimen, and a 
photomultiplier tube then detects the fluorescent light emitted from the sample (Gadella 
et al., 2012). With this technique, the excitation of fluorescent species is achieved above 
and below the plane of focus, resulting in blurring of the image. To overcome this, 
confocal microscopes utilise a pinhole to exclude out-of-focus background fluorescence 
from detection and increase the spatial resolution from within thick samples (Fine et al., 
1988;Piston et al., 2012).  
Fluorescence laser scanning microscopy offers the possibility of working with 
living specimens. However, applications of one-photon microscopy have been limited 
due to photobleaching of the intrinsic fluorophores, photodamage to biological samples 
and significant light scattering. The high intensity UV radiation is particularly damaging 
to living cells and tissues (Piston & Knobel, 1999). In addition, although fluorescence is 
excited throughout the specimen, only a signal originating in the focal plane passes 
through the confocal pinhole, allowing background data to be collected. Thus, the entire 
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specimen can be bleached even when only a single plane is imaged (Denk et al., 1990; 
Piston et al., 2012).  
These difficulties are overcome by using two photon (or multiphoton) 
microscopy with near-infrared excitation. According to the physical principle that the 
absorption depends on the square of the excitation intensity, it is possible for multiple 
photons to add their energy to bring the molecule to the excited state (Zipfel et al., 
2003; Lichtman & Conchello, 2005). With two photon excitation, the fluorescence 
arises from the simultaneous absorption of two photons of about twice the wavelength 
required for single photon excitation. Thus, NAD(P)H that normally absorbs UV of 
about 360 nm, can also be excited by two photons of near-infrared light of ~750 nm if 
both reach the fluorophore at the same time. The resulting emission is the same as 
emission generated in one-photon excitation with the same high level of resolution.  
In addition to reduced photobleaching and photodamage (resulting in increased 
viability of the biological samples), two photon microscopy provides intrinsic 3-D 
resolution due to the capability of deep imaging (up to 500 μm) and minor light 
scattering (Zipfel et al., 2003;Cicchi & Pavone, 2011). The probability of two photons 
being scattered simultaneously to the same specimen location is close to zero. Since 
out-of-focus fluorescence is never generated, two photon microscopy provides optical 
sectioning without the introduction of a pinhole in the detection path. All of the signal is 
collected by a large area detector and contributes to the final image (nondescanned 
acquisition mode) (Rubart, 2004;Piston et al., 2012).   
Two photon NAD(P)H fluorescence has become the preferred method to image 
living cells and tissue providing spatiotemporal information at subcellular resolution. 
Since the probes are active participants in cellular processes, NAD(P)H imaging yields 
the optical dissection of dynamic metabolism. So far, NAD(P)H multiphoton imaging 
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has been applied to  a range of cell types (Patterson et al., 2000;Shuttleworth et al., 
2003;Rocheleau et al., 2004;Kasischke et al., 2004).   
 
4.1.3 Fluorescence Lifetime Imaging Microscopy (FLIM)     
 
In combination with multiphoton fluorescence microscopy, FLIM allows the 
protein bound and free NAD(P)H native fluorescence to be distinguished in living cells.  
Instead of the measurement of the fluorescence intensity, FLIM is based on the 
measurement of the fluorescence lifetime. The fluorescent lifetime is one of the inherent 
characteristics of a fluorophore, along with brightness and wavelength. Its value derives 
from the measurement of the average time the fluorophore spends in the excited state, 
before returning to the ground state, or otherwise, the decay rate of the fluorescence 
emission after the excitation radiation has ceased (Tadrous, 2000; Sud et al., 2006). 
Lacowicz et al. firstly showed that free NAD(P)H and bound NAD(P)H in malate 
dehydrogenase had different fluorescence lifetimes in solution and were able to map the 
spatially-dependent decay times on 3-D projection in which the height represents the 
local decay time (Lakowicz et al., 1992b). NAD(P)H have typical fluorescence lifetimes 
in the range of hundreds of picoseconds when free, to a few nanoseconds when protein-
bound. 
The advantage of FLIM is that fluorescence lifetime is independent of 
fluorophore concentration, photobleaching, absorption and scattering, but it is 
determined by the local microenvironment of the fluorophore. Oxygen, pH, ions such as 
Ca
2+
, energy transfer and molecular associations may all influence its value. Therefore, 
the measurement of the fluorescence lifetime of a fluorophore can be used to probe the 
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local chemical composition of the cell or tissue (Lacowicz et al., 1992a; Lacowicz et al., 
1992b;Bastiaens & Squire, 1999;Tadrous, 2000;Cicchi & Pavone, 2011). Each pixel 
from an image obtained by means of FLIM maps such measurements and provides a 
contrast based on the local biophysical and biochemical properties of the sample. 
Accordingly, pixel values in a FLIM image calculated for NAD(P)H lifetimes, besides 
the imaging of free vs. protein bound NAD(P)H in cells recovered from 
(sub)nanosecond fluorescence lifetimes, also reflect the chemical variation in the 
intracellular milieu.  
The multiphoton FLIM instrumentation setup employs the multiphoton 
microscope system with the laser mode-locked titanium sapphire pumped by an Argon 
Ion Laser as light source, nondescanned detectors connected with the data acquisition 
computer with Time Correlated Single Photon Counting (TCSPC) card (French et al., 
1998;Van Munster & Gadella, 2005;Niesner et al., 2008b). TCSPC is a precise 
technique applied with the time domain method for FLIM and requires fast electronics. 
With the time domain method, the fluorescence lifetime is determined by the 
measurement of the fluorescence decay when the fluorescence intensity drops to about 
37% of its initial value, after the sample has been excited by a pulse of laser scanning 
imaging systems with picosecond and femtosecond pulsed sources (pulsed diode laser 
and Ti:Sapphire) (Bastiaens & Squire, 1999;Tadrous, 2000;Cicchi & Pavone, 2011).  
The TCSPC method measures the distribution in time of the exponential of the 
fluorescence emission of the molecules (Cicchi & Pavone, 2011). Multidimensional 
TCSPC recording process builds up a 4-D photon distribution over the times of the 
photons in the excitation pulse period, the wavelengths of the photons and the co-
ordinates of the scan area and can be used for double exponential decays such as 
NAD(P)H free and NAD(P)H protein bound fluorescence lifetimes (Becker et al., 
 135 
2007b). TCSPC is the preferred technique for measuring fluorescence lifetime of tissue 
endogenous molecules because it is sensitive to the low signal fluorescence (Cicchi & 
Pavone, 2011).  
 
4.1.4 Selective vulnerability of the prevertebral CG/SMG sympathetic neurons in 
diabetes      
 
In clinical and experimental diabetes, the sympathetic ganglia do not all respond 
in the same way to diabetes. The prevertebral CG/SMG complex that innervates the 
stomach, gall bladder and small intestine, selectively develops neuroaxonal dystrophy 
as a morphologic response to metabolic alterations caused by diabetes and aging 
(Schmidt et al., 1993; Schmidt, 1996; Schmidt et al., 1997; Schmidt, 2002). 
Neuroaxonal dystrophy is characterised by the presence of abnormal neurites and 
synaptic constituents and impaired neuroaxonal regenerating capability without 
neuronal loss (Schmidt et al., 1993;Schmidt, 1996;Schmidt et al., 1997;Schmidt, 2002).  
In contrast, the paravertebral SCG or prevertebral IMG are resistant to diabetes. 
SCG innervate the face and the neck and are located behind the bifurcations of the 
superior cervical arteries. Extensive literature provides evidence that SCG are not 
affected by human and experimental diabetes whereas the CG/SMG are (Schmidt, 
2002). Also, the IMG that innervates the distal colon is relatively spared. NA 
accumulates in the CG/SMG but not the IMG in the STZ-diabetic rats and this is 
accompanied by a decrease in the level of NA in the ileum but not in the distal colon 
(Belai et al. 1991;Shotton et al., 2007). Thus, pathologic lesions affecting the 
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sympathetic innervation of the alimentary tract primarily affect the sympathetic neurons 
innervating the small intestine.  
The activity and the mRNA levels of TH increase in the CG/SMG of diabetic 
STZ rats (Schmidt & Cogswell, 1989) and TH and NA immunoreactivity levels are 
reduced in the diabetic STZ rat ileum (Shotton et al., 2007), suggesting 
neurodegeneration of the nerve fibres. Increased activity of TH in CG/SMG was 
accompanied with increased endogenous NGF, but not with changes in its receptors 
(Schmidt et al., 2000). The increase in this case was considered to be indicative of a 
harmful role of the neurotrophic factor. Also, the ability of CG/SMG nerve fibres to 
regenerate is diminished in several diabetic animal models (Yagihashi & Sima, 
1985;Schmidt et al., 2003;Schmidt et al., 2004). 
In vitro studies comparing CG/SMG and SCG provide evidence that 
vulnerability in diabetes may reflect properties of the neurons themselves, since 
CG/SMG are particularly susceptible to oxidative stress and glucose toxicity. CG/SMG 
showed a slower neurite regenerative capacity than SCG neurons in vitro after exposure 
to high glucose for 24 h (Semra et al., 2004). Oxidative stress selectively caused 
increased TH immunoreactivity in CG/SMG but not in SCG, a pattern that was also 
observed in diabetes in vivo (Semra et al., 2006). Application of NGF in vitro prevented 
the decreased cell viability induced by hyperglycaemic stress in SCG but not in 
CG/SMG (Semra et al., 2009). 
It is important to note that neuronal cell death is not a feature in sympathetic 
ganglia in STZ-diabetes (Schmidt, 2001). Using dissociated sympathetic neurons from 
embryonic SCG, high glucose has been shown to cause inhibition of neurite outgrowth 
and growth cones and apoptosis (Russell & Feldman, 1999). However, studies from this 
laboratory have demonstrated that neonatal SCG neurons are more susceptible to high 
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glucose than adult SCG neurons and that less cell death occurs in explants than 
dissociated neurons on exposure to high glucose (Semra et al., 2006;Semra et al., 2009). 
NAD(P)H metabolism has not been investigated in sympathetic neurons. However, 
NAD(P)H lifetimes are known to change on activation of  hippocampal neurons  (Chia 
et al., 2008). NADPH oxidase activation has been demonstrated in CG neurons in 
hypertensive rats (Cao et al., 2009). In addition, the mitochondrial enzyme, NADH 
oxidase has been reported to be activated in embryonic DRG neurons on exposure to 
high glucose (Vincent et al., 2005a).      
 
          The overall aim of this chapter was to investigate NAD(P)H metabolism in living 
SCG and CG/SMG explants from adult rats after exposure to hyperglycaemic stress in 
vitro using two photon microscopy and FLIM. Specifically, in living SCG and 
CG/SMG neurons, we aimed to compare the effects of high glucose on native 
NAD(P)H fluorescence, to determine the lifetimes of free and bound NAD(P)H using 
FLIM and to compare the effects of exposure to high glucose on NAD(P)H lifetimes 
between the ganglia. 
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4.2 Materials and methods  
4.2.1 Tissue preparation  
 
 Adult male Sprague–Dawley rats (275-350 g) were killed by CO2 asphyxiation 
complying with UK Home Office legislation. The SCG and the CG/SMG ganglia 
complexes were dissected out, desheathed and washed in antibiotic solution (HBSS 
containing 1% penicillin-streptomycin, 2% gentamycin and 2% 5mg mlˉ¹ 
metronidazole). Each ganglion was cut into 2-3 segments and pinned onto glass 
petridishes with a Sylgard covered base (VWR, Buffalo Grove, IL, USA). The samples 
were cultured in defined culture medium without Phenol Red, containing 10 mM 
glucose (M199, supplemented with 1% L-Glutamine, 1% Hepes Buffer, 1% penicillin-
streptomycin, 0.35% Pathocyte-4-BSA, 60 ng mlˉ¹ progesterone, 0.016 mg mlˉ¹ 
putrescine, 400 ng mlˉ¹ l-thyroxine, 38 ng mlˉ¹ sodium selenite, 340 ng mlˉ¹ 
triiodothyronine, 100 μg mlˉ¹ transferrin) in the absence of NGF and serum. The 
presence of Phenol Red in the culture medium has been found to absorb approximately 
30% of the emitted fluorescence signal thus significantly reducing sensitivity (Becker et 
al., 2007a). Ganglia were allowed to equilibrate for 24 h under control conditions (10 
mM glucose) before acute exposure to 30 mM glucose concentration (30 min and 120 
min). Additional experiments included CG/SMG and SCG neurons maintained for 24h 
in media containing 10mM and 30mM glucose.  
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4.2.2 Imaging 
 Multiphoton imaging of ganglia was performed in the dark on a Leica SP2 
multiphoton microscope (Leica, Milton Keynes, UK) with a Spectra-Physics (Didcot, 
Oxon) Millennia 8 W pump laser driving a mode-locked Tsunami Ti:Sapphire laser. 
The pulse width was 100fs at 80MHz repetition rate with the laser power set to deliver 
30-70 mW of average power to the specimen at 750 nm.  
Detection of the signal was via the non-de-scanned detectors by a photon-
counting photomultiplier tube (H7422P-40; Hamamatsu Photonics K.K., Hamamatsu, 
Japan).  
The microscope utilized a Gibraltar motorized xy- stage and was housed inside a 
Ludin chamber which maintained the temperature at 37
o 
C with a delivery of 5% CO2 to 
the specimen. The specimen was kept stable in a sylgard-coated petridish, and viewed 
using a 63x (0.9 NA) ceramic dipping objective. In order to overcome problems of 
relative movement of microscope and tissue associated with temperature changes, it was 
necessary to heat the Ludin chamber to 37°C for at least 30 min prior to imaging and to 
allow the specimen to equilibrate for at least 30 min before imaging began.  
To compare the emitted fluorescence intensity between controls and treated 
cells, images from 4D data sets were saved using the Leica SP2 Multiphoton confocal 
LCS (Leica Microsystems Ltd, Milton Keynes, UK) software package. Image resolution 
was set to 1024 × 1024 pixels at 8-bit gray depth. All images were obtained under 
identical experimental conditions. Preliminary experiments were carried out to 
determine if exposure of the neurons to FLIM analysis had an effect on native 
fluorescence intensity.  
Time domain FLIM images were captured using a BH SPC-830 multichannel 
single-photon counting board (Becker & Hickl GmbH, Berlin, Germany). NAD(P)H 
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fluorescence was filtered through a 550 nm short-pass filter (Chroma Technologies, 
Rockingham, VT). Additional short pass and Instrument Response cut off filters were 
used to reject reflected or scattered excitation light at 750 nm. Images were acquired by 
summation of 30, 4-second scans to ensure enough photon counts were collected at the 
laser power used for further data/statistical analysis.      
Fluorescence decay curves in image pixels were processed using SPC Image 
software (version 2.9.4, Becker & Hickl). The software was able to calculate the basic 
fluorescence lifetimes on a pixel-by-pixel basis and account for the instrument response 
function. For every pixel in the image, the four nearest-neighbor pixels relative to each 
central pixel were binned together to increase photon counts for improved decay fits. 
All NAD(P)H lifetime calculations were fitted to two-components (T1 and T2), as 
determined by obtaining the lowest χ² value; this gives an indication of how accurate the 
fit is and should be as close to 1 as possible. Typical signal levels after binning were 
roughly 1,000 photons per pixel. The software minimizes the χ² value between the data 
and the model function during the fit process (Becker, 2008). The result is a set of 
parameters such as lifetimes of individual species and their relative amplitudes for each 
individual pixel of the image. In this study the selected fit parameters were T1 and T2 
(free NAD(P)H and bound NAD(P)H fluorescence lifetimes, respectively), a1% 
(percentage or amplitude of the T1 lifetime) and χ² (accuracy of fit for a 2-component 
system).  
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4.2.3 Analysis and statistics 
Estimation of the fluorescence intensity was processed using Image J (ver. 
1.43u). For each image, all the fluorescent neurons were delineated and the fluorescence 
intensity was measured in each neuron. The average fluorescence intensity (from a 
minimum of 8 neurons) was calculated for each explant and this value was used for 
statistical analysis. Images from the same field in each explant were acquired following 
exposure to high glucose and fluorescence intensity measured as above and the effect of 
glucose was assessed using a paired student’s t-test. Separate explants, maintained in 10 
mM or 30 mM glucose, were used for the study of the effect of 24 h exposure to high 
glucose. The analysis of native fluorescence intensity was as described above except 
that an unpaired student’s t-test was used for statistical analysis. 
In preliminary experiments on SCG explants, the SPC image acquired by FLIM 
was analyzed in two ways. Firstly, the fluorescence lifetimes T1 and T2 were calculated 
for the entire field (neurons and neuropil) and the lifetime ranges were colour coded to 
examine the distribution of lifetimes throughout the explant. In the same image T1 and 
T2 were also calculated for individual delineated neurons in order to exclude the 
contribution from the neuropil and the average was taken from a minimum of 10 
neurons. In all subsequent experiments, T1, T2, a1% and χ2 were calculated in 
delineated neurons and an average was taken from a minimum of 10 neurons per 
explant under control conditions (10 mM glucose) and after exposure to 30 mM glucose 
for 30, 120 mins and 24 h. Two-way ANOVA followed by Bonferroni post hoc tests 
(GraphPad Prism 3 software) were used to analyze the effects of the ganglionic source 
of the sympathetic neurons (CG/SMG or SCG) and of high glucose. A level of 
probability of p < 0.05 was taken to indicate statistical significance. Micrograph 
pictures were produced using Photoshop Elements 8 software.   
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4.3 Results  
 
Using two photon excitation at 750 nm, the native NAD(P)H fluorescence at 
~550nm emission was readily observed without photobleaching the specimen. 
Examples are given in figs. 4.1 and 4.2 with green pseudocolour mapping representing 
native NAD(P)H fluorescence. Only the neuronal soma could be discerned and the 
neuronal nuclei were negative. Within the cytoplasm the fluorescence appeared 
punctate.  
 
4.3.1 NAD(P)H fluorescence intensity in CG/SMG and SCG after acute and 24 h 
exposure to high glucose 
 
Preliminary experiments were carried out on SCG explants maintained under 
control conditions to examine the effect of exposure to FLIM on native NAD(P)H 
fluorescence and the results are given in fig. 4.3. NAD(P)H intensity was measured 
before exposure to FLIM and then in the same neurons following either one (at t0) or 
two successive exposures to FLIM (t0 and t12). NAD(P)H fluorescence intensity was 
significantly increased within 24mins following two exposures to FLIM and within 
50mins following one exposure. As a consequence all subsequent analyses on the effect 
of high glucose on native NAD(P)H fluorescence were only performed on fields within 
the explants that had not been exposed to FLIM.      
The acute effect of high glucose was assessed by measuring native NAD(P)H 
fluorescence in the same neurons before and after exposure to 30mM glucose for 30 and 
120 mins and the results are given in fig. 4.1. The values within each explant have been 
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given individually to illustrate the effect on the paired samples. In all CG/SMG 
explants, exposure to high glucose resulted in an increase in native NAD(P)H 
fluorescence and there was a statistically significant (p < 0.001) increase in the mean 
values at after both 30 and 120 mins. In contrast, no consistent effect was observed in 
SCG explants after 30 mins and there was no significant difference between the means. 
There was a trend for an increase in fluorescence intensity in the SCG after 120 mins. 
However, only 3 SCG explants were available for analysis 120 mins after 
administration of high glucose that had not been exposed to FLIM.    
NAD(P)H fluorescence intensity was also measured in explants exposed to 
30mM glucose for 24h and compared with explants maintained under control conditions 
(10mM glucose) for 24h and the results are given in fig. 4.2. The increase in NAD(P)H 
fluorescence observed in CG/SMG neurons after 30 mins was not maintained such that 
there was no significant difference between the two groups after 24 h. SCG neurons 
were unaffected by exposure to high glucose for 24 h.    
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Figure 4.1: Effect of incubation with 30 mM glucose for 30 minutes on native 
NAD(P)H fluorescence in living CG/SMG (CG) and SCG neurons. 
(A) Photomicrographs of native NAD(P)H fluorescence of SCG and CG/SMG neurons 
incubated with control glucose (t0, 10mM) and 30 minutes after incubation with high 
glucose (t30, 30 mM). No difference was observed in SCG neurons, however, 
fluorescence increased in CG/SMG neurons after exposure to 30mM glucose. Arrows 
indicate neurons that become visible after exposure to high glucose. Calibration bar 
represents 30 µm.  
(B and C) Quantitation of fluorescence intensity (Gray values). Fluorescence intensity 
was measured in the same SCG and CG/SMG neurons before and after exposure to 
30mM glucose for 30 and 120 mins respectively. The average value for each SCG 
explant is represented by open circles (n = 3-4) and for each CG/SMG explant by closed 
circles (n = 7). Note the significant increase in fluorescence intensity in CG/SMG 
neurons (p < 0.001, paired t-test) while fluorescence intensity in SCG neurons was not 
affected. 
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Figure 4.2: Effect of incubation with 30 mM for 24 hrs on native NAD(P)H 
fluorescence in living CG/SMG (CG) and SCG neurons. 
(A) Photomicrographs of native NAD(P)H fluorescence of SCG and CG/SMG neurons 
incubated with control glucose (t0, 10 mM) and after overnight incubation with high 
glucose (t24h, 30 mM). No difference was observed in either SCG or CG/SMG neurons 
after exposure to 30 mM glucose for 24 h. Calibration bar represents 30 µm.  
(B) Quantitation of fluorescence intensity (Gray values). Intensity was measured in 
control neurons (t0, clear bars) in SCG (n = 6) and CG/SMG (n = 7) explants. Different 
explants were assessed after 24 h incubation with 30 mM glucose (t24h, black bars, 
SCG n = 6; CG n = 5) Data are presented as the mean ± SEM. No significant 
differences were observed in either SCG or CG/SMG neurons (unpaired t-test). 
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Figure 4.3: Effect of repetitive FLIM photoexcitation on native NAD(P)H fluorescence 
intensity. Data for two individual experiments on SCG explants are represented and 
given as the mean ± SEM. In the first experiment, intensity was measured before (t0, 
clear bar, n = 13 neurons) and 12 mins (t12, gray bar, n = 15) and 24 mins (t24, hatched 
bar, n = 15) after exposure to FLIM. In the second experiment, intensity was measured 
before (t0, clear bar, n = 24) and 50 mins after exposure to FLIM (t50, black bar, n = 
24). Note that in both cases, exposure to FLIM resulted in a significant increase in 
fluorescence intensity for NAD(P)H over time. * p < 0.05, *** p < 0.001. 
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Figure 4.4: NAD(P)H fluorescence lifetime analysis of an SCG explant.  
The explant was scanned from 0 to 4000 psecs and revealed two species, T1 
representing free NAD(P)H and T2 representing bound NAD(P)H. 
(A) The whole field was analyzed without discrimination of the neurons from the 
neuropil and colour coding was used to visualize different lifetime ranges. T1: red 
represents 200-650 psecs and green 650-1300 psecs. T2: blue represents 2000-2700 
psecs and yellow 2700-4000 psecs. Note that for both T1 and T2 the lower lifetime 
range was localized exclusively in neurons and the higher range was localized in the 
neuropil. Calibration bar respresents 50 µm. 
(B) Lifetime analysis was performed on the entire field and exclusively on the neurons 
within the same field and the data are represented graphically. Note that when the entire 
field including both neurons and neuropil was analyzed the peaks for both T1 and T2 
were broader and skewed indicating the presence of more than one component for each 
species. In contrast, when neurons were analyzed separately the peaks for T1 and T2 
were narrow and symmetrical. 
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4.3.2 FLIM analysis 
 
Preliminary experiments using SCG explants demonstrated that when the field 
was analysed as a whole, without discrimination of the neurons from the neuropil, two 
main components, free NAD(P)H (T1) and bound NAD(P)H (T2) were revealed. 
However, the peaks were not symmetrical indicating that each component might not be 
homogeneous over the entire field (fig. 4.4B). This was confirmed when using colour 
coding. It was demonstrated that both T1 and T2 lifetimes in neuronal cell bodies 
tended to be shorter than those in the neuropil (fig 4.4A). It should be noted that in order 
to obtain sufficient photons in the neuropil for analysis, it was necessary to increase the 
bin width (15) which reduced the resolution such that the distribution of free and bound 
NAD(P)H no longer appeared punctate. When T1 and T2 were analysed selectively in  
delineated neurons from the same field, the peaks were sharp and symmetrical (fig. 
4.4B) indicating that components with slightly longer lifetimes from the neuropil had 
been excluded. As a consequence all subsequent analysis was performed on delineated 
neuronal cell bodies alone. 
 
 
4.3.3 FLIM analysis of the effects of glucose and ganglionic source 
 
FLIM analysis was performed for the following parameters: T1 [free 
NAD(P)H], T2 [bound NAD(P)H], a1 (the percentage of the total photons within the T1 
component), and χ2 values. The results for CG/SMG and SCG neurons under control 
conditions and following exposure to high glucose for 30 min and 24 h have been given 
in fig. 4.5. The values for χ2 were close to 1 for all the groups indicated that the 
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NAD(P)H fluorescence did conform to a two component system. There were no 
significant differences between the ganglia and exposure to high glucose had no effect. 
The majority of NAD(P)H was in the unbound form since the average a1 was 70%. 
There was no significant difference in this percentage between the different ganglia or 
on exposure to high glucose. The fluorescence lifetime of free NAD(P)H (T1) tended to 
be higher in CG/SMG neurons than SCG neurons. Two way ANOVA revealed that 
there was a significant effect of the ganglionic source on T1 (p < 0.01). Comparisons 
between individual groups demonstrated that following exposure to high glucose for 30 
mins, the difference in T1 between CG/SMG and SCG neurons was significant (p < 
0.05). However, glucose did not significantly affect T1 in neurons from either ganglion. 
The values for T2 were similar in all groups with no significant effect of ganglionic 
source or high glucose.   
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Figure 4.5: Comparison of the effect of high glucose on fluorescence lifetime analysis 
of NAD(P)H in SCG and CG/SMG (CG) neurons. Analysis was performed before (t0) 
and 30 min (t30) and 24 h (t24h) after exposure to 30 mM glucose. Data are given as the 
mean ± SEM and were analyzed using two-way ANOVA with high glucose and 
ganglionic source as factors. Clear bars represent SCG neurons (n = 6 for all time 
points). Black bars represent CG/SMG neurons (t0 and t30, n = 7; t24h, n = 5).  
A. T1: Fluorescence lifetime of free NAD(P)H. Exposure to high glucose did not have 
any effect on T1 in either SCG or CG/SMG. T1 tended to be lower in the CG/SMG than 
SCG and this was statistically significant after 30 min exposure to high glucose. B. T2: 
Fluorescence lifetime of bound NAD(P)H. T2 was not affected by exposure to high 
glucose or ganglion. C. a1: Percentage of the total number of photons due to T1. The 
proportion of photons detected due to free NAD(P)H was not affected by either 
exposure to high glucose or ganglion. D. χ²: Assessment of the two component analysis. 
Neither exposure to high glucose nor ganglion influenced χ².                
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4.4 Discussion 
 
In this study we investigated the pyridine nucleotide metabolism after acute and 
24 h exposure to high glucose in vitro using two photon excitation of NAD(P)H native 
fluorescence and FLIM analysis of the free and bound components of NAD(P)H. The 
results from this study show that adult CG/SMG and SCG neurons from normal rats 
survive after exposure to hyperglycemic insult. However, changes in NAD(P)H 
metabolism were detectable after exposure to high glucose for 30 min that were not 
maintained with longer exposure for 24 h. These acute effects occurred selectively in 
CG/SMG and not in SCG neuronal cell bodies.     
The non-invasive technique of fluorescence microscopy offers the possibility to 
detect four species of autofluorescence in a cell. Besides NAD(P)H, flavoproteins, 
catecholamines and indoleamines are autofluorescent. The parameters used for the two 
photon microscopy (excitation 750 nm, emission 550 nm) were similar to those used for 
imaging NAD(P)H in rat brain slices (Chia et al., 2008). Serotonin and tryptophan 
fluoresce in the near UV range (340 nm). Furthermore, serotonin, dopamine, 
norepinephrine and tryptophan do not fluoresce at excitation wavelengths above 580 nm 
(Balaji et al., 2004;Botchway et al., 2008). Flavins do fluoresce in the 550 nm region. 
However, flavins require an excitation wavelength of at least 890 nm and, at an 
excitation wavelength of 750 nm, fluorescence has been reported to be due to NAD(P)H 
(Huang et al., 2002a;Skala et al., 2007b). In addition, the fluorescence lifetimes 
corresponded to those reported for NAD(P)H rather than flavins (Skala et al., 2007b). 
Thus, the fluorescence quantified here represents NAD(P)H rather than other potential 
autofluorescent species within the cell.  
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Only the neuronal cell bodies could be visualized with native NAD(P)H 
fluorescence which probably reflects the high density of mitochondria in neurons (Kann 
& Kovacs, 2007). In cardiac myocytes, the contribution of cytosolic NAD(P)H to native 
fluorescence has been reported to be negligible compared with that of mitochondria. On 
its own, fluorescence does not distinguish between NADH and NADPH. However, 
changes in fluorescence in cardiac myocytes in response to cyanide and a mitochondrial 
uncoupler indicated that it was primarily due to NADH rather than NADPH (Eng et al., 
1989). After synaptic activation, mitochondrial NADH transients dominate NAD(P)H 
autofluorescence signals in CNS neurons (Shuttleworth et al., 2003;Brennan et al., 
2006;Brennan et al., 2007;Shuttleworth, 2010). Thus, it is likely that the fluorescence 
measured here reflects mitochondrial NADH but similar experiments are required to 
establish unequivocally that this is the case for sympathetic neurons.  
  
4.4.1 Effect of exposure to high glucose on NAD(P)H metabolism 
 
It was originally intended to measure NAD(P)H fluorescence and fluorescence 
lifetimes in the same neurons. However, FLIM requires more prolonged excitation than 
that required for native fluorescence alone with potential cellular effects. Preliminary 
experiments demonstrated that exposure to FLIM caused an increase in NAD(P)H 
fluorescence. Therefore, NAD(P)H fluorescence intensity was only measured in 
neurons that had not been exposed to FLIM.  
Exposure to high glucose for 30 min caused a significant increase in NAD(P)H 
fluorescence intensity in CG/SMG neurons. A transient decrease in NAD(P)H 
fluorescence was observed in adult DRG neurons 10 min after exposure to 50 mM 
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glucose (Huang et al., 2003). However, this was measured using one photon confocal 
microscopy and it cannot be excluded that this was harmful to the cells. Our results are 
in line with a study by Evans and colleagues who reported similar increased 
fluorescence in response to high glucose in vitro in adipocytes and fibroblasts and 
attributed this to mitochondrial NADH (Evans et al., 2005). Vincent et al. (2005a) 
reported that mitochondrial NADH oxidase activity increased in embryonic DRG 
neurons within 1 h after exposure to high glucose and suggested that this was due to 
increased production of NADH by the TCA cycle and overloading of the electron 
transport chain. The results presented here provide evidence that NADH levels do 
increase rapidly in neurons in response to high glucose. Interestingly, no change in 
fluorescence intensity was observed in SCG neurons on exposure to high glucose for 30 
min.  
In the 1960s Chance and colleagues, pioneers in the measurement of the 
fluorescence of reduced pyridine nucleotides, established that the increased fluorescence 
due to the reduced form of pyridine nucleotides was indicative of cell metabolism 
(Chance & Baltscheffsky, 1958;Chance & Thorell, 1959;Chance & Hollunger, 1960). 
Initially it was held that increased autofluorescence indicated changes in the binding of 
mitochondrial NADH (Chance & Baltscheffsky, 1958). Later, Jobsis at al. argued that 
changes in the intensity of NADH fluorescence can be interpreted as changes in 
intracellular NADH concentrations. They performed parallel studies using fluorometric 
and biochemical methods and reported that under circumstances, such as hypoxia, 
where NADH levels increase and NAD+ levels decrease, fluorescence does indeed rise 
(Jobsis et al., 1971). The results presented here indicate that high glucose may cause an 
increase in the NADH/NAD+ ratio in CG/SMG neurons, a condition that has been 
characterized as pseudohypoxia and proposed to contribute to the development of 
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diabetic complications (Wahlberg et al., 2000; Ido, 2007). The effect of high glucose on 
NAD(P)H fluorescence in CG/SMG neurons was temporary since there was not a 
significant difference in fluorescence intensity in CG/SMG neurons following 24 h 
exposure to high glucose. It is possible that fluctuations in glucose concentrations would 
have had a greater effect than constant exposure. Intermittent exposure to high glucose 
has been shown to be more harmful to endothelial cells in vitro than constant high 
glucose levels (Risso et al., 2001).  
Brownlee and colleagues have proposed a unifying mechanism and the link 
between the pathways responsible for oxidative stress and hyperglycemic damage in 
endothelial cells. Hyperglycemia-induced accelerated glycolysis and increased flux 
through the TCA cycle is the source of the increased ROS in the mitochondria of 
endothelial cells. Hyperglycemia causes overproduction of electron donors like NADH 
by the TCA cycle, the proton gradient is increased, the electrochemical potential 
difference across the inner mitochondrial membrane rises above the limit and 
superoxide production is markedly increased (Du et al., 2001;Brownlee, 2001). 
However this mechanism may not apply to neurons. Studies of adult DRG neurons have 
demonstrated mitochondrial membrane depolarization rather than hyperpolarization in 
diabetic rats and no evidence for the production of ROS in mitochondria (Akude et al., 
2011). It remains to be determined how long term diabetes in vivo affects NAD(P)H 
metabolism in sympathetic neurons. 
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4.4.2 Mitochondrial and cytosolic NAD(P)H and NAD(P)H oxidase 
4.4.2.1 FLIM analysis      
The FLIM analysis was carried out on the basis that the native fluorescence 
consisted of two components, free (T1) and bound NAD(P)H (T2). However, 
fluorescence lifetimes are sensitive to environment and may vary in different cell types 
and in different cellular compartments. Two major peaks were observed when the 
overall field (neurons plus neuropil) was analyzed. The peaks were not symmetrical 
indicating that each peak probably contained more than one species. When FLIM data 
was analyzed exclusively in neuronal cell bodies in the same field, the peaks sharpened. 
Colour coding of lifetime ranges revealed that both T1 and T2 lifetimes were shorter in 
the neurons than the neuropil. A study by Chia et al. also demonstrated that the 
fluorescence lifetimes were different in the neuropil and neuronal cell bodies (Chia et 
al., 2008). Since χ2 values were close to 1 throughout the rest of the study where only 
neurons were analyzed, this indicates that the data conformed closely to a two 
component system. This is unlike a study of cardiac myocytes where a third component 
was observed (Blinova et al., 2005). In control SCG and CG/SMG neurons, the lifetime 
of free NAD(P)H, (T1) was in the range 520-600 ps and of bound NAD(P)H, (T2) 
2000-3000 ps. This is similar to the ranges reported for NAD(P)H fluorescence 
lifetimes (T1 300-600 ps; T2, 2000-3000 ps) in a range of cell types (Bird et al., 
2005;Skala et al., 2007a;Niesner et al., 2008a). The majority of the NAD(P)H 
fluorescence was in the free form as the average a1% was approximately 70% in both 
ganglia, and, by substraction, 30% was in the bound form. This is very similar to values 
reported for epithelial cells (Skala et al., 2007b). It should be noted that this does not 
mean that the majority of the native fluorescence intensity was due to free NAD(P)H.  
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Fluorescence molecules with long lifetimes contribute almost 80% to fluorescence 
intensity images due to their greater quantum yield (Blinova et al., 2008;Chia et al., 
2008). A diminution of the amplitude of the bound form (a2) reflects a very low 
metabolic activity (Niesner et al., 2008a).  
 
4.4.2.2 FLIM Analysis of the effect of High Glucose     
A study of embryonic DRG neurons reported that the increase in mitochondrial 
NADH oxidase activity within 1h of high glucose exposure was followed rapidly by 
caspase activation and apoptosis (Vincent et al., 2005a) and embryonic SCG neurons 
also undergo apoptosis in response to high glucose (Russell & Feldman, 1999). 
Apoptosis has been reported to cause a significant increase in average NAD(P)H 
fluorescence lifetimes (Wang et al., 2008). Since fluorescence lifetimes were not 
significantly altered after 24 h exposure to high glucose, there was no evidence in this 
study that exposure to high glucose initiated neuronal cell death in adult sympathetic 
ganglia. This probably reflects greater susceptibility of embryonic neurons to apoptosis 
since there is also no evidence for apoptosis being induced in adult DRG neurons by 
high glucose (Huang et al., 2003).   
Similarly there was no evidence for the activation of NADPH oxidase by high 
glucose in this study. Activation of NADPH oxidase requires the translocation of 
regulatory subunits to the cellular membrane. Activated NADPH oxidase has been 
demonstrated in CG neurons from hypertensive but not control rats by increased 
immunostaining in the plasma membrane (Cao et al., 2007). However, no shift in the 
distribution of NAD(P)H fluorescence was observed during FLIM analysis after 
exposure of sympathetic neurons to high glucose. In addition, activation of 
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polymorphonuclear cells involves translocation and activation of NADPH oxidase 
resulting in the production of superoxides for host defence. FLIM analysis of activated 
cells revealed the development of a new fluorescence lifetime species with the longer 
lifetime of 3700 ps with NADPH oxidase activation but no new fluorescence lifetime 
species were detected in sympathetic neurons here. Since a1% values were similar in 
SCG and CG/SMG neurons with and without exposure to high glucose, the increase in 
fluorescence intensity observed in CG/SMG neurons 30 min after exposure to high 
glucose was not due to a change in the distribution of NAD(P)H  between the free and 
bound forms. T2 values were also similar in all neurons studied. However there were 
subtle differences between neurons from the two ganglia. Two way ANOVA with 
ganglionic source and exposure to glucose as factors revealed that the ganglionic source 
did have a significant effect. T1 values tended to be higher in CG/SMG neurons than 
SCG neurons and this was significant following exposure to high glucose for 30 min, 
the time at which NAD(P)H fluorescence intensity was significantly increased 
selectively in CG/SMG neurons. This may reflect an initial change in the environment 
of free NADH in CG/SMG neurons with high glucose.         
CG/SMG are particularly vulnerable in human and experimental diabetes 
(Schmidt et al., 1993). The differences in CG/SMG and SCG in response to diabetes 
have been attributed to their differences in their blood-ganglion-barrier (Chau & Lu, 
1995), levels of anti-oxidant defence and responses to NGF (Semra et al., 2004;Semra 
et al., 2006;Semra et al., 2009). There are also metabolic differences between 
prevertebral and paravertebral sympathetic ganglia. CG/SMG display more tonic 
activity than paravertebral neurons (Szurszewski, 1981), demonstrate higher metabolic 
activity (Carroll et al., 2004) and have different expression of genes coding glycolytic 
and mitochondrial based enzymes (Carroll et al., 2004).  
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4.4.3 Conclusion 
 
In conclusion, this is the first study using time domain fluorescence and FLIM to 
explore the changes induced by high extracellular glucose in living neurons in vitro. 
Temporary effects of glucose in NADH/NAD+ redox ratio were observed selectively in 
CG/SMG neuronal cell bodies. However, the CG/SMG neurons were able to recover 
and return to the control state after 24 h high glucose stimulation. These results suggest 
that acute exposure to high glucose causes subtle abnormalities in redox ratio from 
which the CG/SMG neurons are able to adapt and such changes do not cause cell death. 
Longer term studies both in vitro and in vivo are required to determine the stage at 
which CG/SMG neurons are no longer able to adapt to high glucose and if this is 
reflected by altered NAD(P)H metabolism.    
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Chapter 5: Discussion, Conclusions 
and Future Study 
 
 
In vitro models of diabetes provide a useful tool for studying pathological 
mechanisms in greater detail than in vivo, since they enable the cellular environment to 
be strictly controlled. In vitro models are also valuable for the preclinical screening of 
therapeutic agents prior to studies in animal models in vivo and subsequently clinical 
trials. In a simplified system, it is possible to accomplish the mapping of biochemical 
pathways induced by toxic compounds mimicking the diabetic environment. 
Investigating isolated parts of a living organism permits the manipulation of 
experimental parameters and the prediction of drug efficacy and toxicity in early stage 
drug testing. In diabetic neuropathy, in vitro models also allow potential mechanisms to 
be studied in isolation from vascular abnormalities that may occur in parallel as part of 
the disease processes. The identification of changes in vitro may also provide 
information for the design of functional studies to elucidate how neuropathy leads to 
motility disorders in diabetes. These reasons, in conjunction with ethical and financial 
considerations, have raised the necessity of developing in vitro methods for 
investigating diabetic neuropathy. 
 
A variety of in vitro models of diabetic neuropathy have already provided 
significant information about the pathogenesis of diabetic neuropathy and the 
possibilities for treatment. The most common model used to date has been cultures of 
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embryonic sensory neurons from non-diabetic rodents treated with high glucose. These 
have demonstrated defective neurite outgrowth, mitochondrial degeneration and 
apoptosis, caused by high glucose-induced oxidative stress. In diabetic 
gastroenteropathy, in vitro studies have mainly used cell lines. In these studies, 
proapoptotic factors, oxidative stress and apoptosis were also the consequences of high 
glucose insult (Russell et al., 1999;Russell et al., 2002;Vincent et al., 2004b;Vincent et 
al., 2005a;Vincent et al., 2007b). All these findings have concluded that normal neurons 
are extremely sensitive, cannot adapt and die due to the toxicity induced by high 
glucose. However, these findings do not correlate well with what occurs in the in vivo 
state, since there is little evidence for the death of sympathetic and sensory neurons in 
experimental or human diabetes (Schmidt et al., 1993;Schmidt et al., 
2001;Zherebitskaya et al., 2009;Chowdhury et al., 2012).  
 
 
5.1 Cell death as an experimental endpoint 
 
A loss of myenteric neurons has been reported in STZ-induced diabetic rats 
(Izbeki et al., 2009;De Mello et al., 2009). Such reductions were based on finding 
significant decreases in HuC/D neuronal density per unit area. Studies using other 
neuronal markers have also used this method of assessment. However, it is well 
recognized that there is marked distension and hypertrophy of the gastrointestinal tract 
in experimental diabetes (Schmidt, 2002). Thus, any increase in the area of the gut wall 
in diabetes would result in a decrease in neuronal density when expressed per unit area, 
even if there were no change in neuronal number. Studies from this laboratory have 
demonstrated that this is a significant factor since no loss of myenteric neurons was 
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observed in STZ-diabetic rats when this was assessed on the basis of the average 
number of HuC/D neurons per myenteric ganglion which is independent of area 
(Voukali et al. 2011).     
Enhanced cleaved caspase-3 staining has been reported in human colonic enteric 
neurons in diabetes (Chandrasekharan et al., 2011). In sensory neurons, enhanced 
caspase-3 staining in diabetes is not always accompanied by TUNEL staining or 
neuronal loss (Guo et al. 2004). After 4-8 weeks diabetes in the rat, caspase 3-staining 
was increased in nodose ganglion, dorsal root ganglion and myenteric ganglia. 
However, in all cases the percentage of neurons expressing caspase-3 was significantly 
higher than the percentage expressing TUNEL. Furthermore, only 1.1 % of the 
myenteric neurons were TUNEL-positive in experimental diabetes indicating that 
apoptosis was not occurring in the vast majority of the neurons. Although apoptotic 
factors are present, counter regulatory elements appear to prevent apoptosis (Cheng & 
Zochodne, 2003;Guo et al., 2004;Kamiya et al., 2005).  
When it was first reported that high glucose causes apoptosis in DRG and SCG 
neurons it was proposed that neuronal cell death was responsible for the loss of axons 
that occurs in diabetic neuropathy (Russell et al., 1999; Russell & Feldman, 1999).  
However, in the light of subsequent studies, the current view of the pathological process 
has reverted back to the traditional concept that diabetic neuropathy is a dying back type 
of axonopathy resulting in neuroaxonal dystrophy in the absence of neuronal cell death 
(Zherebitskaya et al., 2009).  It has been proposed that neurons have two distinct self-
destruct programs in response to insult. The first involves neuronal cell death via 
apoptosis. The second occurs exclusively in the axons and is more common in 
polyneuropathies such as occur in diabetes where axonal degeneration occurs 
progressively from the distal end. The importance of this distinction is that with dying 
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back axonopathy the neuron can retain the ability to regrow its axon should conditions 
improve (Raff et al., 2002). This is of key significance to the prospect of treating 
diabetic neuropathy once it has developed.  It is concluded that diabetes does not cause 
a significant decrease in the number of HuC/D-positive neurons per myenteric ganglion 
and neuronal cell death is not a prominent feature of sensory, sympathetic and enteric 
neurons in diabetes in vivo (Schmidt et al., 1993;Schmidt et al., 1997;Schmidt, 2001, 
Zochodne et al., 2001;Voukali et al., 2011). This calls into question whether cell death 
is a valid endpoint with which to assess the mechanisms underlying diabetic neuropathy 
in in vitro models.  
 
 
5.2 Establishment of the in vitro model for studying the effects of diabetes on 
myenteric neurons  
 
Several factors were taken into consideration here when developing an in vitro 
model for studying diabetic enteropathy. The first was that the neurons should be fully 
mature. Studies of both DRG and sympathetic neurons have demonstrated that neurons 
that are not fully developed are more likely to respond to high glucose by undergoing 
apoptosis than adult neurons (Zherebitskaya et al., 2009;Semra et al., 2009). Secondly, 
the neurons should be subjected to as little disruption as possible since apoptosis of 
adult rat SCG neurons in response to high glucose occurs to a greater extent in cultures 
consisting of dissociated neurons than in ganglionic explants (Semra et al., 2004;Semra 
et al., 2009). Thirdly, the endpoints used for assessing responses should be the same as 
 163 
those that are known to occur in animal models of diabetes in vivo and should take into 
account that not all neurons are affected in the same way in diabetes.  
Some enteric neuronal subpopulations exhibit degeneration (Belai et al., 1988), 
some undergo change in neurotransmitter content without degeneration (Belai et al., 
1988) while some are unaffected (Belai et al., 1985). Myenteric neurons in the ileum are 
more affected than those in the large intestine (Belai et al., 1991). In addition, intrinsic 
motor inhibitory neurons appear to be more affected than excitatory motor neurons 
(Chandrasekharan & Srinivasan, 2007). Therefore, wholemount preparations of the 
myenteric plexus from the ileum of the adult rat were used for the in vitro model. For 
the purposes of this study, three subpopulations of myenteric neurons containing VIP, 
nNOS or calbindin were selected for investigation since it had been shown that they 
respond differently following 12 wks STZ-diabetes (Shotton et al., 2006; Voukali et al., 
2011). Therefore the endpoints used to determine whether the in vitro model did reflect 
the in vivo pattern were an increase in the expression of VIP, a decrease in the 
expression of nNOS and no change in the expression of calbindin. The only previous 
study to date that had investigated the response of wholemount myenteric plexus 
preparations to potential diabetic stimuli (Korenaga et al. 2006) examined the effect of 
BSA-AGE exposure for 24 h and only studied nNOS-containing neurons, reporting a 
decrease in expression. We extended this approach, not only by studying additional 
populations of myenteric neurons but also by investigating additional stimuli that may 
mimic the diabetic environment. A concentration of 30 mM glucose was used to 
examine the effect of high glucose per se since this is a level known to occur in poorly 
controlled diabetes. The possibility that reactive carbonyl species formed as a 
consequence of increased glucose levels induced diabetic-like changes was examined 
using methylglyoxal. In addition, menadione was used to investigate the effect of 
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oxidative stress since this has been proposed to be a key element in sensory neuropathy 
(Figueroa-Romero et al., 2008). In all cases it was established that the concentrations of 
diabetic stimuli used did not cause a loss of HuC/D myenteric neurons in our culture 
system.  
Using this model, an interesting pattern was observed. Only oxidative stress 
could replicate completely the changes that occur in vivo. High glucose and carbonyl 
stress only affected VIP expression and AGE only affected nNOS expression. VIP and 
nNOS have been reported to be colocalized in the same myenteric neurons following 
colchicine treatment. However, a study of myenteric neurons in Parkinson’s disease 
demonstrated similar changes in VIP and nNOS expression as those demonstrated here 
using triple immunolabelling and in the absence of colchicine. Following analysis of 
neurons that contained nNOS or VIP on their own or both nNOS and VIP, the authors 
concluded that nNOS expression was decreased in a subpopulation of nNOS-containing 
neurons that was separate from the subpopulation of nNOS-containing neurons in which 
VIP expression was induced (Colucci et al., 2012).    If a similar situation applies in 
diabetic neuropathy, the results presented here indicate that individual subpopulations 
may be more or less susceptible to specific pathways implicated in the development of 
neuropathy but that oxidative stress is the common element. Myenteric neurons that 
contained calbindin were consistently resistant to all the stimuli. These results imply 
that calbindin has a neuroprotective role and its presence in a neuron could reflect an 
intrinsic advantage to buffer elevated intracellular waves of calcium (Mattson et al., 
1991;Iacopino et al., 1992;McCormack et al., 2006).   
Why VIP expression but not nNOS expression should be affected by high 
glucose and carbonyl stress is not known. However, the selective effect of AGE on 
nNOS may reflect the selective expression of RAGE in a subpopulation of nNOS-
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containing neurons in which VIP expression is not induced.  RAGE expression has been 
demonstrated in myenteric ganglia where it is colocalized with neurons but not enteric 
glia (Korenaga et al., 2006). However, it has not been established whether RAGE is 
present in all myenteric neurons or in specific subpopulations. Similarly, susceptibility 
to methylglyoxal could be related to the levels of glyoxalase I, the enzyme that 
detoxifies reactive carbonyl species, in individual subpopulations of neurons. A study of 
DRG has demonstrated that glyoxalase I is selectively expressed in small, nociceptive 
DRG neurons and that activity is reduced in STZ-diabetes (Jack et al., 2011). Whether 
there is heterogeneous expression of glyoxalase I in myenteric neurons has not been 
investigated.        
It is important to acknowledge that culture per se did have an effect on 
myenteric neurons. The expression of both nNOS and VIP was increased in 
preparations maintained for 24 h under control culture conditions relative to 
preparations that had not been subjected to culture. In the case of VIP, this has been 
reported previously and it has been suggested that VIP may be protective (Lin et al., 
2003). However, the results presented here indicate that it is not likely that the same 
pathways that caused the changes under control culture conditions were the same as 
those that occurred in response to the diabetic stimuli. In the case of nNOS, AGE and 
oxidative stress caused a decrease rather than an increase in nNOS expression. In 
addition, the anti-oxidant α-lipoic acid, prevented the altered expression of nNOSand 
VIP in response to high glucose, carbonyl stress or AGE but had no effect on nNOS or 
VIP expression in control culture preparations.     
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5.3 Prevention of induced changes and oxidative stress as the unifying factor  
 
 
Having identified the changes that occur in myenteric neurons in vitro to 
different diabetic stimuli, this established a model with which to examine further the 
mechanisms involved and to screen potential therapeutic agents. Four agents were 
selected for investigation here based on the fact that they had already been investigated 
for the treatment of diabetic sensory neuropathy and that they differed in their proposed 
sites of action. The effects of -lipoic acid, an anti-oxidant (Packer, 1995); 
nicotinamide, a PARP inhibitor (Stevens et al., 2007); aminoguanidine, a carbonyl 
scavenger (Thornalley 2003b); and thiamine, an inhibitor of carbonyl stress (Mehta et 
al., 2008) on VIP- and nNOS- containing myenteric neurons on the responses to 
oxidative stress, carbonyl stress, high glucose or AGEs were examined.  
In sensory nerves, several pathologic mechanisms have been proposed to 
account for neuropathy such as defects in neural blood flow and metabolic deficits 
(Cameron et al., 2001; Zochodne, 2007) and these are not mutually exclusive. However, 
it has been proposed that such deficits join to form the common link of oxidative stress 
which is responsible for the development and progression of sensory neuropathy (see 
Figueroa-Romera et al., 2008).  Whether this is also the case with autonomic neurons 
has not been investigated before. Having demonstrated that oxidative stress mimicked 
the effects of diabetes on myenteric neurons, the effects of -lipoic acid on the changes 
induced by individual diabetic stimuli were investigated. The data presented here 
confirmed that all these stimuli appeared to be acting via the production of oxidative 
stress since the anti-oxidant prevented the changes in VIP- and nNOS containing nerves 
whatever the stimuli used.   
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Oxidative stress has been implicated in a wide range of diseases affecting the 
nervous system including neurodegeneration disorders such as Alzheimer’s disease, 
Parkinson’s disease, Motor Neuron disease, Huntington’s disease (Valko et al., 2007). 
While cell necrosis or apoptosis usually follow oxidative stress in the CNS, this is not 
necessarily the case in the peripheral nervous system. In diabetic sensory neuropathy, 
there is evidence that the production of ROS occurs selectively in the axon providing a 
mechanism whereby oxidative stress could cause axonal degeneration without initiating 
apoptosis (Leinninger et al., 2006;Zherebitskaya et al., 2009).  
Additional experiments were performed with aminoguanidine and nicotinamide 
to examine the contribution that the production of carbonyl species or the activation of 
PARP made to the effect of high glucose on VIP-containing neurons. Unfortunately, 
both agents were shown to have anti-oxidant properties as they prevented the response 
of both VIP- and nNOS-containing neurons to oxidative stress induced by menadione. 
More specific carbonyl scavengers or PARP inhibitors will be required to differentiate 
the roles of these individual pathways. However, these results did demonstrate the 
advantages of studying the effects of drugs on in vitro models of diabetes, using 
individual diabetic stimuli, and using oxidative stress induced by menadione in parallel. 
In contrast, thiamine did not prevent changes induced by oxidative stress but did 
prevent increased VIP-expression induced by carbonyl stress. Since thiamine was 
unable to prevent the response of VIP-containing nerves to high glucose this provided 
evidence that the effect of high glucose does not occur via the production of reactive 
carbonyl species.  
Taken together these studies on wholemount preparations of the myenteric 
plexus have demonstrated its potential use in the investigation both of individual stimuli 
that mimic the diabetic environment and of potential therapeutic agents. It should be 
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noted that the model used here only investigated the prevention of diabetes-induced 
changes. For effective therapy, it is also important to establish whether agents can also 
reverse changes once they are induced.    
 
 
5.4 Energy metabolism and intrinsic heterogeneity of sympathetic neurons  
 
It is well recognized that diabetes does not affect all sympathetic neurons. In 
both humans and animal models, CG/SMG neurons undergo axonal dystrophy while 
SCG neurons are spared (Schmidt, 2002). In addition, in STZ-diabetic rats, the nerves 
supplying the ileum from the CG/SMG undergo degeneration while the nerves 
supplying the distal colon from the inferior mesenteric ganglion are unaffected (Belai et 
al., 1991). The understanding of the causes of such heterogeneity could shed light on the 
mechanisms underlying diabetic gastroenteropathy. While changes in the target of 
innervation has been suggested to contribute (Schmidt, 2002), inherent characteristics 
such as the axon length, the neuronal activity and the level of anti-oxidant defence may 
also be significant factors.  
Spencer & Schaumburg noted the importance of axon diameter & length in 
determining the hierarchy of fiber vulnerability (Spencer & Schaumburg, 1977a, 
Spencer & Schaumburg, 1977b). In diabetic sensory neuropathy, there is general 
consensus that longer fibres are more vulnerable to degeneration. DRG neurons isolated 
from the lumbar L4-L6 segments of spinal cord are more susceptible than DRG from 
higher spinal cord levels (C3-L3) and this was correlated with the axonal length (Huang 
et al., 2002b). However, sympathetic axons supplying the ileum are dystrophic in 
diabetes but equally long sympathetic axons supplying the mesenteric vessels of the 
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ileum do not develop dystrophy. Therefore, axon length is not the only factor that 
determines the susceptibility of different sympathetic nerves in diabetes (Schmidt, 
2002). 
There is considerable heterogeneity in the intrinsic morphological and 
physiological properties between SCG and CG/SMG neurons. The activities of the anti-
oxidant enzymes glutathione peroxidase and superoxide dismutase have been shown to 
be lower in CG/SMG than in SCG under normal conditions (Semra et al., 2004). In 
addition, the blood-ganglion barrier is less effective in the CG/SMG (Chau & Lu, 
1995). Both of these properties could contribute to the greater susceptibility of 
CG/SMG neurons to hyperglycaemia and subsequent oxidative stress. Some differences 
are related to the different functional roles of CG/SMG and SCG neurons within the 
ANS. It has been reported that SCG neurons may have fundamentally different calcium 
dynamics because they display a differential expression of a significant range of ion 
channels (Jobling & Gibbins, 1999). The dendritic field in SCG neurons is small and 
simple in whereas the dendritic field of CG/SMG neurons is large and complex (Jobling 
& Gibbins, 1999). CG/SMG and SCG also have different neuronal firing properties that 
reflect the nature of their synaptic inputs and the pattern of activity induced in their 
targets. Half of CG/SMG neurons have tonic activity, meaning that they fire 
continuously in response to a maintained depolarising stimulus. In contrast, all SCG 
neurons have phasic activity meaning that they respond with transient bursts of action 
potentials after one suprathreshold synaptic input from spinal cord (Wang & McKinnon, 
1995). These distinct properties may be reflected with different degrees of metabolic 
activity.  
Preliminary evidence has been obtained from this laboratory that susceptibility 
to diabetes may be related to metabolic activity. Cytochrome oxidase activity was 
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measured histochemically together with the intensity of TH-immunofluorescence in the 
same neurons from CG/SMG and SCG from STZ-diabetic rats. Cytochrome oxidase 
activity was shown to be higher in CG/SMG neurons under normal conditions but was 
unaffected by diabetes. However, the intensity of TH-immunofluorescence was 
correlated positively with cytochrome oxidase activity in CG/SMG neurons. This 
indicates that the accumulation of TH, a characteristic of diabetic neuropathy was more 
likely to occur in the CG/SMG neurons with higher metabolic activity. No such 
correlation was observed in SCG neurons and TH-immunoreactivity was unchanged in 
diabetes (Shotton, 2008). Diabetes has also been shown to selectively induce significant 
changes in the expression of genes involved in the structure and function of synapses, 
mitochondria and oxidative stress in CG/SMG (Carroll et al., 2004). Metabolic activity 
has not been measured in intrinsic inhibitory motor neurons in the GI tract but it has 
been reported that they discharge continuously and action potentials and contractions in 
the muscle occur only when the inhibitory neurons are switched off by input from 
interneurons (Wood et al., 1999; Hansen et al., 2003b).  
Sustained hyperglycaemia brings about fundamental metabolic changes in cells. 
As early as 1979, when Cavanagh described the “dying back” process of degeneration 
of multifocal neuropathies, it was held that the principle pathway that is seriously 
disturbed by a metabolic insult like the hyperglycemia is the TCA cycle. Lack of energy 
follows and this is critical to the initiation of pathological changes (Cavanagh, 1979). 
Current theory suggests that the polyol pathway, accelerated glycolysis and increased 
flux by the TCA cycle leads to the inhibition of Complex 1 activity in mitochondria and 
decreased production of ATP. In addition, such metabolic changes lead to changes in 
the balance between the oxidized and reduced forms of the pyridine dinucleotides, NAD 
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and NADP potentially altering the redox status of the cell (Ido et al., 1997; Brownlee, 
2001; Ido, 2007;Hinder et al., 2012).  
Recent technological advances now allow NAD(P)H metabolism to be examined 
in living cells using two photon microscopy with FLIM. To date, this experimental 
approach has not been used to investigate sympathetic neurons. Therefore, the last part 
of this thesis involved the investigation of the effect of high glucose in vitro on 
NAD(P)H levels and fluorescence lifetimes in living sympathetic neurons. Both SCG 
and CG/SMG neurons were studied to provide a comparison between a neuronal 
population that is susceptible to diabetic neuropathy with one that is unaffected. As 
discussed for the model of myenteric neurons, the system investigated used adult 
neurons in ganglion explants to avoid the increased vulnerability of immature neurons 
and minimize disruption. Exposure to high glucose caused a selective increase in 
NAD(P)H fluorescence in CG/SMG within 30 min. However, this effect was not 
maintained and no differences in NAD(P)H fluorescence intensity were observed in 
either ganglia after exposure to high glucose for 24 h. FLIM analysis of NAD(P)H 
fluorescence in neuronal soma did not reveal any significant changes on exposure to 
high glucose in either ganglia. However, there was a subtle difference between the 
ganglia. The fluorescence lifetime (T1) for the unbound form of NAD(P)H tended to be 
higher in the CG/SMG than the SCG and this was significant 30 mins after exposure to 
high glucose, the stage when NAD(P)H levels were increased in the CG/SMG. These 
results demonstrate that it is feasible to study NAD(P)H metabolism in living 
sympathetic neurons using two photon microscopy with FLIM but provided no evidence 
for the activation of NAD(P)H oxidase or mitochondrial dysfunction leading to 
oxidative stress and apoptosis that has been reported in embryonic SCG or DRG 
neurons in response to high glucose (Russell & Feldman, 1999;Vincent et al., 2005a). 
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This is in line with a study of adult DRG neurons in vitro where exposure to high 
glucose had no effect on mitochondrial membrane potential (Huang et al., 2003). It 
should be noted that these findings do not exclude the possibility that NAD(P)H 
metabolism is altered in diabetes in vivo or that changes occur in the axons rather than 
the neuronal cell soma. Altered mitochondrial membrane potential (measured in vitro) 
has been reported in DRG isolated from STZ-diabetic rats and high glucose causes 
oxidative stress selectively in neurites growing in vitro from DRG isolated from 
diabetic but not control rats (Huang et al., 2003;Zherebitskaya et al., 2009). In the 
present study, it was observed that NAD(P)H fluorescence lifetimes differed depending 
on whether the NAD(P)H was present in the cell soma or the neuropil and 
measurements were only made on the cell soma. 
 
 
 
5.5 Conclusions  
 
One of the demands of an appropriate in vitro model is that it should closely 
mimic the in vivo setting. A major contribution of this thesis was the development of an 
in vitro model that mimics the response of myenteric neurons to diabetes in vivo 
replicating the pattern of changes that occur in terms of susceptibility and resistance of 
individual populations of myenteric neurons. It provided a tool to elucidate mechanisms 
of pathogenesis by examining diabetic stimuli that mimic hyperglycemia, carbonyl 
stress, AGEs and oxidative stress. It provided evidence that oxidative stress is a 
common factor unifying various pathways through which the peptide/enzyme changes 
occur in myenteric plexus in vivo. However, the pathways leading to oxidative stress do 
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not appear to be the same for all subpopulations of myenteric neurons. A population of 
nNOS-containing neurons that do not express VIP may be particularly vulnerable to 
pathways involving AGE resulting in decreased nNOS expression. In contrast, high 
glucose and carbonyl stress may induce increased expression of VIP in a separate 
population of neurons that also contain nNOS. It was also demonstrated that this model 
can be used to screen potential therapeutic agents for their ability to prevent changes 
induced by the different diabetic stimuli. From these experiments it was possible to 
show that an agent with anti-oxidant properties was able to prevent induced changes 
whatever the stimulus. In addition, the study of thiamine which inhibited the effect of 
carbonyl stress but not oxidative stress provided evidence that the effect of high glucose 
on VIP-containing neurons did not occur via the production of carbonyl species.  
Finally, the dynamics of the changes that short term exposure to high glucose 
elicits in living normal adult sympathetic neurons were studied for the first time. This 
was made possible by multiphoton FLIM using the NAD(P)H autofluorescence 
intensity and lifetimes as a marker of altered metabolism. Although no evidence was 
found for sustained effects of glucose on mitochondrial function, this study has 
established the feasibility of using this approach for investigating NAD(P)H metabolism 
following chronic exposure to high glucose and for comparing the effects in different 
sympathetic ganglia or between the cell soma and axons.   
 
 
 
 
 
 
 174 
5.6 Future work 
 
 
The observations of the studies in this thesis suggest a number of areas that 
merit future investigation. In the case of the in vitro model of myenteric plexus adherent 
to muscularis externa it would be possible to examine whether the accumulation of VIP 
on exposure to high glucose is due to a failure of release as has been demonstrated in 
STZ-diabetes in vivo (Belai et al., 1987). Colocalization studies of RAGE or glyoxalase 
I in specific subpopulations of myenteric neurons could determine whether their 
presence or absence may contribute to selective vulnerability to AGEs or carbonyl 
stress. Additional stimuli could be investigated for their ability to mimic the diabetic 
environment. For example, it has been previously reported that oxidised LDLs can 
directly affect adult sensory neurons in culture and induce neuropathy in mice (Vincent 
et al., 2009). It would be interesting to investigate whether dyslipidemia can also affect 
myenteric or sympathetic neurons. This would be of particular significance to type 2 
diabetes since it has been demonstrated dyslipidemia is a risk factor for diabetic 
neuropathy and may explain why strict glucose control is not sufficient for the 
prevention of diabetic complications in type 2 diabetic patients (Vincent et al., 2009). 
Additional agents could be screened for their ability to prevent diabetes-induced 
changes prior to in vivo studies and to provide further information on the mechanisms 
involved in such changes. For example, pyridoxamine (vitamin B6) has been shown to 
react with intermediates involved in the formation of both glyoxidation and lipoxidation 
endproducts (Onorato et al., 2000). The role of the polyol pathway in diabetes-induced 
changes could be examined with the use of aldose reductase and sorbitol dehydrogenase 
inhibitors. Furthermore, the model could readily be adapted to investigate whether 
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therapeutic agents are able to reverse diabetes-induced changes by adding them to the 
culture medium after the preparations have been exposed to diabetic stimuli.  
       
Finally, the new technologies of multiphoton FLIM generally offer a wide range 
of new opportunities for cell biology. In this thesis, the characterisation of short-term 
changes in the cell bodies of living sympathetic neurons after exposure to high glucose 
was only the beginning. The same protocol could be used to investigate SCG and 
CG/SMG explants from STZ-diabetic rats to examine the effects of chronic exposure to 
hyperglycaemia on NAD(P)H metabolism. Analysis could be done in conjunction with 
the use of fluorescent markers for mitochondria, calcium and ROS.  Explants could be 
adapted to include the nerve trunks exiting from the ganglia. This would enable a 
comparison to be made of the effect of high glucose (or other diabetic stimuli) on the 
neuronal cell soma and the axons. In the present study the presence of axons in 
individual ganglionic explants was not sufficiently consistent to allow reliable 
quantitation. Finally, this approach could be used to investigate a recent controversy 
that has arisen concerning the precise source of ROS in diabetes. Most of the studies to 
date have assumed that ROS are produced by excessive flux through the electron 
transport chain (see Hinder et al., 2012 for review). However, a recent study involving 
proteomic analysis of mitochondria and assessing mitochondrial function has proposed 
that this is not the case, since respiration was reduced in DRG from diabetic rats despite 
the fact that ROS were evident in their axons. It was suggested that NADPH oxidase 
could provide an alternative source of ROS in the axon (Akude et al., 2011). NADPH 
oxidase is present in both sympathetic and sensory axons (Cao et al., 2009). FLIM 
analysis could be used to determine if additional fluorescent species involving 
NAD(P)H are present in the axon on exposure to high glucose.  
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Appendix 1 
Details of the contents of solutions used in chapters 2 & 3 
M199 serum free medium 100 ml 
10 ml 10x medium 199 (Sigma, Poole, UK) 
1 ml 20 mM glutamine (Sigma, Poole, UK) 
1 ml penicillin-streptomycin solution (containing 10’000u penicillin and 10mg/ml 
streptomycin, from Sigma, Poole, UK) 
1 ml 20mM Hepes buffer (Sigma, Poole, UK) 
1.5 ml 7.5% Sodium Hydrogen Carbonate solution (VWR, Lutterworth, UK) 
1 ml N1 supplement 
1
 
1 ml 1M glucose
2 
Plus one of the following experimental stimuli and/or treatments:  - 
- 10 ml of 1 mM D L-6,8- Thioctic acid (-lipoic acid, from Sigma, Poole, UK) 3 
- 2.5 ml of 10 mg/ml AGE-conjugated BSA (Biovision, Mountain View, CA) to 
give a final concentration of 250 g/ml of AGE-BSA4 
- 10 l of 1 mM menadione sodium bisulfite (Sigma, Poole, UK) to give 1M 
concentration of menadione for oxidative stress experiment. 
- 5 l, 50 l, 250 l, 500 l, 2,500 l of methylglyoxal solution (1.17g/ml, Sigma, 
Poole, UK) to give 1 M, 10 M, 50 M, 100 M, 500 M concentrations 
respectively of methylglyoxal for carbonyl stress experiment. 
- 100 l or 500 l of 1 mM aminoguanidine (Sigma, Poole, UK) to give 100 M or 
500 M concentrations respectively of aminoguanidine. 
 177 
- 100 l of 1 mM thiamine pyrophosphate (Sigma, Poole, UK) to give a 100 M 
final concentration of thiamine pyrophosphate.  
- 100 l of 1 mM nicotinamide (Sigma, Poole, UK) to give a 100 M final 
concentration of nicotinamide.  
 
And made up to 100 ml with sterile distilled water. 
 
1 
N1 Supplement 50 ml  
Putrescine 2 ml (40 mg/ml) 
Tri-iodothryonine 170 l (10mg/ml) 
L-Thyroxine 5 ml (400 mg/ml) 
Progesterone 300 l (1 mg/ml in ETOH) 
Bovine Serum Albumin Pathocyte 4 (Miles Laboratories, Inc., Elkhart, Ind) 17.5 ml 
Sodium Selenite 3.75 ml (0.5 mg/ml) 
 
2
 for 10 mM glucose solution. 
For 30 mM: 3 ml 1M glucose (VWR, Lutterworth, Leistershire, UK) 
 
 
3
 -lipoic acid was initially dissolved at 0.5 M in dimethylsulfoxide (DMSO), then 
diluted to 1 mM in M199 medium. In order to counteract the possible pro-oxidant effect 
of dissolving reagent preincubated for 30 minutes in the dark at 37C with 1000u/ml of 
lyophilised catalase (Sigma, Poole, UK), after Vincent et al. (Vincent et al, 2005a).
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Control experiments for α-lipoic acid study included in addition to the standard control 
and experimental groups: incubation with DMSO with and without BSA-AGE, 
methylglyoxal.  
 
 
4
In AGE experiments, BSA (without conjugated AGE) was added to control media to 
give a concentration of 250 g/ml, equivalent to the concentration of AGE-BSA in 
experimental media (over and above the BSA already in the media as standard). 
 
Dissecting Buffer 100 ml 
10 ml 10x HBSS (Sigma, Poole, UK) 
1 ml penicillin-streptomycin solution (as above) 
1 ml 1M glucose (Sigma, Poole, UK) 
1 ml 7.5% Sodium hydrogen Carbonate (VWR, Leicester, UK) 
 
Antibiotic wash 100 ml 
10 ml 10x HBSS (as above) 
1 ml penicillin-streptomycin solution (as above) 
0.5ml of 10mg/ml gentamicin solution (Sigma, Poole, UK) 
0.5 ml of 5mg/ml metrodiazole (Sigma, Poole, UK) 
1 ml of 7.5% Sodium hydrogen Carbonate (as above) 
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Appendix 2 
Publication arising from this thesis 
 Voukali, E.;Shotton, H R;Lincoln, J., 2011, Selective responses of myenteric 
neurons to oxidative stress diabetic stimuli, Neurogastroenterol. Motil., 23, (10)  
964-e411. 
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